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University of Pittsburgh, 2006
Neuroinflammation is a major component of several neurodegenerative disorders such as 
Alzheimer’s disease, HIV-associated dementia, Multiple sclerosis and Parkinson’s disease. 
Although the primary pathology underlying each of these diseases is vastly different, 
neuroinflammation, consisting of chronic activation of brain macrophages, is a significant factor 
that contributes to neuronal damage in all these conditions. Were it possible to image chronic 
activation of brain macrophages, it would be possible to monitor developing neuroinflammation 
and assess the efficacy of therapies that are targeted at modulating CNS inflammation. 
The goal of this thesis is to determine if activated brain macrophages can be imaged in 
vivo using positron emission tomography. We propose to take advantage of increased expression 
of the peripheral benzodiazepine receptor in activated brain macrophages and hypothesize that 
ligands that bind specifically to this receptor will label activated brain macrophages in vivo 
using positron emission tomography. The peripheral benzodiazepine receptor is normally 
expressed at low levels in the central nervous system in astrocytes and brain macrophages and is 
hypothesized to increase specifically on brain macrophages in neuroinflammation. 
We show that PK11195, a specific ligand to the peripheral benzodiazepine receptor, 
shows increased binding to brain macrophages in HIV encephalitis and that PK11195 can be 
used to image brain macrophages in vivo using positron emission tomography in a macaque 
model of HIV encephalitis. PK11195 binding is also increased in activated brain macrophages in 
Alzheimer’s disease and shows age dependent increases in transgenic mice models of 
Alzheimer’s disease. Finally we compare binding characteristics of DAA1106, a novel 
peripheral benzodiazepine receptor ligand, with PK11195 to show that DAA1106 binds with 
greater affinity in rat models of neuroinflammation both in brain tissues as well as in vivo. These 
data suggest that ligands of the peripheral benzodiazepine receptor specifically label activated 
brain macrophages and may be used to image neuroinflammation in vivo using positron emission 
tomography. 
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1.0  INTRODUCTION 
 In the following section, I discuss the role played by brain macrophages in health and 
disease, then discuss their role in HIV related dementia and Alzheimer’s disease and the 
applicability of labeling the peripheral benzodiazepine receptor to image brain 
macrophages in vivo. 
1.1 BRAIN MACROPHAGES IN HEALTH AND DISEASE 
1.1.1 Brain macrophages: origin and function 
Microglia constitute 5-10% of the total cell population in the brain and are the resident 
macrophages that function as phagocytes, clearing debris around damaged neurons and 
synapses (168). Recognition of microglia as pathologically important cells in the CNS is 
ascribed to Del RioHortega, who is also credited with coining their name (70).  It is 
generally accepted that microglia are derived from cells of the monocyte lineage from the 
embryonic mesoderm that migrate from the bone marrow into the CNS (196). Alternate 
views assign a neuroectodermal origin to microglia based on tissue culture experiments 
(83). However, the functions of microglia and the expression of cell surface markers are 
very similar to bone marrow derived macrophages, favoring a mesodermal origin. 
Microglia undergo changes from a resting phenotype to an activated phenotype in 
response to CNS insults that enable them to function as phagocytes (93). This change in 
morphology has been best documented in the facial-nerve axotomy model, which results 
in microglial activation assessed by the expression of several surface markers, 
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morphological changes and proliferation of these cells around the motor neurons of the 
facial nucleus (135).  
In addition to activation of resident brain microglia, monocytes migrate from the 
vascular compartment into the CNS during CNS-inflammation and differentiate to form 
macrophages (197). These cells have been referred to as perivascular macrophages. 
Experiments conducted in chimeric mice suggest that these cells are regularly replaced 
from the bone marrow (116). Although, these two populations of cells may be viewed as 
separate, it is possible that cells from the perivascular regions may traffic into the 
parenchymal space and vice versa. Macrophages derived from the periphery also have 
similar morphology and function as activated brain microglia. Besides, current 
immunohistochemical markers are unable to distinguish between these two populations 
of cells. Due to their similar embryonic origin and function and the absence of current 
markers to differentiate peripheral macrophages that infiltrate into the brain and 
resident microglia, these cells will be collectively referred to as brain macrophage 
henceforth. 
Resident brain macrophages were previously thought to be quiescent and non-
motile in the resting state. However, recent evidence imaging fluorescently labeled 
resident brain macrophages in transgenic mice using two photon microscopy shows that 
these cells are far from static (67, 180). These cells showed highly ramified processes that 
were highly motile and displayed cycles of formation, extension and withdrawal. Each of 
these processes also showed foot-like appendages that formed and withdrew. These 
authors hypothesized that resident brain macrophages serve a housekeeping function, 
enabling them to sample and maintain homeostasis of local environments. Following 
injury induced using a laser, time-lapse imaging showed rapid movement of ramified 
processes to the site of injury, which fused to form an area of containment between 
healthy and injured tissues within about 30 seconds, suggesting that resident brain 
macrophages may represent the first line of defense in CNS injury (67, 86, 180). 
The phagocytic function of brain macrophages is mediated in a receptor 
dependent fashion. Brain macrophages express receptors for Fc (constant fragment of 
antibodies) and complement, which enable them to engulf antibody-coated cells and 
opsonized antigen (48, 240, 247). Brain macrophages also express MHC II that enable 
 14 
them to present antigen to CD4-T cells (93). In addition, brain macrophages also express 
costimulatory substances such as B7-1, B7-2 and CD40 that enable them to stimulate T 
cells (102). These functions of phagocytosis and antigen presentation enable brain 
macrophages to serve an immune surveillance function in the CNS. 
1.1.2 Brain macrophages: role in neurodegeneration 
Activation of brain macrophages is seen in several neurodegenerative disorders. Neuritic 
plaques, which constitute the central pathology in Alzheimer’s disease (AD), are 
surrounded by activated macrophages (162). In multiple sclerosis, areas of demyelination 
are rich in activated brain macrophages (25). HIV-dementia is characterized by viral 
infection of brain macrophages (255), and other neurodegenerative diseases such as 
Parkinson’s disease (161), Creutzfeldt-Jakob disease (173) and Amyotrophic Lateral 
Sclerosis (214) are also associated with activated brain macrophages.  
A wealth of literature suggests that activated brain macrophages produce toxins, 
that are detrimental to neurons. Several studies report that these cells synthesize and 
secrete several neurotoxins, which may cause neuronal damage or aggravate the 
underlying pathology. These neurotoxins include cytokines such as interleukin-1 (96), 
interleukin-6 (208) and tumor necrosis factor α (53), chemokines such as MIP-1α (175), 
MIP-1β (164) and MCP-1(64), free radicals (52), nitric oxide (51), proteinases (61) and 
eicosanoids (114). Although some of these studies are based on tissue culture systems 
and remain to be confirmed in vivo, it is generally accepted that activated brain 
macrophages can produce a complexarray of neurotoxins. 
 Further, inhibition of brain macrophage activation using non-steroidal anti-
inflammatory drugs or minocyclin reduces the extent of neuronal damage in animal 
models of Parkinson’s disease (76) and AD (143). Activation of brain macrophages also 
inhibits neurogenesis in the hippocampus in rats that are irradiated or injected with 
lipopolysaccaride. Hippocampal regeneration was restored in these conditions by 
blocking brain macrophage activation with either indomethacin (170) or minocyclin (77). 
These studies suggest that activation of brain macrophages is indeed a perpetuator of 
pathology in degenerative disorders. 
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However, recent evidence suggests that activated macrophages may also serve 
more positive roles. For example, in therapeutic immunization protocols in AD, 
activation of brain macrophages is thought to play a role in the clearance of Aβ from the 
CNS by activation of phagocytic mechanisms (155, 179, 218). In fact, the efficacy of 
antibodies in clearance of plaques from the brain correlated with the affinity of the 
antibody for the Fc receptor on brain macrophages (21). It has also been suggested that 
brain macrophages can exist in different states of activation depending on the 
microenvironment, with some states favoring the secretion of substances damaging 
neurons and other states favoring a phagocytic role such as in immunization protocols in 
Alzheimer’s disease (172). 
 
 
Figure 1 Brain macrophages in health and disease 
The main function of brain macrophages is to defend the CNS against pathogens by immune surveillance, 
phagocytosis and antigen presentation to T cells. Brain macrophages transform from a resting state to an 
activated state in response to CNS pathologies. Activation enables these cells to carry out their immune 
surveillance functions. Chronic activation of brain macrophages results in the production of several 
substances, including cytokines like TNF α and interleukins, chemokines such as MIP-1α which may 
recruit other immune cells into the CNS, free radicals, nitric oxide, eicosanoids and proteinases which are 
toxic to neurons and may exacerbate the disease specific pathology. 
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1.2 NEUROINFLAMMATION IN HIV ENCEPHALITIS 
It has been about 25 years since initial reports of patients suffering from previously rare 
diseases such as Kaposi’s sarcoma and pneumocystitis pneumonia heralded the AIDS 
epidemic.  In 1983, a retrovirus later called the human immunodeficiency virus-1 was 
identified as the primary cause of acquired immunodeficiency syndrome (AIDS) in 
humans (23). Since then, AIDS has grown to be one of the greatest challenges that 
mankind has ever faced.  
HIV associated dementia arises in 25 % of terminally ill AIDS patients due to 
direct consequences of HIV-infection and inflammation of the CNS termed HIV 
encephalitis (HIVE), discussed in detail below. 
1.2.1 The HIV epidemic 
The United Nations AIDS program estimates that 40 million people around the world are 
currently living with HIV infection with five million new infections in 2004 (see 
http://www.unaids.org) (241). The HIV epidemic is a devastating public health issue in 
Africa and Asia, which together hold more than 70% of the world population living with 
AIDS (241). The several ways that HIV can be transmitted is through unprotected sex 
with infected partners, infected blood or blood products, sexual fluids, sharing of un-
sterilized injection materials previously used by infected persons and materno-fetal routes 
(141). 
The natural life cycle of HIV in humans displays two phases, acute infection and 
chronic infection that then progresses to AIDS (141). Acute infection presents with 
symptoms and signs very similar to infectious mononucleosis including, fever, myalgia, 
nausea, headache, sore throat, fatigue and lymphadenopathy (141).  Acute infection is 
mainly characterized by high viral replication and a decrease in CD4+ T cell counts (82). 
The “latency period” or “window period” is largely asymptomatic and is characterized by 
a decreased rate, but continued viral replication due to host immune responses that may 
last from months to years (189). The chronic phase of infection is characterized by 
progressive declines in CD4+ T cell counts that culminates in AIDS (82). Based on 
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criteria defined by the Center for Disease Control and the World Health Organizations, 
patients with AIDS display fever, diarrhea, lymphadenopathy, cachexia, and several 
opportunistic infections including Kaposi’s sarcoma, pnuemocystitis pneumonia, 
toxoplasmosis, candidiasis, cytomegalovirus retinitis, cryptosporidiosis, listeriosis, 
Burkitt’s lymphoma, progressive multifocal leukoencephalopathy, atypical mycobacterial 
infections and histoplasmosis (141).  
HIV productively infects cells that express the CD4 receptor and the CXCR4 or 
CCR5 co-receptors which are expressed mainly on CD4 + T cells and macrophages 
respectively (75, 84, 131). Although in tissue culture systems, viral stains can be 
classified into T-cell tropic and macrophage tropic depending on the preferred cell type 
infected, most viral strains in vivo are able to use both receptors for entry with varying 
efficiency (9, 75). The life span of CD4 T cells is significantly shortened by viral 
infection as opposed to macrophages, which may act as a reservoir for persistent viral 
infection and produce chronic inflammation and tissue damage (11, 12). 
1.2.2 HIV associated dementia 
One in four immunosuppressed patients infected with HIV develop a neurodegenerative 
syndrome clinically characterized as HIV-associated dementia (HIVD) (3, 38, 57, 74, 
158).  This syndrome is characterized by cognitive impairments such as memory and 
concentration deficits, motor abnormalities such as tremors and limb weakness, and 
psychiatric symptoms such as depression, apathy and social withdrawal (98, 198, 201). 
Patients with terminal AIDS often also develop various CNS opportunistic infections and 
neoplasia such as cytomegalovirus encephalitis, cryptococcal meningitis, toxoplasmosis, 
B cell lymphomas and progressive multifocal leukoencephalopathy (10). These diseases 
may present with similar clinical signs and symptoms to HIVD; thus, the diagnosis of 
HIV associated dementia is one of exclusion of these conditions. The more definitive 
diagnosis obtained on autopsy, is characterized by the presence of classic 
immunohistochemical pathologic features termed HIV encephalitis (HIVE) (252).  
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1.2.3  HIV encephalitis 
HIV encephalitis is considered to be the pathological substrate of HIV associated 
dementia (154, 252). HIVE is characterized by the presence of microglial nodules, 
multinucleated giants cells, and abundant HIV-infected and activated macrophages (39, 
40, 178, 253). Microglial nodules are regional aggregations of HIV-infected and activated 
brain macrophages. Fusion of HIV-infected macrophages are thought to form 
multinucleate giant cells (223, 255). Infiltration of HIV-infected and activated 
macrophages is seen in perivascular and brain parenchymal compartments of the CNS in 
both subcortical gray and white matter regions (166, 181). The predominant cell types 
infected with HIV in the CNS are brain macrophages, including resident brain 
macrophages and macrophages derived from monocytes trafficking into the CNS (255). It 
is thought that these monocytes act as “Trojan horses” that bring the virus into the CNS 
(68, 195, 250). This hypothesis draws support from immunohistochemical, in vitro 
studies and several reports suggesting that the main viral strains isolated from the CNS 
are macrophage tropic (104).  
1.2.4 Brain macrophages are central to the pathology of HIVE 
Current hypotheses implicate HIV infected and activated macrophages infiltrating into 
the brain as central players in the pathogenesis of HIV-associated dementia (128). 
Evidence from in vitro studies, animal models and postmortem studies suggest that 
macrophages are the main group of cells that are productively infected with virus in the 
CNS and mediate neuropathology in an indirect fashion by producing toxic secretory 
products and viral proteins (128, 255).  
Controversy exists regarding the relative contributions of activated macrophages 
versus HIV infected macrophages towards the neurodegenerative process (97). Initial 
studies suggest that the severity of dementia, assessed ante mortem correlate with the 
extent of macrophage staining in post mortem tissue but correlate poorly with the extent 
of HIV gp41 immunoreactive cells (97). These data suggest that dementia may correlate 
better with the abundance of activated macrophages than the abundance of HIV infected 
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cells. However, HIVgp41 positive cells correlate with decreases in immunoreactivity of a 
dendritic protein MAP-2 suggesting a role for both activated and HIV infected 
macrophages in synaptic damage (153). More recent data from the primate model of 
HIVE suggest that loss of synaptic proteins correlate with both infected and activated 
macrophages (32). 
Toxins derived from macrophages are generally classified into two groups: viral 
proteins and toxic host secretory products. While, the relative contributions of either 
group of toxins are continuously debated, it is conceivable that the toxic effects of both 
viral proteins and secretary products may not be mutually exclusive. Viral proteins 
derived from macrophages include HIV envelope proteins such as gp41 and gp120 that 
may interact with the HIV receptor and coreceptors that may be expressed in neurons 
(213). Other viral proteins implicated in neuronal toxicity and dysfunction includes Tat, 
Vpr, Nef, Vpu, and Rev (177).  
Neurotoxic secretory products including cytokines such as TNF-α (107) and 
interleukins (2), chemokines such as SDF-1 (261) and MCP-1 (101), free radicals 
generated by activation of NADPH oxidase and reactive nitrogen intermediates (4) and 
eicosanoids such as quinolinic acid products (115). These substances may cause neuronal 
dysfunction directly by triggering pathways that decrease neuronal viability and alter 
synaptic plasticity or indirectly through affects on glial cells (128).  
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Figure 2 Pathogenesis of HIV Encephalitis 
 Monocytes harboring the HIV virus cross the blood brain barrier and differentiate to form macrophages in 
the central nervous system. Neuroinflammation then recruit, infect and activate other macrophages (both 
resident brain macrophages and macrophages from the periphery). These cells may then aggregate to form 
microglial nodules and may fuse to form multinucleated giant cells. Secretary products and toxins derived 
from HIV infected and activated macrophages may cause neuronal damage and activate astrocytes to cause 
astrogliosis. 
 
1.2.5 Neuronal damage in HIVE 
Although, it is generally accepted that activated and HIV infected macrophages are the 
central mediators of neuronal damage in HIVE, the mechanisms of neuronal damage and 
degeneration are continuously debated. Despite the absence of convincing evidence 
supporting productive neuronal infection, neuronal damage and loss are reported in 
HIVE. Dementia may arise from loss of pyramidal neurons (254) and specific decreases 
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in clabindin staining neurons in the cortex (79). However, cognitive abnormalities in 
these patients seem to correlate better with decreases in neuronal synaptic proteins rather 
than decreases in neuronal numbers suggesting that synaptic damage plays a central role 
in HIV-associated dementia (156). Both presynaptic and postsynaptic neuronal damage 
have been reported in HIVE and animal models of this disease (32, 153). Presynaptic 
changes have been mainly studied by documenting changes in a 38kd calcium-binding, 
synaptic vesicle protein named synaptophysin (SYN) (153). Postmortem decreases in 
SYN staining in HIVE are interpreted as damage to presynaptic terminals and correlate 
with poor ante mortem neuropsychological performance in HIV-infected cognitively 
impaired patients (79). Similarly, decreases in a dendritic protein called microtubule-
associated protein-2 (MAP-2), reflective of postsynaptic damage, have also been 
observed in HIVE and correlate with poor ante-mortem cognitive testing (156). These 
data suggest that neurocognitive dysfunction may arise as a direct result of synaptic 
damage. 
 
1.2.6 Effect of HAART on HIV dementia and neuroinflammation 
Highly active antiretroviral therapy (HAART) was introduced in 1995 and since then 
markedly decreased the mortality associated with HIV infection (13). HAART consists of 
multiple anti-HIV drugs including one nucleoside analogue, one protease inhibitor and 
either a second nucleoside analog or a non-nucleoside reverse transcription inhibitor that 
target different aspects of the HIV life cycle (reviewed in (203)). The incidence of 
several opportunistic infections along with HIV associated dementia has decreased with 
the advent of HAART. In fact, the incidence of HIV associated dementia is thought to 
have decreased by 10%. However, it has been suggested that the prevalence of HIV 
associated dementia will increase due to the longer life spans of HIV infected patients on 
HAART (94, 242). Despite the observation that few antiretroviral drugs attain effective 
concentrations in the CNS, the incidence of HIVE has decreased in patients on HAART 
(105, 106). With HAART, abundant HIV infected macrophages are still observed in 
brains with HIVE but are associated with a more subtle degeneration of dendritic arbors 
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and interneuron populations (139). Interestingly, the clinical neurological symptoms in 
patients treated with HAART are reported to be less severe than frank dementia and are 
termed minor cognitive motor disorder (MCMD) (1). MCMD differs from HIV 
associated dementia in that; the symptoms of higher cortical dysfunctions such as 
disorientation, memory losses, and executive skill dysfunctions are milder. It has been 
estimated that 25-30% of HIV infected patients on HAART suffer from MCMD (55, 
211). 
1.2.7 Primate model of HIV encephalitis 
The simian model of lentiviral infection closely resembles the human disease with a 
variable percentage of infected macaques developing neurological disease (24). 
Histopathologic hallmarks of both HIV and SIV encephalitis (HIVE or SIVE) include 
abundant brain tissue infiltration by macrophages, multinucleated giant cells, microglial 
nodules and perivascular chronic inflammatory cells (39, 137).  
The macaque model of HIVE has been extensively used to understand the 
pathogenesis of HIVE. As in the human disease the predominant strain of SIV in the CNS 
of macaques with SIVE is macrophage-tropic (63). Macaque models have been 
extensively studied to determine correlates of encephalitis that can be translated to the 
human disease. Some of the factors associated with the development of encephalitis in 
macaques include, rapid progression to AIDS (182, 251), high levels of CSF viral loads 
(264), elevated CSF monocyte chemotactic protein (MCP)-1 concentrations (58, 263) and 
low anti-SIV antibody titers 1 month after infection (182). 
SIV in macaques is a natural pathogen and the natural disease course of SIV, 
including the development of encephalitis, closely resembles HIV infection in humans. 
The macaque model thus continues to serve a key role in understanding the pathogenesis 
of HIVE. 
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1.3 NEUROINFLAMMATION IN ALZHEIMER’S DISEASE 
1.3.1 Pathology of Alzheimer's disease 
Approximately 50% of individuals over 85 years of age and over 10% of individuals over 
65 years of age suffer from Alzheimer’s disease (AD), making it the leading causes of 
dementia (8). Clinically, AD is characterized by progressive memory and cognitive 
impairment and behavioral abnormalities. The disease begins as a decrease in short term 
memory, followed by a progressive impairment of mental functions and daily activities, 
accompanied by behavioral changes such as social withdrawal and depression (110). 
Terminally ill patients are usually bed ridden, incontinent and completely dependent on 
custodian care with death occurring at an average of nine years after diagnosis (26). AD 
is a major public health problem from the devastating nature of the disease on patients 
and resources available to health providers and patient attendants (174). Current therapies 
available are at best palliative and do not address the underlying pathogenesis of AD.  
The pathology of Alzheimer’s disease is first seen in the cerebral cortex and 
subsequently spreading to more subcortical structures. Limbic structures such as the 
hippocampal formation are one of the first regions to degenerate (152).  
Two main features characterize the neuropathology of AD: the formation of 
intraneuronal neurofibrillary tangles and extracellular Aβ deposition (167). Aβ deposition 
leads to the formation of diffuse plaques that are believed to progress to neuritic plaques 
with a dense core of β-amyloid protein (Aβ), dystrophic neurites, astrocytes, and 
activated brain macrophages (161). Neurofibrillary tangles are intraneuronal inclusion 
bodies found with the cell soma, proximal dendrites, distal axon terminals and synaptic 
terminals (134). These inclusion bodies consist mainly of hyperphosphorylated isoforms 
of the microtubule-associated protein Tau, causing it to form paired helical filaments that 
are insoluble which consequently aggregate (99). The major constituent of neuritic 
plaques was identified to be the Aβ peptide nearly 20 years ago (157). It is now generally 
accepted that Aβ is formed due to abnormal cleavage of the amyloid precursor protein 
(APP) by the two enzymes β and γ-secretase (221). 
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Figure 3: Schematic depiction of a neuritic plaque 
Neuritic plaques consist of a dense core of β-amyloid  (brown) surrounded by dystrophic neurites (blue) 
containing hyperphosphorylated Tau, activated brain macrophages (red) and activated astrocytes (not 
shown in the figure). 
 
While several studies show that Aβ  may initiate neuronal damage through 
various mechanisms, the relative contributions of Aβ and Tau to disease pathogenesis 
and progression are continuously debated. The amyloid hypothesis suggests that 
overproduction of Aβ, or failure to clear this peptide, leads to the formation of Aβ 
deposits, which cause the formation of neurofibrillary tangles; these abnormalities then 
cause neuronal damage and death (111). Several arguments and experiments, beyond the 
scope of this thesis, favor or oppose this hypothesis and it remains to be either 
conclusively proved or disproved. 
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1.3.2 Transgenic mouse models of AD 
Transgenic mice have been created that express various mutations related to AD.  These 
include mice that express Familial-APP mutations (such as Swedish, Indiana, and 717) 
presenilins-1 (PS1), combinations of mutant APP and PS1 (258), and more recently, the 
triple transgenic mouse expressing mutant APP, PS1 and Tau (P301L) (183). Various 
aspects of the disease pathology are seen in these mice including deposition of 
extracellular Aβ, dystrophic neurites, memory deficits, hippocampal synaptic 
abnormalities, mild neuronal loss and glial activation. The degree to which each of these 
models displays AD pathology depends on the level of the transgene and the specific 
mutation. Activation of brain macrophages is more variable depending again on the 
transgene expressed, but is reported to be lower than the human disease overall (72). 
Transgenic mice have revolutionized the study of AD and other 
neurodegenerative disorders by providing models suitable to study therapeutics and 
mechanistic hypotheses in vivo. However, studies utilizing transgenic models have to be 
interpreted with caution in terms of applicability to the human disease. Levels of 
expression of aberrant proteins may far exceed actual pathological condition in the 
human disease. Further, transgenic mice may not model all the aspects of a complex 
chronic human neurodegenerative disease. For example, mice that model Huntington’s 
disease and Alzheimer’s disease rarely show frank neuronal loss (258).  Also mice 
expressing the APP and PS1 mutations mice show decreased retention of the PIB-
amyloid PET ligand as compared to human AD subjects, which may be due to 
differences in the secondary structure of the deposited Aβ (133).  
1.3.3 Brain macrophage activation in Alzhiemer's disease  
Aβ is the main protein in the dense core of neuritic plaques and is formed by abnormal 
protein cleavage of the amyloid precursor protein (APP). Aβ deposits are thought to 
activate brain macrophages that then surround the neuritic plaque (165). Evidence for this 
hypothesis comes from cultured brain macrophages which when exposed to the Aβ 
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peptide show upregulation of MHC-II, complement receptor, chemokines, expression of 
cytokines such as TNFα and interleukins and other acute phase proteins similar to 
changes seen in activated brain macrophages in AD postmortem brain tissue (16, 102, 
209).  
Transgenic mice overexpressing human APP show deposits of Aβ surrounded by 
activated brain macrophages (28, 89, 143, 229). Mice injected with fibrillar Aβ also show 
activated brain macrophages (88). Aberrant chemokine and cytokine expression may also 
recruit and activate other macrophages from the periphery (209). The mechanisms by 
which Aβ causes brain macrophages activation are not clearly understood. Several 
receptors and pathways have been implicated, but it has not been clearly demonstrated 
that binding to such receptors is the principal mediator of activation (148).   
1.3.4 Role of activated brain macrophages in Alzhiemer's disease  
While the biochemical processes related to Aβ processing have been studied extensively, 
the role of activated brain macrophages in the pathogenesis of AD is not well understood 
and is continuously debated. One hypothesis is that brain macrophages are primarily 
activated to serve a phagocytic function in response to deposited Aβ (219). 
Ultrastructural studies suggest that intracytoplasmic Aβ fibrils may be found in activated 
brain macrophages in AD and transgenic mouse brain tissue (7, 142, 229). However, a 
recent study suggests that these amyloid fibrils may be extensions of extracellular 
amyloid forming finger-like channels into the brain macrophages cytoplasm, but not 
directly contained within it (228). Evidence from in vitro experiments suggest that 
activated brain macrophages are capable of ingesting Aβ, but may be defective in their 
phagocytic capacity due to poor degradation of ingested amyloid within brain 
macrophages (87, 192). Also, no phagocytosis is observed when brain macrophages are 
incubated with AD frozen sections containing Aβ,  but is enhanced by incubation with 
specific Aβ antibodies (21). 
Brain macrophages are sources of several neurotoxins that may enhance the 
neurodegenerative process seen in AD and several other chronic neurological disorders. 
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On activation, brain macrophages express several proteins that may accentuate the 
neurodegenerative process (30, 225, 236). Activated macrophages produce cytokines 
such as TNF-α and interleukins, free radicals generated by activation of NADPH 
oxidase, reactive nitrogen intermediates, eicosanoids, complement associated proteins, 
antigen presentation and co-stimulatory molecules and matrix metaloproteinases which 
have been implicated in disease pathogenesis (30, 225, 236). These substances are 
thought to trigger various cellular processes including cell death cascades in neurons. 
Further, Non Steroidal Anti-Inflammatory Drugs (NSAIDs) which are associated with a 
decrease in the incidence of AD (119) may reduce the extent of brain macrophages 
activation in animal models (143, 260). These studies suggest a detrimental role for 
activated brain macrophages in AD.  
 
1.3.5 Therapeutic approaches to AD 
Current standards of medical care include acetylcholine esterase inhibitors in mild to 
moderate AD and the NMDA antagonist, Memantine, in advanced AD (33, 73). These 
therapies although reported to have improvements in cognition, do not address the 
underlying pathology in AD. Other therapies include mood stabilizers and antipsychotics 
used to manage behavioral abnormalities seen in AD (73).  No current FDA approved 
therapies have disease-modifying effects and are of limited use in the clinic. 
Several therapeutic approaches target various aspects of AD pathology. These 
include the use of neurotrophic factors like NGF targeted to increased neuronal survival, 
drugs that potentially interfere with Aβ aggregation or modulate enzymes that process 
APP, anti inflammatory compounds and immunotherapies targeted at clearing Aβ from 
the brain. Nerve growth factor (NGF) is a neurotrophic factor that promotes survival of 
cholinergic neurons (reviewed in) (59). Cholinergic neurons in the basal nucleus of 
mynert are the first group of neurons to degenerate in early stages of AD (147). Clinical 
trials delivering NGF to the CNS show initial promise, however, the widespread 
involvement of neurons including non-cholinergic neurons in AD may preclude 
significant clinical improvement in advanced AD (36). Aβ-42 is generated by sequential 
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cleavage of APP by two enzymes called β-secretase and γ-secretase. A third enzyme 
called α-secretase competes with β-secretase and may decrease the production of Aβ42 
(221).  Therapies targeted at either inhibiting β-secretase and γ-secretase or stimulating 
α-secretase activity may be beneficial in decreasing Aβ production and are currently 
under active research (reviewed in)(243).  
1.3.5.1 Immunization aganist Abeta 
Both active and passive immunizations in animal models have proved promising in 
clearing Aβ loads from the brain and improving behavioral/memory tests (22, 120, 171, 
218).  PDAPP mice immunized with Aβ peptides over a six-month period show 
generation of antibodies against Aβ, clearance of Aβ brain deposits and improvements in 
cognitive testing. Passive immunization utilizing antibodies targeted against the Aβ 
peptides cross the blood brain barrier and clear Aβ deposits from the CNS. Immunization 
against Aβ in aged vervets, which shows Aβ deposition in older age groups, also clears 
plaques (140). Active immunizations in human subjects have generated both positive and 
negative outcomes. Postmortem studies from 3 immunized patients showed clearance of 
Aβ from the brain, however ~5% of subjects developed severe T-cell encephalitis on 
immunization (85, 155, 179).  Despite mixed enthusiasm, immunization against Aβ 
shows great promise in the treatment of AD (219).  
Several mechanisms have been proposed for Aβ  clearance with immunization. 
Some of these hypotheses propose that (1) antibodies generated against Aβ interfere with 
fibrillogenesis and neurotoxicity of Aβ (163, 226), (2) clearance of amyloid by transfer to 
the CSF/vascular compartment which act as a “peripheral sink” (71) and (3) phagocytosis 
of Aβ  by activated brain macrophages via Fc and non-Fc dependent mechanisms (66, 
217). Clearance of CNS Aβ may occur through one or more of these processes, however 
the observation that the clearance of Aβ is consistently associated with activation of brain 
macrophages raises the possibility that the efficacy of immunizations is related to the 
extent of activation of brain macrophages.  
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1.3.5.2  Brain macrophages in Aβ immunization 
Brain macrophage activation is seen with both active and passive immunization and is 
consistently associated with “collapsed” plaques in both animal models and human 
subjects (22, 85, 155, 179, 218).  Phagocytosis is enhanced with the addition of 
antibodies to cultured brain macrophages in the presence of Aβ (22). Further, the efficacy 
of clearance with passive immunization correlated with the ability of the antibody to bind 
Fc receptors on activated brain macrophages rather than binding to Aβ (21), suggesting a 
central role for activated brain macrophages in Aβ clearance. However, mice deficient in 
the Fc-receptor, which plays a role in Aβ phagocytosis by brain macrophages, crossed 
with amyloid precursor protein transgenic mice show efficient clearance with 
immunization against Aβ (66). This raises the possibilities of other mechanisms, such as 
the peripheral sink hypothesis, playing a more important role in Aβ clearance than Fc 
dependent phagocytosis by brain macrophages. Alternatively, phagocytosis in brain 
macrophages may also be mediated by scavenger receptors or other FC independent 
mechanisms (66).  Although, both active and passive immunization protocols are 
associated with brain macrophage activation, the exact role of these cells in clearance of 
Aβ remains to be understood. 
1.4 THE PERIPHERAL BENZODIAZEPINE RECEPTOR 
1.4.1 The peripheral benzodiazepine receptor-structure and function 
Two pharmacologically distinct benzodiazepine receptors exist in the CNS: the central 
and the peripheral benzodiazepine receptors. The central benzodiazepine receptor is a 
part of the ionotropic GABA receptor located on the plasma membrane of GABA-ergic 
neurons (232). The peripheral benzodiazepine receptor (PBR), on the other hand is 
located on the outer mitochondrial membrane of astrocytes and brain macrophage (45).  It 
is part of a hetero-oligomeric complex comprised of the voltage-dependent anion channel 
 30 
and an adenine nucleotide carrier forming the mitochondrial permeability transition pore 
(160).  
The functions of this receptor in the CNS are not entirely known.  It is thought to 
be involved in neurosteroid synthesis by serving to transport cholesterol from the outer to 
the inner mitochondrial membranes (190). As a constituent of the mitochondrial 
permeability transition pore it is thought to regulate cell death (160) and mitochondrial 
respiration (117).  Although the functions of this receptor in the resting CNS have not 
been entirely elucidated, several studies have focused on changes in PBR expression in 
CNS diseases.  
1.4.2 PBR in CNS diseases 
After early reports that the PBR was present in the CNS, several studies have focused on 
determining changes in PBR expression in CNS disease. These studies mainly utilize the 
isoquinoline carboxamide derivative PK11195, a specific pharmacological ligand that 
binds to PBR with high affinity. [3H](R)-PK11195 was first used to label giloma cell 
lines implanted into mice brains using autoradiography (230). Several binding studies 
using homogenized brain tissue and autoradiography studies have now shown increased 
[3H](R)-PK11195 binding (reflecting increases in PBR protein expression) in a wide 
variety of neurological diseases such as multiple sclerosis (20, 246), experimental 
autoimmune encephalitis (246), stroke (231), brain trauma (204), facial nerve transaction 
(19, 92), and SIVE (151). In the majority of these studies cellular localization of 
increased PBR expression is specific to activated brain macrophage elements, but not 
astrocytes as discussed below. 
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Figure 4 Structure of the mitochondrial permeability transition pore showing the location of 
the peripheral benzodiazepine receptor 
The mitochondrial permeability transition pore consists mainly of the voltage dependent anion channel 
(VDAC), the adenine nucleotide transporter (ANT) and the peripheral benzodiazepine receptor (PBR). 
Note that PBR is situated on the outer mitochondrial membrane. 
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1.4.3 PBR is increased specifically in brain macrophages during disease 
In the resting CNS, PBR was first reported to localize to ependymal cell lining the 
ventricles, the olfactory bulb and the choroids plexsus (248). Subsequently PBR was 
found to be expressed in low levels in glial cells including astrocytes and brain 
macrophages and was increased specifically in brain macrophages in a rat model of 
stroke (176). This phenomenon has been confirmed in other CNS pathologies associated 
with gliosis such as models of ischemia in rats (231), experimental autoimmune 
encephalitis (246), multiple sclerosis (20), facial nerve axotomy in rats (19), brain trauma 
in rats (204) and SIV encephalitis in macaques (151). However, some studies report 
increased astrocyte expression of PBR following an initial increase in brain macrophages 
in rodents treated with the neurotoxin trimethyltin (136) and cuprizone (54). In vitro 
studies also suggest that neurons may express PBR (121), but not in brain tissues in vivo. 
It is, however, generally accepted that increase in PBR is specific to glial cells. 
1.4.4 Potential functions for PBR in brain macrophages 
The effects of increased PBR expression in macrophages are unknown. The association 
of PBR with the mitochondrial permeability transition pore suggests a role in the 
regulation of cell death. At the mitochondrial permeability transition pore, PBR interacts 
with several resident mitochondrial proteins including the voltage dependent anion 
channel and the adenine nucleotide carrier which in turn interact with proteins regulating 
apoptosis (160). Interestingly, PBR prevents myxoma-infected macrophages from 
apoptosis (80, 81). In these studies, forced macrophage-PBR overexpression prevented 
these cells from undergoing myxoma virus-mediated apoptosis. Forced PBR expression 
in neurons in vivo and jurkat cells in vitro protects these cells against apoptosis (125, 
234). PBR upregulation in testicular leydig cells protects them from cytokine-induced 
toxicity (207, 237). This is also seen in blood phagocytic cells where PBR protects 
against oxidant induced cell death (44). Macrophage specific PBR expression may thus 
protect these cells from various toxins including the cytopathic effects of HIV, 
contributing to longer macrophage life spans in the brain.  
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1.4.5 Potential mechanisms for PBR upregulation in brain macrophages 
The mechanisms responsible for increased PBR expression in macrophage elements in 
the CNS are not known. In pancreatic islet cells, the cytokines TNF-α, IFN-γ and IL-1β 
cause an increase in PBR mRNA and [3H](R)-PK11195 binding in a transcription 
dependent manner (20). Similar results are seen in testicular leydig cell exposed to TNF-
α (237). In the CNS, rats injected with IL-1, or TNF-α , or LPS resulted in increased 
[3H](R)-PK11195 binding to macrophages, reflecting increased PBR expression in these 
cells (31, 35). IL-1 and TNF-α also increase [3H](R)-PK11195 binding in cultured 
astrocytes (184). In experimental autoimmune encephalitis, IL-6 and TNF-α expression 
profiles correlate with increase in spinal cord [3H](R)-PK11195 binding (5). These data 
suggest that cytokines increase PBR expression in various cell types including 
macrophages. However, the mechanisms mediating this increase are not known. It has 
been proposed that cellular upregulation of PBR in these systems may serve as a 
protective strategy against cytokine toxicity. Since activated brain macrophages 
themselves are sources of cytokines, increase in PBR expression would be an autocrine-
paracrine phenomenon. 
Since PBR upregulation is associated with cell survival, it is possible that cell 
pathways that promote survival regulate PBR expression. One of the major pathways that 
regulates cell survival is the Phosphatidylinositol-3-kinase (PI3K)/Akt pathway. PI3K is 
a lipid kinase essential for the activation of Akt, which plays a pivotal role in cell survival 
and proliferation (187). PI3K/Akt activation is an important survival-regulation pathway 
in brain macrophages (129), peripheral macrophages and other hemopoietic cell (169, 
239). Activation of PI3K/Akt protects against toxicity induced by multiple cytokines 
(100, 169). Further, inhibition of PI3K pathway in peripheral macrophages causes cell 
death by loss of mitochondrial transmembrane potential by mechanisms not fully 
understood (144). Since PBR is a constituent of the permeability transition pore and may 
play a role in maintaining mitochondrial transmembrane potential, it is possible that PBR 
is directly regulated by activation of the PI3K/Akt pathway. 
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1.4.6 PBR ligands may be used to image activated brain macrophages in vivo 
Several ligands have been synthesized that bind specifically to PBR. Labeling these 
ligands with [3H] and [11C] has enabled their use in autoradiography and PET 
respectively. Of these ligands PK11195, a lipid soluble isoquinoline carboxamide, has 
been the most extensively characterized (17). [11C](R)-PK11195 has been used to label 
activated brain macrophages in patients with multiple sclerosis (20, 69) Rasmussen’s 
encephalitis (18), stroke (206), Herpes encephalitis (43), gliomas (191), multiple system 
atrophy (95), animal models of HIV encephalitis (245) and AD (41). 
Studies in AD patients showed high [11C](R)-PK11195 binding in the entorhinal, 
temporoparietal and cingulate cortices, brain regions which show the highest degree of 
AD pathology (41). However, this study also reported high levels of [11C](R)-PK11195 
binding in regions not involved in AD, such as the thalamus and the brainstem (41). 
Similarly, a recent study using [11C](R)-PK11195 to image activated brain macrophages 
in amyotrophic lateral sclerosis (ALS) patients showed high binding in the occipital 
cortex, regions of the prefrontal cortex, and the thalamus, which are areas that are not 
traditionally implicated in ALS pathology (238). Both these studies were not followed up 
by neuropathologic assessments and the presence of activated brain macrophages in brain 
regions usually not involved in the disease pathology cannot be ruled out. However, these 
findings may be attributed to some degree of non-specific binding of PK11195, 
underscoring the importance of using a ligand with high specific binding to PBR.  
DAA1106 [N-(2,5-dimethoxybenzyl)-N-(4-uoro-2-phenoxyphenyl) acetamide], 
an aryloxyanilide derivative, is a recently synthesized ligand that binds selectively and 
with higher affinity to PBR (47). DAA1106 shows a higher affinity to PBR compared to 
PK11195 suggested by the differences in the dissociation constants. The Kd (dissociation 
constant) of PK11195 ranges between 4nM to 20nM, while the Kd of DAA1106 is around 
0.1nM (dissociation constant being inversely proportional to binding affinity) (47, 185). 
Due to a high affinity, DAA1106 may serve as a better ligand to label PBR both ex vivo 
and in vivo (149, 262).  This may also address some of the issues related to nonspecific 
binding seen in studies with PK11195.  
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2.0  SPECIFIC AIMS 
Activated brain macrophages play a significant role in several neurodegenerative diseases 
including HIV-associated dementia, Alzheimer’s disease and Parkinson’s disease. 
Neurotoxins such as cytokines and free radicals produced from activated brain 
macrophages are thought to promote the degenerative process by causing neuronal 
damage. Several therapies such as anti inflammatory drugs and immunization protocols 
in Alzheimer’s disease target activated macrophages. Were it possible to detect the 
presence of brain macrophages in vivo, in may be possible to monitor the development 
and progression of neuroinflammation as well as determine the efficacy of therapies 
targeted at altering neuroinflammation. 
The peripheral benzodiazepine receptor is abundant on activated brain 
macrophages and expressed in low levels in the normal brain. We investigated the 
feasibility of imaging activated brain macrophages using Positron Emission Tomography 
(PET) by taking advantage of elevated levels of peripheral benzodiazepine receptor 
expression (PBR) on brain macrophages. We tested the overall hypothesis that selective 
ligand to PBR will specifically label activated brain macrophages in 
neuroinflammation. We propose to use the extensively characterized peripheral 
benzodiazepine ligand PK11195 to image brain macrophages in vivo using animal 
models of HIV encephalitis and Alzheimer’s disease. We also propose to characterize 
DAA1106, a novel ligand that binds with high affinity and specificity to the peripheral 
benzodiazepine. Accordingly, the following four specific aims are proposed. 
Subhypothesis1: PK11195 will selectively label brain macrophages in a macaque 
model of HIV encephalitis in vivo, using PET. 
SPECIFIC AIM 1: Determine if (1); [3H](R)-PK11195 shows higher specific 
binding in SIVE brain tissue compared to SIV infected, non encephalitic tissue, and 
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control uninfected tissue, (2); [11C](R)-PK11195 can label brain macrophages in vivo in 
SIVE. 
In this specific aim, we will utilize PET imaging with [11C](R)-PK11195 to 
compare binding characteristics in macaques infected with SIV that develop encephalitis 
with macaques that do not develop encephalitis. We will also use filtration-binding 
techniques to compare [3H](R)-PK11195 binding in SIVE with SIV infected, non-
encephalitis, and control uninfected brain tissue derived from macaques that have been 
PET imaged. PET finding will be correlated with histopathology and filtration binding 
data to determine if PK11195 can label brain macrophages in vivo in SIVE.  
Subhypothesis2: PK11195 will selectively label brain macrophages in HIV 
encephalitis. 
SPECIFIC AIM 2: Determine (1); if [3H](R)-PK11195 shows higher specific 
binding in HIVE brain tissue compared to HIV infected, non encephalitic tissue, and 
control uninfected tissue, (2); if activated macrophages show higher specific binding with 
[3H](R)-PK11195 compared to astrocytes in vitro, (3); if HIV infected macrophages 
show higher specific binding of [3H](R)-PK11195 compared to astrocytes treated with 
supernatants derived from HIV infected macrophages in vitro, and (4) determine the cell 
signaling pathways that mediate upregulation of PBR in macrophages. 
In this aim, we will confirm data obtained from SIVE in aim 1 in HIVE 
postmortem tissue. We will also use cell culture systems to determine the effects of 
activation and HIV infection in primary human macrophages. We will also use 
pharmacologic blockers of the PI3K/Akt and the MAP-kinase pathways to determine if 
these pathways are responsible for upregulation of PBR in macrophages. 
Subhypothesis3: PK11195 will selectively label brain macrophages in 
Alzheimer’s disease postmortem tissue and transgenic mice models of Alzheimer’s 
disease in vivo. 
SPECIFIC AIM 3: We will compare (1); [3H](R)-PK11195 binding in 
postmortem Alzheimer’s disease brain tissue from Alzheimer’s disease patients with age 
matched controls using filtration binding assays, and (2); [3H](R)-PK11195 binding in 
brain tissue derived from APPSwe/PS1dE9 mice with wild type controls and (3); 
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[11C](R)-PK11195 binding in APPSwe/PS1dE9 mice with wild type age matched 
controls in vivo. 
In this aim we will compare data obtained from filtration binding techniques, PET 
imaging, and immunohistochemistry in postmortem tissue obtained from Alzheimer’s 
disease and transgenic mice to determine if PK11195 can label brain macrophages in 
Alzheimer’s disease in vivo. 
Subhypothesis4: DAA1106 will bind to regions of neuroinflammation with higher 
affinity compared to PK11195 
SPECIFIC AIM 4: We will compare the binding characteristics of the novel PBR ligand 
[3H]-DAA1106 with [3H](R)-PK11195 in (1); normal human and rat brain tissue, and 
(2); rat models of neuroinflammation. We will also use ex-vivo autoradiography to 
compare binding characteristics of [11C]-DAA1106 with [11C](R)-PK11195 in rat 
models of neuroinflammation in vivo.  
In this aim we will use two extensively characterized models of 
neuroinflammation, rat injected with lipopolysaccaride and 6-hydroxy dopamine to 
compare binding characteristics of DAA1106 with PK11195. 
 
In the first three aims, we will test if PK11195, a specific ligand that binds to the 
PBR, will label activated brain macrophages in post mortem tissue and animals models of 
HIV encephalitis and Alzheimer’s disease.  In the final aim, we will characterize a newer 
ligand, DAA1106, which binds to PBR with higher affinity compared to PK11195, in 
normal brain tissue as well as rat models of neuroinflammation. These studies will help 
determine if ligands to PBR will label brain macrophages in HIV encephalitis and 
Alzheimer’s disease. 
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3.0  RESULTS 
3.1 PET IMAGING OF BRAIN MACROPHAGES USING THE PERIPHERAL 
BENZODIAZEPINE RECEPTOR IN A MACAQUE MODEL OF NEUROAIDS. 
3.1.1 Abstract 
HIV infection in humans and simian immunodeficiency virus (SIV) infection in 
macaques results in an encephalitis in approximately one-quarter of infected individuals, 
and is characterized by infiltration of the brain with infected and activated macrophages. 
PK11195 is a ligand specific for the peripheral benzodiazepine receptor abundant on 
macrophages and expressed in low levels in the non-infected brain. We hypothesized that 
[11C](R)-PK11195 positron emission tomography (PET) could image brain macrophages 
and hence the development of encephalitis in vivo. [11C](R)-PK11195 binding was 
assessed in the brain using PET in eleven SIV infected macaques, six of which showed 
increased binding in vivo. Postmortem examination of the brain in these six macaques 
demonstrated encephalitis, while macaques that did not show an increase in [11C](R)-
PK11195 binding did not develop SIV encephalitis. Brain tissue from SIV encephalitic 
macaques also showed increased [3H](R)-PK11195 binding compared to binding in non-
encephalitic macaques. Increased PK11195 binding in vivo and in postmortem brain 
tissue correlated with abundance of macrophages but not astrocytes. Our results suggest 
that PET [11C](R)-PK11195-imaging can detect the presence of macrophages in SIV 
encephalitis in vivo and may be useful to predict the development of HIV encephalitis 
and in studies of the pathogenesis and treatment of HIV dementia. 
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3.1.2 Introduction 
Approximately one quarter of immunosuppressed AIDS patients develop a 
neurodegenerative disorder clinically characterized as HIV associated dementia complex 
(37, 57, 74, 158). Early neurological symptoms appear to be reversible; however, later a 
progressive neurological deficit becomes fixed (202). The simian model of lentiviral 
infection closely resembles the human disease with a variable percentage of infected 
macaques developing neurological disease (24). Histopathologic hallmarks of both HIV 
and SIV encephalitis (HIVE or SIVE) include abundant brain tissue infiltration by 
macrophages, multinucleated giant cells, microglial nodules and perivascular chronic 
inflammatory cells (39, 137). The pathogenesis of neurodegeneration is unknown. 
Current hypotheses implicate viral proteins and toxins derived from both HIV infected 
and activated macrophages that cause neuronal damage (128).   
Several imaging modalities have been used to assess central nervous system 
(CNS) changes associated with lentiviral infection (14, 194, 200). While X-ray computed 
tomography has been considered relatively insensitive, magnetic resonance imaging 
(MRI) has demonstrated a spectrum of lesions including white matter abnormalities and 
brain atrophy in demented HIV-infected subjects (15 , 159, 199, 205 , 227, 249). 
Functional imaging studies using PET with the fluorine-18 labeled glucose analog [18F]2-
fluoro-2-deoxyglucose, single-photon emission computed tomography, magnetic 
resonance spectroscopy, and functional MRI have offered tantalizing insights into 
lentiviral infection, but no definitive relationship between abnormalities and onset of 
neurological disease has been observed (49, 50, 78, 193, 210). If HIVE could be 
evaluated during life, it would be possible to identify developing neurological damage 
and monitor efficacy of therapy before development of fixed deficits. Since activated and 
infected macrophages are the sine qua non of HIVE and SIVE (39, 128), it may be 
possible to monitor the progression of HIVE if it were possible to monitor the presence of 
macrophages in vivo.  
Radiolabeled ligands have been recently synthesized that selectively bind to the 
peripheral benzodiazepine receptor (PBR), which is abundantly expressed on brain 
macrophages (17, 42). The isoquinoline carboxamide derivative PK11195 [1-(2-
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chlorophenyl)-N-methyl-N- (1-methylpropyl)-3-isoquinolinecarboxamide] is a specific 
ligand for PBR. Because PBR is expressed only at low levels in the normal brain, several 
in vitro and in vivo studies have examined whether PK11195 can be used to radiolabel 
activated macrophages in the diseased CNS. Autoradiographic studies have demonstrated 
increased binding of [3H](R)-PK11195 to macrophages in a wide variety of neurological 
diseases such as multiple sclerosis and experimental autoimmune encephalitis (20, 246), 
stroke (231) and brain trauma (204). Several studies have utilized PET with [11C](R)-
PK11195 to detect activated macrophages in the CNS of patients with multiple sclerosis 
(20, 69, 246), Rasmussen’s encephalitis (18), Herpes encephalitis (43), Alzheimer’s 
disease (41) and Multiple System Atrophy (95). In the current study we used both in vivo 
PET imaging and binding analysis of post mortem tissues to demonstrate increased 
specific binding of both [11C](R)-PK11195 and [3H](R)-PK11195 to macrophages in 
SIV encephalitic macaques. Increased PK11195 specific binding in SIVE suggests that 
PET utilizing [11C](R)-PK11195 may permit in vivo monitoring of the evolution and 
treatment of HIV dementia. 
3.1.3 Methods 
Animals 
All animals were housed and maintained according to strict standards of the 
Association for Assessment and Accreditation of Laboratory Animal Care, and 
experiments were approved by the University of Pittsburgh Institutional 
Animal Care and Use Committee. Fourteen macaques: 4 pigtail macaques (Macaca 
nemestrina) and 10 rhesus macaques (Macaca mulatta) varying from ages 84 to 
168 months were challenged with SIVDeltaB670 (SIVDB670) with the length of 
infection varying from 56 to 1622 days (Table 1). 
We used six CD8 T-cell depleted macaques (to compress the disease time course) 
and eight non-depleted macaques in this study. Preliminary studies from our laboratory 
have shown that the CD8 T-cell depleted macaques develop encephalitis (unpublished 
data). CD8 T-cell depletion was performed using protocols analogous to those previously 
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described (220) using the CD8 T-cell specific antibody cM-T807 (gift from Dr. Keith 
Reinman). Eleven macaques were available for PET scanning after infection. 
Macaques were sacrificed at pre-specified time points or when moribund with 
AIDS (Table 1). Complete neuropathological microscopic analysis was performed in all 
macaques and no opportunistic infections were identified in the CNS. SIVE was 
diagnosed and classified as mild, moderate or severe on the basis of distribution of 
perivascular and parenchymal macrophage infiltrates, microglial nodules, multinucleated 
giant cells and abundant macrophages that immunostained for SIV envelope protein 
(assessed in multiple10X and 40X fields per brain region) in various brain regions (137) 
(Table 2). Brain tissue from two non-infected macaques served as additional controls.  
Table 1 Macaque experimental parameters. 
Macaque 
number 
Species 
CD8 T-cell 
depletion 
Virus 
Length of 
infection, 
days 
PET 
scan 
Filtration binding 
analysis in post 
mortem brain tissue 
Time of sacrifice 
1259 Pigtailed Yes SIVDB670 66 Yes Yes Moribund with AIDS 
2263 Rhesus Yes SIVDB670 80 Yes No Moribund with AIDS 
2265 Rhesus Yes SIVDB670 56 Yes Yes Moribund with AIDS 
2266 Rhesus Yes SIVDB670 56 Yes Yes Moribund with AIDS 
1220 Pigtailed No SIVDB670 171 Yes No Moribund with AIDS 
0222 Pigtailed No SIVDB670 121 Yes No Moribund with AIDS 
9240 Rhesus No SIVDB670 64 Yes No Timed sacrifice 
9244 Rhesus No SIVDB670 1622 Yes No Moribund with AIDS 
9243 Rhesus No SIVDB670 408 Yes No Moribund with AIDS 
2229 Rhesus No SIVDB670 722 No Yes Moribund with AIDS 
9231 Rhesus No SIVDB670 351 Yes No Timed sacrifice 
2233 Rhesus No SIVDB670 1062 No Yes Moribund with AIDS 
1260 Pigtailed Yes SIVDB670 70 Yes No Timed sacrifice 
2264 Rhesus Yes SIVDB670 69 No Yes Moribund with AIDS 
7405 Rhesus No NA NA No Yes Not infected  
7421 Rhesus No NA NA No Yes Not infected 
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Time of sacrifice indicates if macaques were sacrificed at predetermined time points or sacrificed when 
moribund with AIDS. SIVDB670 - SIVDeltaB670, NA - Not applicable. 
 
PET imaging 
High specific activity [11C](R)-PK11195 ([N-methyl-11C]-PK11195) was produced at 
the UPMC PET Facility using methods similar to those previously described by the 
Hammersmith PET Group (222), except that the methylation  
was performed at room temperature for 2 min to minimize the  
dechlorination side reaction (60). Chemical and radiochemical purities were ≥95% with 
specific activities ≥2.0 Ci/µmol at the end of a 40 min synthesis. Typical end of synthesis 
yields of high purity [11C](R)-PK11195 were in the range of 40-100 mCi.  
Chronically infected macaques were imaged using PET with [11C](R)-PK11195 
either pre-mortem (non CD8 T-cell depleted animals) or before SIV infection and at two 
months post infection (CD8 T-cell depleted animals). After a 10-min transmission scan 
using rotating 68Ga/68Ge rod sources, approximately 5 mCi (average dose 4.92±0.6 mCi, 
range 3.33 mCi – 5.92 mCi) of high specific activity [11C](R)-PK11195 in 5 ml of sterile 
isotonic saline was injected intravenous, into each macaque. PET data were acquired in 
3-D imaging mode using an ECAT HR+ PET scanner (CTI PET Systems, Inc., 
Knoxville, TN).  This instrument simultaneously acquired 63 image planes (15.2 cm field 
of view) with a reconstructed image resolution of 5.8 mm FWHM (ramp filter).  A 
dynamic series of PET scans was acquired over 90 min in 33 frames.  Emission data were 
corrected for attenuation, dead time, scatter, and radioactive decay. 
[11C](R)-PK11195 PET scans of each macaque were co-registered to the baseline 
PET scan using the Automated Image Registration algorithm (259). Regions of interest 
were defined on summed PET images (0-8 min post-injection) and applied to the 
dynamic PET images to generate time-activity curves for the midfrontal cortex, basal 
ganglia, cerebellum, occipital cortex and hippocampal (mesial temporal lobe) brain 
regions. In the non CD8 T-cell depleted animals, the regional brain radioactivity 
concentration summed over the scan frames at various time points was normalized to 
both the injected dose of [11C](R)-PK11195 and the body mass of the animal 
(%ID/Kg*g) to represent a semi-quantitative measure of [11C](R)-PK11195 binding. 
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In the CD8 T-cell depleted macaques, we used the reference-Logan graphical 
analysis method to determine the specific binding of [11C](R)-PK11195 (146). [11C](R)-
PK11195 PET scans obtained prior to SIV infection allowed each animal to serve as its 
own control because of the difficulty of identifying a consistent brain region devoid of 
disease pathology to serve as reference tissue. 
 
MRI  
Imaging was performed using a 3.0 Tesla whole body MRI scanner (General Electric 
Medical Systems, Milwaukee, WI) operating under version VH3 of the scanning 
software. The scanner has peak gradient strength of 4 Gauss/cm and peak slew rate of 
15,000 Gauss/cm/sec. A custom-built, quadrature, birdcage extremity coil (15cm 
diameter, 32 legs) was used for scanning the animals, placed supine on the imaging table. 
Data acquisition was performed using an imaging protocol of standard imaging 
sequences used for the evaluation of anatomical detail, followed by the acquisition of a 
high-resolution gradient echo data set to be used for MRI PET co-registration and a 
dynamic, contrast-enhanced EPI acquisition.  
High Resolution Spoiled Gradient-Recalled (SPGR) Acquisition: Three-
dimensional gradient echo images were acquired prior to contrast injection to provide a 
high-resolution data set for MRI-PET co-registration. This SPGR data set was acquired 
using a TE, TR and flip angle combination (7 ms, 25 ms and 40o, respectively) chosen to 
maximize contrast between brain tissue and its surroundings (including meninges and 
CSF). Contrast-enhanced Gradient Echo EPI:  Multi-slice (21 axial slices, 3.0 mm thick, 
no gap, 80 images per slice) gradient recalled, single shot, EPI images (Flip = 60o) were 
acquired one minute before and one minute after bolus venous injection (3 ml saline 
solution with 0.1 mM/kg of contrast agent, duration = one second) of Gadodiamide 
(Omniscan, Nycomed, Princeton, NJ). These data were acquired after collection of all 
other MR data sets. Volume measurements were determined as described before using 
the MORPH software (123, 124). 
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Autoradiography 
Autoradiography was performed using 15 µm thick frozen sections obtained from the 
frontal cortex (204). Brain sections were placed on SuperfrostTm glass slides (Sigma, St 
Louis, MO) and incubated in ice-cold 50 mM TRIS-HCl (pH 7.4) containing 1 nM 
[3H](R)-PK11195 (sp. Act., 89.9 Ci/mmol; NEN Life Sciences Products, Boston, MA) 
for 30 min. Specificity of binding was ensured by the inclusion of 10 µM PK11195 
(Sigma, St Louis, MO) in parallel sections. The sections were mounted with a layer of 
autoradiographic LM-1 emulsion (Amersham, UK) using a wire loop, following which 
they were developed after 4 weeks and imaged on the confocal microscope.  
Filtration radioligand binding assays 
Brain tissue from various regions was dissected, weighed and homogenized in ice-cold 
50 mM Tris-HCl buffer (pH 7.4). Homogenates were washed four times by centrifugation 
at 40,000 g for 20 min at 40C. Total binding (per mg tissue) was determined by 
incubating tissue (total protein concentration ranging from 150 to 200 µg determined 
using the BCA protein assay kit; Pierce, Rockford, IL) with 1 nM [3H](R)-PK11195 
(except in saturation binding experiments where 0.5-80 nM [3H](R)-PK11195 was used) 
at 40C for 2 hr in a final volume of 250 µl of Tris-HCl. Nonspecific binding was 
determined by the inclusion of 10 µM PK11195. Specific binding (in fmoles per mg 
protein incubated in each test tube) was defined as the difference between total and 
nonspecific binding (204). The reaction was terminated by the addition of ice-cold buffer 
in a vacuum cell harvester (Brandel, Gaithersburg, MD). All samples were run in 
duplicate. 
Immunohistochemical labeling and confocal microscopic quantification 
Immunostaining and laser confocal microscopic quantification was performed as 
described before (32, 126). Sections were stained with antibodies to GFAP (mouse 
monoclonal, DAKO, Carpinteria, CA), or CD68 (mouse monoclonal, DAKO), or SIV 
gp110 (a gift from Dr. Kelly Stephano-Cole and Dr. Ronald Montelaro) or MAP2 (SMI 
52; Sternberger Monoclonals Inc., Lutherville, MD) used at concentrations 1:500, 1:100, 
1:100 and 1:1000 respectively. Sections were then incubated with Cy5-conjugated goat 
 45 
anti-mouse or Cy3-conjugated anti-rabbit IgG at a concentration of 1:200 (Jackson 
Immunoresearch Laboratories Inc., West Grove, PA). Different anatomic regions were 
identified using a dissection microscope and marked on the slides. Immunostained 
sections were scanned and quantified on a laser confocal microscope (LSM 150, Zeiss, 
Heidelberg, Germany). This scope is equipped with an argon laser with 458 nm, 477 nm, 
488 nm and 514 nm primary emission lines. Each section was scanned along the z-axis to 
define the middle optical plane used in quantification (262,144 pixels/plane; 1 pixel= 
0.25 µm2). Image analysis was performed on a Silicon Graphics computer (Windows NT 
4.0 operating system, Microsoft, Redmond, Washington) using the LSM software 
(version 3.0, Zeiss). Scanning parameters such as laser power aperture, gain, and 
photomultiplier tube settings were kept constant for each wavelength.  
In each anatomic region, an individual blinded to the experimental design imaged 
10 areas (40X) encompassing 106,100 µm2. For each cell phenotype scanned, 
contribution to signal intensity from autofluorescence was minimized using a threshold 
that was kept constant. In each area the average pixel fluorescence along with the pixel 
counts for a given cell phenotype marker that exceeded the threshold were enumerated. 
The average pixel fluorescence was multiplied by the total number of pixels to measure 
the total florescence for that cell phenotype marker in that area. The total fluorescence 
values determined from the 10 scanned areas in one brain region were averaged to 
represent a measure of the cell phenotype in that brain region.  
To evaluate cellular localization of [3H](R)-PK11195 binding in SIVE brain 
tissue we combined immunostaining with autoradiography. Sections were first 
immunostained, subjected to autoradiography (see above) and then imaged on the 
confocal microscope. 
Statistical analysis  
Data were analyzed using PRISM software (Graphpad, San Diego, CA). Student’s t tests 
or one-way ANOVA tests with post-test Bonferroni correction and 95% confidence 
intervals were used to analyze data. Correlations using 95% confidence intervals were 
performed to quantify the relationship between PK11195 binding and macrophages or 
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astrocytes. Results from correlational analyses are represented by r, the Spearman’s 
coefficient. 
3.1.4 Results 
[11C](R)-PK11195 PET binding is higher in macaques that develop SIV 
encephalitis 
To test if PET imaging of macaques using [11C](R)-PK11195 correlates with the 
development of SIVE, we compared PET findings in SIVDB670 infected macaques 
immediately prior to sacrifice with neuropathological features. Our macaque cohort 
consisted of fourteen animals (six animals were CD8 T-cell depleted to compress the 
disease time course and eight were non CD8 T-cell depleted) (Table 1). Eleven of these 
macaques were imaged using 3D PET (Tables 1 and 2). Six of the eleven SIV infected 
macaques (four CD8 T-cell depleted and two non CD8 T-cell depleted macaques) 
demonstrated increased uptake and retention of [11C](R)-PK11195 with PET compared 
to the other macaques (p<0.03, Table 2 and Figure 5).  
Brain histopathology was assessed in all macaques after PET imaging. SIVE was 
defined by the presence of parenchymal and perivascular macrophages, multinucleated 
giant cells, microglial nodules and abundant macrophages that stained for the SIV 
envelope protein. The six macaques that demonstrated increased [11C](R)-PK11195 PET 
binding showed various degrees of SIVE (Table 2). Macaque 9231 showed some 
macrophage infiltration in the basal ganglia without other classical histopathological 
features of SIVE, which corresponded to a 29%, increase in [11C](R)-PK11195 specific 
binding in vivo in the basal ganglia (Table 2) and might represent a pre-encephalitic 
stage of disease. The remaining macaques either showed subtle inflammatory changes in 
the form of perivascular mononuclear cell infiltrates, or failed to show any significant 
abnormalities and were therefore considered non-encephalitic controls. These macaques 
showed marginal or no PET [11C](R)-PK11195 uptake and binding (Table 2). Increased 
[11C](R)-PK11195 specific binding in vivo correlated with the post mortem diagnosis of 
SIVE. 
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Figure 5 [11C](R)-PK11195 specific binding is higher in macaques that develop SIVE in vivo 
compared to SIV infected macaques that do not develop encephalitis. 
(A) Time Activity curve of [11C](R)-PK11195 specific binding in the mesial temporal lobe of non CD8 T-
cell depleted macaques imaged before necropsy. [11C](R)-PK11195 specific binding is represented as 
radioactivity concentrations summed over the scan frames and normalized to both the injected dose of 
[11C](R)-PK11195 and the body mass of the animal (%ID/g*kg, y-axis) and is plotted against time in 
minutes (x-axis). Macaques were then classified into SIV encephalitic (SIVE, n=2, black squares) and 
control SIV infected, non-encephalitic groups (SIV, n=4, clear triangles) based on histopathology 
(Table 2). [11C](R)-PK11195 specific binding determined prior to neuropathological evaluation was 
compared in these two macaque groups. SIVE macaques show increased [11C](R)-PK11195 retention 
and specific binding over time in the late scan frames (40-90 min) compared to SIV infected, non-
encephalitic macaques. Data was analyzed using students t test with 95% confidence intervals **, p< 
0.004, *, p< 0.03. 
(B) Representative horizontal-section parametric images of [11C](R)-PK11195 specific binding in SIV 
encephalitic (SIVE) and SIV infected, non-encephalitic (SIV) macaques. SIVE macaque brains show 
increased [11C](R)-PK11195 specific binding compared to SIV infected, non-encephalitic macaques. 
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Table 2 Increased [11C](R)-PK11195 binding in vivo corresponds to the presence of SIVE 
and increased [3H](R)-PK11195 binding in post mortem brain tissue. 
Macaque 
number 
PET binding value (% increase 
over control) 
Histopathology 
Post mortem tissue binding (% 
increase over control) 
1259 313  Severe SIVE 104 
2263δ 213  Mild SIVEδ NA 
2265 122  Moderate SIVE 71 
2266 174 Severe SIVE 37 
1220 55 Severe SIVE NA 
0222 39 Moderate SIVE NA 
9240 11 No encephalitis NA 
9244 0 No encephalitis NA 
9243 0 No encephalitis NA 
2229 NA No encephalitis 0 
9231* 29* No encephalitis* NA 
2233 NA 
No 
encephalitis 
9 
1260 0 
No 
encephalitis 
NA 
2264 NA 
No 
encephalitis 
1 
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Representative data obtained from the basal ganglia of fourteen SIV infected macaques (similar results 
were observed in other areas). Eleven SIV infected macaques were imaged with 3D PET using [11C](R)-
PK11195 prior to sacrifice, following which they were grouped into mild, moderate or severe SIV 
encephalitic (SIVE) or SIV infected, non-encephalitic (SIV) categories based on the histopathology 
(frequency of distribution of multinucleated giant cells, microglial nodules, abundant activated and SIV 
infected macrophages, perivascular chronic inflammation per 10X and 40X field in different brain regions). 
An increase in [11C](R)-PK11195 specific binding (represented as % increase in specific binding over 
controls) corresponded with the post mortem diagnosis of SIV encephalitis. Macaques that did not exhibit 
increased [11C](R)-PK11195 binding did not exhibit SIVE. ™Macaque 2263 showed a densely focal but 
low frequency of distribution of microglial nodules and macrophages and was classified as mild SIVE. 
*Macaque 9231 had macrophage (staining negative for SIV antigen) infiltration in the basal ganglia 
(without other histopathological features of SIVE, that might represent a pre-encephalitic state) may have 
resulted in the 29% increase in [11C](R)-PK11195 binding. NA- Not assessed. 
 
MRI imaging of the macaques 
Four macaques underwent head MRI with and without contrast administration. Each 
animal was scanned pre-infection and then at one month post-infection and the day 
before sacrifice. MRI findings were compared to histopathological findings at post 
mortem examination as described before. 
In these macaques, no structural abnormalities were observed in any of the scans 
at baseline pre-infection (Figures 6A and 6C). No qualitatively appreciable contrast 
enhancement was observed at any time in any animal. At autopsy the macaque without 
significant neuropathology and the macaque with mild SIVE (Figures 6A and 6B) 
showed no appreciable structural differences between pre- and post-infection scans with 
any of the MRI sequences. The macaques with moderate and severe SIVE showed no 
appreciable structural abnormalities at one month post-infection. Scans immediately prior 
to sacrifice, however, showed mild atrophy with ventricular dilatation (average increase 
in ventricular volume of 47% relative to pre-infection scans, data not shown) best 
appreciated with T-2 sequences (Figures 6C and 6D). 
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Figure 6 Comparison of pre and post infection MRI scans in SIVE macaques. 
 
Head MRI scans from 2 macaques pre-infection (left, A and C) and immediately before autopsy (right, B 
and D).  
(A,B) Images from a macaque that demonstrated mild SIVE at autopsy. No significant changes were 
observed between pre-infection and post infection images.  
(C,D) Images from a macaque that demonstrated severe SIVE at autopsy. Mild increase in CSF space and 
parenchymal atrophy were observed in the macaque. No contrast enhancement was observed in any 
brain at any time. 
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[3H](R)-PK11195 binding is higher in SIV encephalitic brain tissue 
To confirm increased PK11195 binding in SIVE macaques we used filtration binding and 
autoradiographic analyses to compare [3H](R)-PK11195 specific binding in SIVE brain 
tissue with controls. [3H](R)-PK11195 specific binding (per mg protein) was defined as 
the difference between total binding (determined by incubation of brain tissue with 1nM 
[3H](R)-PK11195) and nonspecific binding (determined by including 10µM PK11195). 
Specific binding was significantly higher in the frontal white and gray matter, basal 
ganglia and hippocampal areas of encephalitic macaques (p<0.004) compared to binding 
in these regions in SIV infected, non-encephalitic and non-infected macaque brain tissue 
(Figure. 7A and Table 2). The cerebellum and occipital cortex of encephalitic macaques 
did not show a significant difference in specific binding over these regions in control 
macaques (Figure. 7A). For autoradiography, frozen brain sections obtained from the 
frontal cortex were incubated with 1 nM [3H](R)-PK11195 with non-specific binding 
determined by the inclusion of 10 µM PK11195. SIVE brain tissue showed higher 
[3H](R)-PK11195 binding compared to the non-encephalitic control brain tissue (Figure 
8A-B).  [3H](R)-PK11195 binding in encephalitic tissue appeared more intense and 
corresponded to the distribution of microglial nodules (Figure 8A) in contrast to the 
diffuse, less intense binding seen in SIV infected, non-encephalitic tissue in all observed 
fields (Figure 8B). Increased [3H](R)-PK11195 specific binding in postmortem brain 
tissue also corresponded to an increase in [11C](R)-PK11195 binding in encephalitic 
macaques in vivo (Table 2).  
Increased PK11195 binding in SIVE macaques may be due to increases in PBR 
expression (Bmax/ binding sites) or due to alterations in receptor-PK11195 affinity (Kd). 
We used [3H](R)-PK11195 saturation binding experiments (range 0.5 nM to 80 nM) to 
compare the total number of binding sites (Bmax) and ligand affinity (Kd) in SIVE with 
SIV infected, non-encephalitic and non-infected controls. SIVE macaques showed a 
significant increase in [3H](R)-PK11195 binding sites (Bmax, Figure 7B) (p=0.009) with 
no significant difference in ligand affinity (Kd, Figure 7C) (p=0.488).  
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Figure 7 [3H](R)-PK11195 specific binding is higher in SIVE brain tissue compared to 
controls. 
A. [3H](R)-PK11195 specific binding (fmoles/mg protein, Y-axis) is higher in the frontal cortical white 
matter (FWM), frontal cortical gray matter (FGM), basal ganglia (BG) and hippocampus (HIP) in 
SIVE macaques (n=3, black bars) compared to non-infected controls (Con, n=2, clear bars) and SIV 
infected, non-encephalitic (SIV, n=3, hatched bars) macaques. No significant difference was seen in 
the cerebellum (CB) and the occipital cortex (OC). Data analyzed using one-sided ANOVA, **, p< 
0.0002, *, p< 0.004. 
B. [3H](R)-PK11195 (0.5nM to 80nM) saturation binding experiments indicate that increase in specific 
binding is due to an increase in total number of [3H](R)-PK11195 binding sites (Bmax, fmoles/mg 
protein, Y-axis) in SIVE (n=3, black bars) as compared to non-infected controls (Con, n=2, clear bars) 
and SIV infected, non-encephalitic (SIV, n=3, hatched bars) frontal cortical brain tissue. Data 
analyzed using one-sided ANOVA, **, p=0.009. 
C. Saturation binding experiments indicate no significant increase in [3H](R)-PK11195 binding affinity 
(Kd, nM, Y-axis) in SIVE (n=3, black bars) as compared to non-infected controls (Con, n=2, clear 
bars) and SIV infected, non-encephalitic (SIV, n=3, hatched bars) frontal cortical brain tissue. Data 
analyzed using one-sided ANOVA, p=0.488. 
 53 
 [3H](R)-PK11195 binding in SIV encephalitic brain tissue localizes to macrophages 
PBR is expressed mainly on astrocytes and brain macrophages (20, 45) and at lower 
levels in neurons (121).  We wanted to determine the relative contributions of these cell 
types to [3H](R)-PK11195 binding. We addressed this question in two ways. First, we 
combined immunostaining for astrocytes (GFAP) and activated macrophages (As a 
macrophage lysosomal marker, CD68 is increased on activation, and is useful to label 
activated macrophages/microglia) with [3H](R)-PK11195 autoradiography on frozen 
brain sections obtained from the frontal cortex of SIVE macaques. [3H](R)-PK11195 
binding in SIVE overlapped with regions rich in activated macrophages and microglial 
nodules (aggregates of macrophages) (Figure. 8C). [3H](R)-PK11195 binding did not 
overlap with GFAP labeled astrocytes in encephalitic brain tissue (Figure. 8D). 
Second, we tested whether [3H](R)-PK11195 binding in homogenized brain 
tissue correlated with the abundance of astrocytes or activated macrophages or neurons. 
Astrocytes, activated macrophages and neuronal elements were immunostained for 
GFAP, CD68 and MAP2 respectively, and quantified in SIVE and SIV infected, non-
encephalitic brain tissue using laser confocal microscopy by an individual blinded to the 
experimental design. Each cell type marker was then correlated with [3H](R)-PK11195 
filtration binding values obtained from the corresponding brain regions in the same 
macaques. Results of correlations are represented by Spearmen’s correlation coefficient r 
(Table 3). [3H](R)-PK11195 binding correlated with the abundance of CD68 stained 
activated macrophages (r = 0.5285, p= 0.0066) but not with the abundance of GFAP 
stained astrocytes (r = 0.1991, p = 0.2915) or with the abundance of MAP2 stained 
neuronal elements (r = 0.0709, p = 0.6767) (Table 3). 
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Figure 8 [3H](R)-PK11195 specific binding in SIVE corresponds to activated macrophages 
but not astrocytes. 
(A,B) [3H](R)-PK11195 autoradiograms (black grains) with light hematoxylin counter stain of sections 
from frontal cortex show higher specific binding in SIVE (8A) compared to SIV infected, non-
encephalitic macaques (8B). Arrow in A shows a region of numerous grains overlying a microglial 
nodule.  
(C,D) Combined [3H](R)-PK11195 autoradiography (green grains) and immunostaining for activated 
macrophages (C, CD68, Red) or astrocytes (D, GFAP, Red) in SIVE frontal cortex. [3H](R)-
PK11195 specific binding overlaps with CD68 (C) and not with GFAP (D) immunostaining.  
Arrowheads in (C) surround a microglial nodule, dotted line in (D) showing the lumen of a blood 
vessel and arrow in (D) showing astrocytic end processes (red). Vessels in SIVE are frequently 
surrounded by mononuclear infiltrates interdigitated between astrocytic processes in regions with 
abundant [3H](R)-PK11195 grains in green. Scale bar in microns. 
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[11C](R)-PK11195 binding in SIV encephalitis in vivo correlates with the presence 
of activated macrophages 
We correlated [11C](R)-PK11195 specific binding in vivo with the presence of 
astrocytes, activated macrophages or neuronal elements in selected brain regions of SIVE 
and SIV infected, non-encephalitic macaques. Astrocytes, activated macrophages and 
neurons were immunostained and quantified using laser confocal microscopy as above 
and compared to in vivo estimates of [11C](R)-PK11195 specific binding in the 
corresponding brain regions in the same macaques. [11C](R)-PK11195 binding 
correlated with the abundance of CD68 stained activated macrophages (r = 0.6424, p= 
0.0013) but did not correlate with the presence of astrocytes (r = -0.1692, p=0.5630) or 
neurons (r = 0.0574, p = 0.563)  (Table 3).   
 
Table 3 [3H](R)-PK11195 binding in post mortem tissue and [11C](R)-PK11195 binding in 
vivo correlate with immunostaining for activated macrophages but not astrocytes. 
 
Spearman’s coefficient (r) with 
[3H](R)-PK11195 binding in post mortem tissue.
Spearman’s coefficient (r) with 
[11C](R)-PK11195 binding in vivo. 
Activated 
macrophages (CD68) 
Astrocytes 
(GFAP) 
Activated 
macrophages (CD68) 
Astrocytes 
(GFAP) 
0.5285** 0.1991 0.6424 ** -0.1692 
 
Activated macrophages and astrocytes were quantified by immunostaining for CD68 (lysosomal 
marker for activated macrophages) and GFAP (astrocytic marker) in the frontal cortex, basal ganglia, 
hippocampus, cerebellum and occipital cortex of SIVE (n=3) and SIV infected, non-encephalitic (n=3) 
macaques, using confocal laser microscopy. Each cell phenotype marker was then correlated with [3H](R)-
PK11195 binding in post mortem tissue or [11C](R)-PK11195 PET binding in vivo in the corresponding 
brain regions in the same macaques. PK11195 binding in post mortem tissue and in vivo correlated with 
activated macrophages but not astrocytes, **p<0.006. 
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 3.1.5 Discussion 
We examined binding of the PBR ligand PK11195 in a macaque model of HIV 
encephalitis. In vivo ligand binding was assessed using [11C]-labeled (R)-PK11195 with 
PET in SIV infected macaques. Out of eleven-imaged SIV infected macaques, six 
showed higher levels of [11C](R)-PK11195 binding (Figure 5 and Table 2). Increased 
binding corresponded to the presence of SIV encephalitis on post mortem examination 
(Table 2). Macaques that did not show an increase in [11C](R)-PK11195 binding did not 
exhibit SIVE (Table 2). In four macaques comparison of MRI before infection and two 
months after infection showed mild brain atrophy and increase in ventricular size only in 
the moderate to severe SIVE cases (Figure 6 and data not shown).  Brain post mortem 
[3H](R)-PK11195 binding was significantly higher in SIVE macaques from controls due 
to an increase in the number of binding sites (Bmax) with no significant changes in 
binding affinity (Kd) (Figure 7) and correlated with in vivo binding measured with PET 
just before sacrifice (Table 2 and data not shown). Brain regions with elevated PK11195 
binding on PET and filtration assays correlated with abundant activated macrophages but 
not with activated astrocytes or neurons quantified by laser confocal microscopy (Table 
3). Finally, combined autoradiography and immunostaining identified macrophages, but 
not astrocytes as the cells with highest [3H](R)-PK11195 binding (Figure 8). 
Our study involves the use of two different species of macaques utilizing two 
different protocols (with and without CD8 T-cell depletion) to induce disease. While this 
is a limitation based on macaque availability and continual evolution of the primate 
model, baseline pre-infection PET studies in animals of the two different species did not 
indicate significant differences (Average PET [11C](R)-PK11195 binding in the basal 
ganglia of Rhesus macaques: 0.06±0.01 %ID/Kg*g versus Pigtail macaques: 0.08±0.02 
%ID/Kg*g, p=0.217. Similarly, other brain regions including the frontal cortex, 
cerebellum, occipital cortex and hippocampus showed no significant differences between 
the two species). Thus data from all control animals were grouped together. However, we 
cannot rule out the possibility of differences resulting from species in the extent of CNS 
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disease. Further, it has been suggested the CD8 T-cell depletion results in an increase in 
the severity of CNS disease by Williams and Hickey (256) and this was the impetus to 
our using this model. Preliminary histopathological comparisons of our two groups of 
animals did not indicate any major differences (Table 2). However, we are unable to 
draw any conclusions regarding this issue due to the small number of CD8 T-cell 
depleted macaques used in this study. 
In the frontal cortex, mesial temporal lobe and the basal ganglia of SIVE 
macaques [3H](R)-PK11195 binding in post mortem tissue correlated with PET 
[11C](R)-PK11195 binding in vivo (Table 2 and data not shown). In the cerebellum and 
occipital cortex PET [11C](R)-PK11195 binding showed significant increases which we 
did not see in post mortem tissue (Figures 5, 7 and data not shown). Further, while 
macaque 2263 showed 213 percent increase in PET binding from control in the basal 
ganglia, it demonstrated mild but densely focal encephalitis on postmortem examination 
in this region. These discrepancies may be due to differences in resolution and sampling 
size between PET, post mortem tissue-filtration binding analyses, and histopathological 
assessment. Neuropathological studies are performed on a section of a given brain region 
and post mortem binding analysis is restricted to a small mass of brain tissue (~100 mg) 
in contrast to larger regions of the brain involved in PET analyses with more limited 
spatial resolution. However, in both post mortem tissue and in vivo PET, PK11195 
binding closely correlated with the histopathological abundance of macrophages (Table 3 
and Figure 8).  
Comparing pre-infection MRI scans with scans at autopsy in four infected 
macaques showed mild atrophy with ventricular dilatation only in macaques with 
moderate and severe SIVE. The macaque with mild SIVE did not show any structural 
changes on comparing pre- and post- infection scans but showed regional increases in 
vivo PK11195 binding corresponding with macrophage infiltration. This suggests that 
PET [11C](R)-PK11195 imaging may be more sensitive than structural MRI in assessing 
neurologic disease in SIVE, although all of the eleven PET scanned macaques were not 
imaged using MRI.  
 The distribution of lesions in SIVE is multifocal without a prominent or 
consistent neuroanatomical distribution (32). This diffuse and multifocal distribution 
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hinders identification of a consistent reference region for application of PET reference-
tissue based analyses. To overcome this issue, the segmentation of dynamic PET images 
into clusters of image voxels with similar concentration time-activity curves has been 
proposed as a viable means to extract a reference ligand kinetic without a priori 
knowledge of the brain distribution of PBR sites (109). This reference kinetic, though not 
necessarily derived from a uniform brain region, has been demonstrated to be capable of 
providing a reasonable estimate of free and non-specific binding and has been 
successfully employed in the study of multiple sclerosis patients with [11C](R)-PK11195 
(20).  
Although all macaques with increased [11C](R)-PK11195 binding showed 
encephalitis, the percent increase in [11C](R)-PK11195 binding from controls was higher 
in CD8 T-cell depleted SIVE macaques (174% - 313%) vis-à-vis the non-CD8 T-cell 
depleted macaques (39-55%) (Table 2). These two groups of encephalitic macaques did 
not show significant neuropathological differences (Table 2). We attribute this 
discrepancy to the incommensurability of the two parameters used to estimate specific 
binding. In the non-CD8 T-cell depleted animals, a semi-quantitative measure of 
[11C](R)-PK11195 binding was defined to be the regional brain radioactivity 
concentration summed over the late scan frames (Figure 5: 40-90 minutes post-injection) 
and normalized to both the injected dose of [11C](R)-PK11195 and the body mass of the 
animal (%ID/Kg*g). In contrast [11C](R)-PK11195 specific binding in the CD8 T-cell 
depleted animals was determined using each macaque’s regional baseline (pre-infection) 
[11C](R)-PK11195 time-activity curve as the reference kinetic for regional post-infection 
assessments based on the reference-Logan graphical analysis method (20, 108, 138). 
Because the reference tissue kinetic provides an estimate of both free and nonspecifically 
bound radiotracer, the binding potential parameter derived by this method of analysis 
from the CD8 T-cell depleted macaques represents a more accurate measure of specific 
binding. This is in contrast to the more qualitative estimates of specific binding (regional 
brain radioactivity concentrations without subtraction of the free and non specific 
binding) obtained over the summed late PET scan frames from the first group of non-
CD8 T-cell depleted macaques.  
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We also found that in the CD8 T-cell depleted group, normalized regional brain 
radioactivity concentrations (%ID/kg*g) were considerably more variable than in non-
CD8 depleted animal (data not shown). Such a discrepancy could be explained by 
differences in systemic infection with variation in non-CNS macrophage proliferation and 
subsequent specific binding of [11C](R)-PK11195 outside the CNS. Such sites of 
systemic binding of [11C](R)-PK11195 could be expected to decrease the partitioning of 
the ligand in the brain with a varying proportion of the injected dose being taken up into 
these non CNS sites of systemic infection.  
A recent report by Lockhart et. al.(145) has shown that the concentration of PBR 
sites in the whole blood of healthy human volunteers to be on the order of 10nM, with 
approximately 85% of the ligand bound in plasma and 15% bound to blood cells. These 
investigators demonstrated that [11C](R)-PK11195 binds with high affinity to α1-acid 
glycoprotein (AGP), which is present in varying degrees in serum. It is possible that 
binding of [11C](R)-PK11195 to AGP is higher with CD8 T-cell depletion in SIV 
infection, contributing to the unstable kinetic behavior of [11C](R)-PK11195 in plasma. 
Future studies defining an arterial input function for the injected PK11195 might clarify 
these modeling problems.  
 Our results in SIVE are in accordance with previous reports where PK11195 
binding (as determined using post mortem tissue and PET) has been used as a marker for 
brain macrophages and a surrogate marker for neuronal damage (42, 151). To determine 
if PK11195 binding correlated better with SIV infected macrophages, we correlated 
PK11195 binding with SIV antigen gp110 quantified using immunostaining in selected 
brain regions of SIV infected macaques. The abundance of the viral antigen varied in 
different regions of the brain, consistent with the multifocal nature of the disease (32, 97). 
Regions with high viral antigen showed high PK11195 binding, but, high PK11195 
binding was also seen in regions that did not show high viral antigen (data not shown), 
thus correlating better with activated macrophages. This is presumably due to the more 
general distribution of activated macrophages in SIV encephalitis than viral infection, 
which is more multifocal (32, 97). Our findings support the hypothesis that PK11195 
binding may be a surrogate marker of activated macrophages and active loci of 
neurodegenerative disease in lentivirus encephalitis. 
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Our results in SIV infected macaques show that PET assessment of [11C](R)-
PK11195 binding can distinguish macaques with and without SIV encephalitis (defined 
at post mortem analysis) in vivo. We are currently conducting serial PET experiments in 
SIV infected macaques to determine the earliest time period where this distinction can be 
made. Importantly, our macaque data can be extended to PET studies in HIV-infected 
humans. One in four late-stage AIDS patients is afflicted by HIV encephalitis in the 
absence of opportunistic infections (37). Its clinical diagnosis requires the presence of 
irreversible clinical symptoms and signs. Traditional imaging studies such as CT and 
MRI have not been of much assistance in the diagnosis of AIDS dementia and dementia 
in general (66). Current methodologies, such as structural MRI assessment of brain 
volume are insensitive late measures of neurological damage and the diagnosis by 
neurocognitive tests is possible only after irreversible neuronal damage has occurred. 
Effective therapy requires early intervention at the onset of neuronal injury prior to the 
appearance of irreversible signs and symptoms. PET imaging of macrophages in HIV 
encephalitis before the onset of signs and symptoms may enable early diagnosis and 
therapeutic interventions. 
To design therapies for neurodegenerative disorders, it is critical to be able to 
monitor their success in arresting the progression of neurological disease. Monitoring 
therapeutic efficacy of any such treatments is also complicated by the fact that one can 
only assess absence of disease progression and not recovery of function. Any attempt to 
develop therapy for AIDS dementia will require some means of monitoring the primary 
pathogenic process, activated macrophages. Issues of CNS drug penetrance and the 
absence of good markers of treatment effectiveness complicate monitoring the course of 
HIV encephalitis. Imaging macrophages may provide a better index of disease 
progression during treatment with antiretroviral and other potentially neuroprotective 
drugs. [11C] (R)-PK11195 PET imaging of macrophages may be able to help in the early 
prediction of HIV encephalitis, monitor the severity and progression of the disease, and 
help evaluate the effectiveness of CNS therapies. 
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 3.2 THE PERIPHERAL BENZODIAZEPINE RECEPTOR IS SPECIFICALLY 
INCREASED IN MACROPHAGES IN A PI3-KINASE DEPENDENT FASHION 
IN HIV ENCEPHALITIS 
 
3.2.1 Abstract 
HIV encephalitis is a neurodegenerative disease seen in approximately one in four 
terminally infected patients. Macaques infected with the simian immunodeficiency virus 
develop encephalitis (SIVE) very similar to the human disease. Neurodegeneration in 
both these conditions is hypothesized to occur mainly from the effects of toxins derived 
from HIV infected and activated brain macrophages. Our goal is to label brain 
macrophages in vivo by taking advantage of potential increases in the peripheral 
benzodiazepine receptor in these cells. Using the peripheral benzodiazepine receptor 
specific ligand PK11195, we have previously shown increases in the peripheral 
benzodiazepine receptor in the SIVE model. In this report, we show that human brain 
tissue derived from HIV encephalitis shows similar increases in binding compared to 
controls with the peripheral benzodiazepine receptor ligands [3H](R)-PK11195 and 
[3H](R)-DAA1106. We further dissect out the cell specific contributions to increased 
PK11195 binding by reporting that primary human macrophage cultures show an 
increases in [3H](R)-PK11195 and [3H](R)-DAA1106 binding on activation with 
lipopolysaccaride or interferon-γ. Macrophages infected with HIV-1 ADAM show an 
increase in [3H](R)-PK11195 binding, which peaks at 14 days post infection. Astrocyte 
cultures treated with LPS or activated with dibutyryl Cyclic AMP or treated with 
supernatants derived from HIV-infected macrophages do not show a significant change in 
ligand binding. Finally, increases in [3H](R)-PK11195 binding on activation with LPS in 
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macrophage cultures is reversed on blocking the PI3K/Akt pathway, but is not affected 
by blocking the MEK-1/2 MAP-kinase pathway. Our results suggest that activated and 
HIV-infected macrophages in HIVE show increased [3H](R)-PK11195 binding due to 
specific increases in [3H](R)-PK11195 binding in a PI3K/Akt dependent fashion. 
3.2.2 Introduction 
About 25% of immunosuppressed patients infected with HIV develop a 
neurodegenerative syndrome clinically diagnosed as HIV-associated dementia (3, 38, 57, 
74, 158). This syndrome is characterized by cognitive impairments, motor abnormalities 
and behavioral symptoms (98, 198, 201). HIV encephalitis is considered to be the 
pathological substrate of HIV associated dementia (252). HIVE is characterized by the 
presence of microglial nodules, multinucleated giants cells formed by fusion of HIV 
infected macrophages, and abundant HIV-infected and activated macrophages (39). 
Macrophage elements (including brain microglia and infiltrating macrophages, hence 
forth referred to as macrophages) constitute the cell type productively infected with HIV 
in the brain (255). Macrophages are hypothesized to be central to neurodegeneration as 
the sources of virus and toxic substances that initiate synaptic damage and neuronal death 
(128).  
The macaque model for HIVE closely resembles the human disease. Like 
humans, only a percentage (dependent on the species) of macaques infected with Simian 
Immunodeficiency Virus (SIV) will develop encephalitis that is very similar to HIVE 
(24, 137). We have previously shown that brain tissue derived from SIVE macaques 
shows higher peripheral benzodiazepine receptor (PBR) expression, as measured by 
binding with a PBR specific ligand PK11195. Increased PK11195 binding has been 
reported in several studies including multiple sclerosis and experimental autoimmune 
encephalitis (20, 69, 246), stroke (231), brain trauma (204), Rasmussen’s encephalitis 
(18), Herpes encephalitis (41), Alzheimer’s disease (41) and Multiple System Atrophy 
(95). In the normal brain, PBR is expressed on astrocytes and brain macrophages in low 
levels, and is hypothesized to specifically increase in brain macrophages in response to 
pathology (17). In this study we examine the relative contributions of astrocytes and 
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macrophages to increases in PBR in the context of HIV encephalitis. We utilize PK11195 
and DAA1106, a newer ligand that binds to PBR with high affinity (47), to show 
increased ligand binding in HIVE. Using primary human macrophage and astrocytes 
cultures, we show increased [3H](R)-PK11195 and [3H]-DAA1106 in activated 
macrophage cultures and HIV-infected macrophage cultures, but not in activated 
astrocytes cultures or astrocytes cultures exposed to HIV. Finally, we show that increased 
[3H](R)-PK11195 binding in macrophages is dependent on activation of the PI3K/Akt 
pathway. Our results suggest that PBR expression is increased specifically in activated 
and HIV infected macrophages in a PI3K/Akt dependent fashion in HIVE. 
3.2.3 Methods 
Human postmortem tissue 
Postmortem brain tissue was obtained from HIV-infected patient and age matched 
controls from the University of Pittsburgh brain bank. HIVE was defined on 
neuropathologic analysis by the presence of microglial nodules; multinucleated giant cell 
and HIV infected macrophages defined by the staining for the viral protein gp41. Five 
cases were defined as HIVE and six cases as HIV infected without encephalitis using 
these criteria. Brain tissue from three non-infected, age-matched controls were included 
as additional controls. Brain tissue from the fontal cortex was dissected out from each of 
these cases and used in filtration binding experiments.  
Macaque model of HIVE 
Archival tissue was obtained from Rhesus macaques that were infected with 
SIVDeltaB670 that developed encephalitis. Tissue obtained from animals that did not 
develop encephalitis served as controls. Histopathologic criteria used for HIV infected 
human tissue were also applied to macaque tissue. Archival frozen brain tissue from the 
frontal cortex of three SIVE, three SIV infected non encephalitic and two non-infected 
macaques were dissected out and used for saturation binding experiments and 
autoradiography. 
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Tissue culture experiments 
Human peripheral blood mononuclear cells (PBMC) were isolated freshly from HIV and 
Hepatitis B seronegative buffy coats obtained from the blood bank (Central Blood Bank, 
Pittsburgh, PA), using histopaque (Sigma, St. Louis, MO). PBMC were counted and 
plated in T-150 flasks (Corning, NY) at a density of 75 x 106 per ml. PBMC were grown 
for 5 days in complete medium consisting of AIM-V medium (Gibco BRL, Grand Island, 
NY), 10% heat inactivated-fetal calf serum (Gibco BRL, Grand Island, NY) and 1% 
penicillin-streptomycin (Gibco BRL, Grand Island, NY). Non-adherent cells were 
washed thoroughly after 5 days and adherent macrophages were cultured for an 
additional two days in complete medium. Macrophage cultures were activated with either 
1µg/ml LPS (Sigma, St. Louis, MO) or 300 units of interferon-γ (Sigma, St. Louis, MO)  
for 48hrs (29). Primary macrophage cultures were infected with HIV-1 ADAM for 24 hrs 
following which cells were washed thoroughly. Infected macrophage cultures were 
harvested at 7, 14 and 21 days post infection. HIV-1 p24 levels using ELISA (Beckman 
Coulter Inc., Fullerton, CA) were assessed to confirm productive HIV-infection in 
macrophage and astrocyte (described below) cultures.  
Primary human embryonic brain cultures. 
Brain tissue was gathered according to the standards of the University of Pittsburgh 
ethics and biosafety guidelines. Human fetal brain tissue was washed thrice and minced 
in ice cold DMEM F12 medium (Gibco BRL, Grand Island, NY), incubated in 0.05% 
trypsin-EDTA (Gibco BRL, Grand Island, NY) for 30 minutes and then triturated with 
graded pasture pipettes to get tissues into single cell suspension. The cell suspension was 
then filtered serially through 100 µm, 70 µm and 40 µm microfilters (Fischer scientific) 
and plated in T-150 tissue culture flasks (Corning, NY) at a density of 7 X 106 cells per 
flask in DMEM with 10 % human serum and 1% penicillin-streptomycin. Shaking the 
cultures overnight at 200 rpm separated Microglial cells out. Astrocytes were then 
passaged thrice and purity of cultures was determined to be between 98-99% by staining 
with GFAP. Mitochondrial extracts were obtained from primary human macrophages and 
astrocytic cultures utilizing a kit according to guidelines provided by the manufactures 
(Pierce, Rockford, IL). 
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Filtration radioligand binding assays 
Tissue was weighed and homogenized in ice-cold 50 mM HEPES buffer (pH 7.4). 
Homogenates were washed four times by centrifugation at 40,000 g for 20 min at 40C. 
Protein values were determined in each sample by the BCA protein assay kit (Pierce, 
Rockford, IL). [3H]-DAA1106 was custom synthesized and was of specific activity 80 
Ci/mmol (American Radiolabeled Chemical, St Lousi, MO). Mitochondrial extracts were 
incubated with 1nM [3H]-DAA1106 and nonspecific binding was excluded by the 
inclusion of 1µM DAA1106. Saturation binding experiments were performed by 
incubating tissue (total protein concentration ranging from 150 to 200 µg) with 0.5-64 
nM [3H](R)-PK11195 (sp. Act., 89.9 Ci/mmol; NEN Life Sciences Products, Boston, 
MA) or 0.2-20 nM [3H]-DAA1106 at 40C for 2 hr in a final volume of 250 µl of HEPES. 
Nonspecific binding was determined by the inclusion of 10 µM PK11195 or 10 µM 
DAA1106 respectively in saturation binding experiments. The reaction was terminated 
by the addition of ice-cold buffer in a vacuum cell harvester (Brandel, Gaithersburg, 
MD). All samples were run in duplicate. Bmax in fmoles per mg protein and kd in nM 
were determined using PRISM software (Graphpad, San Diego, CA).  
Autoradiography 
Autoradiography was performed as described earlier (245). Briefly, 15 µm thick frozen 
sections obtained from the frontal cortex were placed on SuperfrostTm glass slides 
(Sigma, St Louis, MO) and incubated in ice-cold 50 mM TRIS-HCl (pH 7.4) containing 1 
nM [3H](R)-DAA1106 (Sp. Act., 80 Ci/mmol; American Radiolabeled Chemical, St 
Lousi, MO) for 30 min. Specificity of binding was ensured by the inclusion of 1 µM 
DAA1106 in parallel sections. The sections were mounted with a layer of 
autoradiographic LM-1 emulsion (Amersham, UK), following which they were 
developed after 4 weeks and imaged on the confocal microscope.  
Statistical analysis  
Data were analyzed using PRISM software (Graphpad, San Diego, CA). Student’s t tests 
or one-way ANOVA tests with post-test Bonferroni correction and 95% confidence 
intervals were used to analyze data.  
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 3.2.4 Results 
[3H](R)-PK11195 and [3H](R)-DAA1106 binding is higher in HIVE compared to 
controls 
We used saturation filtration binding to compare [3H](R)-PK11195 and [3H]-DAA1106 
specific binding, reflective of PBR expression, in HIVE with age-matched controls. Brain 
tissue from the frontal cortex was dissected from five cases of HIVE; six HIV-infected 
non-encephalitic controls and three age-matched controls. HIVE in postmortem tissue 
was defined by the presence of microglial nodules; multinucleated giant cells and HIV 
infected macrophages defined by the staining for the viral protein gp41. Tissue was 
homogenized and incubated with 0.5-64 nM [3H](R)-PK11195 or 0.2-20 nM [3H]-
DAA1106 to obtain total binding values. Nonspecific binding was determined in parallel 
by including 10µM PK11195 or 10µM DAA1106 respectively. Specific binding at each 
given concentration of  [3H]-ligand was defined as the difference between total binding 
and nonspecific binding. Bmax and kd values reflective of the total number of binding 
sites per mg protein and binding affinity of ligand to PBR respectively were determined 
using PRISM software.  
Bmax was significantly higher in the frontal cortex of HIVE brain tissue 
compared to HIV-infected non-encephalitic and non-infected controls assessed with both 
[3H](R)-PK11195 (p=0.0006) and [3H]-DAA1106 (p=0.0003) (Figure 9, A and C). The 
affinity of either ligand to PBR reflected by the kd did not differ between HIVE and 
controls (Figure 9, B and D).  
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Figure 9 HIVE brain tissue shows increased [3H](R)-PK11195 and [3H]-DAA106 binding 
compared to controls 
Filtration binding was assessed in frontal cortical brain tissue obtained from 5 HIVE, 6 HIV infected non-
encephalitic (HIV) and 3 age matched controls. The Bmax, reflective of the total number of binding sites is 
shown in the left panel (A & C) and the kd reflective of the binding affinity of the ligand to PBR is shown 
in the right panel (B & D). Data analyzed using one-sided ANOVA. 
 (A, B) Bmax with [3H](R)-PK11195 was significantly higher in HIVE compared to controls (A), 
p=0.0006. The kd was not significantly different between HIVE and controls (B), p=0.2293. 
(C, D) Bmax with [3H]-DAA1106 was significantly higher in HIVE compared to controls (C), p=0.0003. 
The kd was not significantly different between HIVE and controls, (D) p=0.0712. 
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  [3H](R)-PK11195 and [3H]-DAA1106 binding is higher in activated macrophages 
compared to controls. 
Since PBR is expressed on both astrocytes and brain macrophages (20, 45), we wanted to 
compare the relative changes in PBR binding in both cell types on activation. Primary 
human macrophages and primary human embryonic astrocytes were cultured for 5 days 
and 14 days respectively. Macrophage cultures were activated with 1 µg/ml LPS or 300 
IU/ml interferon-γ for 48 hrs. TNF-α secretion was assessed using ELISA to confirm 
activation (data not shown). Activated macrophages also displayed a change in 
morphology from a more rounded to a spindle like morphology (Figure 10 B and D) 
compared to controls (Figure 10 A and C). Primary human astrocytes were activated 
with dibutyryl cyclic AMP (dCAMP) 100 µM as described in the literature (188). 
Activation in astrocytes was assessed by changes from a flat morphology (Figure 10 E 
and G) to cells that displayed multiple processes (Figure 10 F and G). Astrocytes 
treated with 1 µg/ml LPS for 48 hrs served as an addition control. Saturation binding 
experiments were conducted on homogenized cells using [3H]-PK11195. Bmax, 
reflective of PBR expression, was significantly higher in macrophages activated with 
either LPS or interferon-γ, compared to non-activated macrophages, dCAMP activated 
astrocytes, LPS treated astrocytes and control astrocytes (p<0.0001) (Figure 11 A). 
Affinity of [3H](R)-PK11195 to PBR reflected by the kd did not significantly change in 
any of these conditions (Figure 11 B). 
Since PBR is a mitochondrial receptor, we assessed [3H]-DAA1106 binding in 
mitochondrial extracts derived from control macrophages, macrophages activated with 1 
µg/ml LPS for 48 hrs, control astrocytes and astrocytes activated with 100 µM dCAMP. 
Mitochondrial extracts were incubated with 1 nM [3H]-DAA1106 and non-specific 
binding was excluded by the inclusion of 1 µM DAA1106. Mitochondrial extracts 
derived from LPS activated macrophages showed significantly higher binding compared 
to macrophage and astrocyte controls (p=0.0008) (Figure 11 C) 
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Figure 10 Primary human macrophages and human embryonic astrocytes activated with 
LPS and dCAMP respectively. 
(A-D) Primary human macrophages were cultured for 5 days and activated with 1 µg/ml LPS for 48 hrs. 
(A-B) Macrophages cultures were stained with CD68 (red), (C-D) Phase contrast images of 
macrophages. On activation with LPS, macrophages show and increase in CD68 staining (B), and 
changes in morphology (D), compared to non-stimulated cultures (A) and (C). 
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(E-H) Primary human embryonic astrocytes were cultured for 14 days and activated with 100 µM dCAMP 
for 48 hrs. (E-F) Astrocyte cultures were stained with GFAP (green) and vimentin (red), (C-D) 
Phase contrast images of astrocytes. On activation with dCAMP, astrocytes show changes in 
morphology with the appearance of several spindle shaped processes (F & H), compared to non-
activated cultures (E & H).  
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Figure 11 Activated macrophages show higher binding with [3H](R)-PK11195 and [3H]-
DAA106 when compared to controls. 
 
(A, B) Filtration binding was assessed in primary human macrophages (denoted by MDM, monocyte 
derived macrophages) and primary human astrocyte cultures with [3H](R)-PK11195. Macrophage 
(MDM) cultures were activated with LPS (1µg/ml) or INF-γ (300U/ml) for 48 hrs. Astrocytes were 
treated with LPS (1µg/ml) or activated with dCAMP (100 µg/ml) for 48 hrs. The Bmax, reflective 
of the total number of binding sites is shown in the upper panel and was found to be significantly 
higher (p<0.0001) in macrophages (MDM) activated with either LPS or INF-γ compared to non-
activated controls, astrocytes activated with dCAMP, non-activated astrocytes or astrocytes treated 
with LPS (A). The kd reflective of the binding affinity of the ligand to PBR is shown in the right 
panel and did not differ in all the conditions (p=0.3963) (B). Data analyzed using one-sided 
ANOVA. 
 (C)   [3H]-DAA1106 binding using 1nM of the ligand (non-specific binding was excluded by 1µM 
DAA1106) was determined in mitochondrial preparations from the above conditions. [3H]-
DAA1106 binding was significantly higher in mitochondrial preparations obtained from 
macrophages (MDM) activated with LPS compared to controls, p=0.0008. 
[3H](R)-DAA1106 binding in SIV encephalitic brain tissue localizes to macrophages 
Our in vitro data suggesting increases in PBR-ligand binding in macrophages were 
confirmed in brain tissue obtained from SIVE macaques. We compared [3H]-DAA11106 
binding in frontal cortical tissue obtained from SIVE (n=3) with SIV infected no-
encephalitic tissue (n=3) and non-infected macaques (n=2). [3H]-DAA1106 binding was 
significantly higher in SIVE compared to controls (Figure 12 A). For autoradiography, 
frozen brain sections obtained from the frontal cortex were incubated with 1 nM [3H]-
DAA11106 with non-specific binding determined by the inclusion of 1 µM DAA1106. 
SIVE brain tissue showed higher [3H]-DAA1106 binding compared to the non-
encephalitic control brain tissue (Figure 12 D-C).  [3H](R)-PK11195 binding in 
encephalitic tissue appeared more intense and corresponded to the distribution of 
microglial nodules (Figure 12 D) in contrast to the diffuse, less intense binding seen in 
SIV infected, non-encephalitic tissue in all observed fields (Figure 12 C). 
Autoradiography with [3H]-DAA1106 combined with immunohistochemistry on frozen 
brain sections obtained from the frontal cortex of SIVE macaques showed [3H]-
DAA1106 binding overlapping with regions rich in activated macrophages and microglial 
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nodules (stained with CD68) (Figure 13 B, D & E) [3H]-DAA1106 binding did not 
overlap with GFAP labeled astrocytes in encephalitic brain tissue (Figure 13 A, D & E) 
 
Figure 12 [3H]-DAA1106 binding is significantly higher in SIVE compared to controls. 
(A, B) Filtration binding with [3H]-DAA1106 was assessed in frontal cortical brain tissue obtained from 3 
SIVE, 4 SIV infected non-encephalitic (SIV) and 3 non-infected controls. The Bmax, reflective of 
the total number of binding sites was significantly higher in SIVE compared to controls (p=0.0038) 
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(A). The kd reflective of the binding affinity of the ligand to PBR did not significantly differ 
amongst the three conditions (p=0.2492). Data analyzed using one-sided ANOVA. 
(C, D) [3H]-DAA1106 autoradiograms (black grains) of sections from frontal cortex show higher specific 
binding in SIVE (C) compared to SIV infected, non-encephalitic macaques (D).  
E D 
C B A 
 
 Figure 13 [3H]-DAA1106 binding corresponds to activated macrophages, but not 
astrocytes  
 
(A-E) Sections obtained from the frontal cortex were stained with GFAP (Blue, A), processed for 
autoradiography with [3H]-DAA1106 (Black grains, B) and immunostained to label either nuclei 
with DAPI (Red, C) or activated macrophages with CD68 (Green C). Panel E shows a merged 
image of all the markers. [3H]-DAA1106 specific binding overlaps with CD68 and not with GFAP 
immunostaining.  
 [3H](R)-PK11195 binding is higher in HIV-1 infected macrophages compared to 
controls. 
Primary macrophage cultures were infected with HIV-1 ADAM for 7, 14 and 21 days. 
Supernatants were collected at each of these time points and HIV-1 p24 levels were 
determined to assess productive HIV infection (data not shown). Supernatants derived 
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from macrophage cultures at 14 days post infection were used to treat primary astrocyte 
cultures. Saturation binding experiments with [3H](R)-PK11195 were performed on 
macrophage homogenates and at each of these post-infection time points and astrocyte 
cultures treated with macrophage supernatants. We found significant increases in Bmax, 
reflective of PBR expression, in HIV-1 ADAM infected macrophages at 7, 14 and 21 
days post infection compared to non-infected controls and astrocytes treated with HIV-
infected macrophage supernatants (Figure 14 A). We also found that the kd was 
significantly higher in HIV-1 infected macrophages at all time points post infection 
(Figure 14 B). 
Increased [3H](R)-PK11195 binding in LPS activated macrophages is mediated by 
PI3K 
We sought to determine the cellular signaling pathways that mediate increased [3H](R)-
PK11195 binding in macrophages. Macrophages were pretreated with either the PI3-
kinase inhibitor LY294002 (10µM) or the MAP-kinase inhibitor U0126 (10µM) for two 
hours after which they were activated with LPS for 48 hrs. Inhibition of PI3-kinase but 
not MAP-kinase reversed LPS induced increase in [3H](R)-PK11195 Bmax (Figure 15 
A). The kd remained unchanged with either treatment (Figure 15 B). 
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Figure 14 [3H](R)-PK11195 binding is increased in HIV infected macrophages. 
Filtration binding was assessed in primary human macrophages (denoted by MDM, monocyte derived 
macrophages) and primary human astrocyte cultures with [3H](R)-PK11195. Macrophage (MDM) cultures 
were infected with HIV-1 ADAM for 7, 14 or 28 days. Astrocytes were treated with supernatants derived 
from macrophage cultures infected for 14 days with HIV-1 ADAM. 
(A) The Bmax, reflective of the total number of binding sites is shown in the upper panel and was found to 
be significantly higher (p<0.01) in macrophages (MDM) infected for 7, 14 and 21 days compared to 
uninfected controls. Astrocytes treated with supernatants derived from macrophage cultures infected 
for 14 days with HIV-1 ADAM, did not show any difference from controls (P=0.2403). Data analyzed 
using one-sided ANOVA. 
 (B) The kd, reflective of the binding affinity of the ligand to PBR is shown in the lower panel and was 
significantly higher (p<0.05) in macrophages (MDM) infected for 7, 14 and 21 days compared to 
uninfected controls. Astrocytes treated with supernatants derived from macrophage cultures infected 
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for 14 days with HIV-1 ADAM, did not show any difference from controls (P=0.3315). Data analyzed 
using one-sided ANOVA. 
 
Figure 15 Pharmacologic inhibition on the PI3-Kinase pathway with LY29002 reverses LPS 
mediated increase in [3H](R)-PK11195 binding in macrophages. 
Filtration binding with [3H](R)-PK11195 was assessed in primary human macrophages (MDM) activated 
with 1µg/ml LPS for 48 hrs pretreated for 3 hrs with 10µM of the PI3-kinase pathway inhibitor LY294002 
or 10µM of the MEK-1/2 inhibitor U0126.  
(A) LPS mediated increase in Bmax (reflective of the total number of binding sites) was reversed by the 
PI3-kinase pathway inhibitor LY294002 but not the MEK-1/2 inhibitor U0126, (p<0.001). Data 
analyzed using one-sided ANOVA. 
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(B) The kd (reflective of the binding affinity) shown in the lower panel, and was not significantly different 
in all the conditions (P=0.2284). Data analyzed using one-sided ANOVA. 
 
3.2.5 Discussion 
We examined expression of PBR in HIV encephalitis using the PBR-specific ligands 
[3H](R)-PK11195 and [3H]-DAA1106. HIVE brain tissue showed a significant increase 
in binding with both ligands compared to HIV infected, non-encephalitic controls and 
non-infected brain tissue. We also saw an increase in [3H]-DAA1106 binding in SIVE 
tissue compared to SIV infected, non-encephalitic and non-infected tissue. Increased 
expression was specific to macrophages as determined by combined 
immunohistochemistry and autoradiography in SIVE tissue. In tissue culture 
experiments, we found increased [3H](R)-PK11195 binding in macrophages activated 
with LPS or INF-γ compared to unactivated macrophages, astrocytes activated with 
dCAMP and unactivated astrocytes. Similar results were seen in mitochondrial fractions 
harvested from activated and unactivated macrophages and astrocytes using [3H]-
DAA1106. Increase in [3H](R)-PK11195 binding was also seen in macrophages infected 
with HIV-1 ADAM, peaking at 14 days post infection and reaching a plateau by 21 days 
post infection. Astrocytes treated with supernatants derived from HIV-1 ADMA infected 
macrophages did not show a significant increase in [3H](R)-PK11195 binding compared 
to untreated cultures. Finally, the increase in [3H](R)-PK11195 binding in LPS treated 
macrophages was reversed using an inhibitor of PI3-kinase, but not of MEK-1/2. 
  Our results suggest that increased [3H](R)-PK11195 binding, reflective of 
increased PBR expression, is specific to macrophages in HIV encephalitis due to both 
activation and HIV infection. This increase in [3H](R)-PK11195 binding was dependent 
on PI3-kinase signaling in macrophages. These results are in agreement with previously 
published results suggesting that [3H](R)-PK11195 binding is increased in macrophages 
in SIVE (151). Direct implications of this study are that PK11195 and DAA1106 may be 
used to image macrophages in vivo using PET. Our data suggests that DAA1106 may be 
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a higher affinity ligand compared with PK11195 because of a significantly lower 
dissociation constant. 
 The functional significance of increased PBR in activated brain macrophages is 
not known.  It is part of a hetero-oligomeric complex comprised of the voltage-dependent 
anion channel and an adenine nucleotide carrier forming the mitochondrial permeability 
transition pore (160). It is thought to be involved in neurosteroid synthesis by serving to 
transport cholesterol from the outer to the inner mitochondrial membranes (190). As a 
constituent of the mitochondrial permeability transition pore, it is thought to regulate cell 
death (160) and mitochondrial respiration (117). PBR overexpression in many cell types 
has also been shown to protect against various apoptotic insults including the cytopathic 
effects of sindbis and myxoma viral infections (80, 125). Forced PBR expression in 
neurons in vivo and jurkat cells in vitro protects these cells against apoptosis (125, 234). 
PBR upregulation in testicular leydig cells protects them from cytokine-induced toxicity 
(20, 237). This is also seen in blood phagocytic cells where PBR protects against oxidant 
induced cell death (44). 
Several proteins involved in apoptosis including Bcl-2, Bcl-Xl and Bax have also 
been shown to physically interact with the voltage dependent anion channel and the 
adenine nucleotide carrier (62, 112). PBR can thus influence the cell death processes 
either by directly affecting the molecular components of the pore or through indirect 
effects by interfering with interactions of the voltage dependent anion channel and the 
adenine nucleotide carrier with proapoptotic proteins like Bax (46). These hypotheses 
draw support from kainic acid-injected rat where hippocampal PBR is increased by 20 
fold with no significant increases in either the voltage dependent anion channel or the 
adenine nucleotide carrier (244). Increases in only the PBR component of the pore might 
result in altering both the channel properties and altering interactions of other pore 
proteins with proapoptoic mediators.  
Very little is known about how macrophages survive in the brain in HIVE in vivo. 
In the SCID mouse model of HIV encephalitis, macrophages survive for several months 
in the brain (197). HIV infected macrophages also survive in culture for as long as 60 
days (90). Since macrophages mediate the pathology of HIV encephalitis, it is 
conceivable that a longer life span of macrophages would lead to exacerbation of the 
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neurodegenerative process seen in HIVE.  PBR expression in activated and HIV infected 
macrophages may prolong their life span by influencing mitochondrial permeability 
transition and preventing apoptosis of these cells in the CNS. 
The biochemical mechanisms by which selective increase in expression or the 
role for this receptor in activated macrophages in several of these CNS diseases is not 
understood (91). In pancreatic islet cells, testicular leydig cells, the cytokines TNF-α, 
IFN-γ and IL-1β caused an increase in mitochondrial PBR mRNA and [3H](R)-PK11195 
binding in a transcription dependent manner (20, 237). In the CNS, rats injected with IL-
1, or TNF-α , or LPS resulted in increased [3H](R)-PK11195 binding to brain 
macrophages (31, 35). IL-1 and TNF-α also increase [3H](R)-PK11195 binding in 
cultured astrocytes (65). Finally, in Experimental Autoimmune Encephalitis, IL-6 and 
TNF-α expression profiles correlate with increase in spinal cord [3H](R)-PK11195 
binding (5). These data suggest that cytokines increase PBR expression in various cell 
types including macrophages. However, the mechanisms mediating this increase are not 
known. It has been proposed that cellular upregulation of PBR in these systems may 
serve as a protective strategy against cytokine toxicity.  
HIV infected macrophages are sources of cytokines in the brain. TNF-α can be 
detected in the CSF (107) and brain tissue (97) of HIV demented patients. In SIVE, TNF-
α and IFN-γ are detected in brain tissue (186).  These studies are complimented with in 
vitro data showing that cytokines including TNF-α and IL-6 are synthesized by HIV 
infected macrophages (29, 257). It is possible that PBR expression is increased in brain 
macrophages in HIVE in response to increased cytokines. 
Interestingly, PI3K/Akt activation is an important survival-regulation pathway in 
brain macrophages (129), peripheral macrophages and other hemopoietic cell (169, 239). 
Activation of PI3K/Akt protects against toxicity induced by multiple cytokines (100, 
169). Further, inhibition of PI3K pathway in peripheral macrophages causes cell death by 
loss of mitochondrial transmembrane potential by mechanisms not fully understood 
(144). Our data suggests that PBR is directly regulated by PI3K, and since PBR is a 
constituent of the permeability transition pore and may play a role in maintaining 
mitochondrial transmembrane potential, it is possible that PBR is an essential player in 
regulating macrophage cell survival in the CNS in HIVE. 
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3.3 PK11195 LABELS BRAIN MACROPHAGES IN ALZHEIMER’S 
DISEASE  
3.3.1 Abstract 
Prominent brain macrophage activation is seen around senile plaques and extracellular 
neurofibrillary tangles in Alzheimer’s disease. Although the role of brain macrophage in 
the pathogenesis of Alzheimer’s disease is not clearly established, activation of brain 
macrophage is associated with amyloid clearance and phagocytosis in Aβ immunization 
protocols in both animal models and humans. Imaging activated brain macrophage in 
vivo using positron emission tomography will help define the role of these cells in both 
Alzheimer’s disease progression and therapeutic protocols targeted at modulating 
neuroinflammation.  PK11195 is a ligand specific for the peripheral benzodiazepine 
receptor abundant on activated brain macrophages and expressed in low levels in the 
normal brain. We hypothesized that [11C](R)-PK11195 positron emission tomography 
(PET) could image brain macrophages in vivo in Alzheimer’s disease. [3H](R)-PK11195 
binding was assessed in postmortem brain tissue obtained from AD cases and age 
matched controls. [3H](R)-PK11195 binding was significantly higher in the frontal 
cortex but did not differ in the cerebellum of AD cases compared to controls suggesting 
that this increase was specific to regions of pathology. Mice expressing the 
APPSwe/PS1dE9 transgene were then scanned using positron emission tomography 
using [11C](R)-PK11195. Transgenic mice showed an age-dependent, moderate increase 
in [11C](R)-PK11195 and [3H](R)-PK11195 binding compared to controls. 
Histopathologic assessment showed significantly higher levels of brain macrophage 
activation in Alzheimer’s disease compared to Tg mice. Further, significant correlation 
was observed between [3H](R)-PK11195 binding and activated brain macrophages in 
Alzheimer’s disease but not in Tg mice. The extent of neuroinflammation is significantly 
lower in these transgenic mice as compared to Alzheimer’s disease, which may 
undermine the utility of these mice in studying the role of neuroinflammation in the 
pathogenesis and treatment of Alzheimer’s disease. However, our results suggest that 
PK11195 may be useful in labeling brain macrophages in vivo in AD. 
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 3.3.2 Introduction 
Alzheimer’s disease is the leading cause of dementia characterized by the presence of 
plaques consisting of Aβ and intraneuronal neurofibrillary tangles (167). Aβ deposition 
leads to the formation of diffuse plaques that are believed to progress to neuritic plaques 
consisting of a dense core of Aβ, dystrophic neurites, astrocytes, and activated brain 
macrophages (161). While the biochemical processes related to Aβ processing have been 
studied extensively, the role of activated brain macrophages in the pathogenesis of AD is 
not well understood.  
In AD and several other neurological disorders, activation of brain macrophages 
is thought to perpetuate the degenerative process. On activation, brain macrophage 
secrete substances such as TNFα and interleukins, free radicals generated by activation of 
NADPH oxidase, reactive nitrogen intermediates, and eicosanoids which are thought to 
trigger various cellular processes including cell death cascades in neurons (30, 225, 236). 
On the other hand, several studies support the idea that activated brain 
macrophages may play a beneficial role in AD by promoting phagocytosis (150, 224). 
Further, brain macrophages may play a role in therapeutic strategies such as 
immunization. Immunization with Aβ is one of the most promising forms of AD 
therapeutics. Both active and passive immunizations in animal models have proved 
promising in clearing Aβ loads from the brain and improving behavioral/memory tests 
(22, 120, 171, 218). Several mechanisms have been proposed for Aβ  clearance with 
immunization. However, the association of activated brain macrophages with the 
clearance of Aβ and “collapsed” plaques in both animal models and human-immunized 
subjects raises the possibility that the efficacy of immunizations may be related to the 
extent of activation of brain macrophages (22, 85, 179, 218).  
Were it possible to image brain macrophages in vivo, then a better understanding 
of the role played by brain macrophages in Alzheimer’s disease and therapies targeted at 
Aβ clearance may be obtained. We investigated the feasibility of imaging activated brain 
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macrophages using Positron Emission Tomography (PET) by taking advantage of 
elevated levels of peripheral benzodiazepine receptor expression (PBR) on brain 
macrophages. We tested the hypothesis that PK11195, a selective ligand to PBR, will 
specifically label activated brain macrophage in AD postmortem tissue and in a mouse 
model of AD in vivo using PET.  
PK11195 is a lipid soluble isoquinoline carboxamide which crosses the blood 
brain barrier rapidly and has been extensively characterized (42). [11C](R)-PK11195 has 
been used to label activated brain macrophages in patients with multiple sclerosis (20, 69) 
Rasmussen’s encephalitis (18), stroke (206), Herpes encephalitis (43), gliomas (191), 
Multiple System Atrophy (95) and AD (41). Studies in AD patients showed high 
[11C](R)-PK11195 binding in the entorhinal, temporoparietal and cingulate cortex, 
which are brain regions that show the highest degree of AD pathology (41). However, the 
relationship between PK11195 binding and the distribution of neuropathology was not 
assessed in this study (41). We used postmortem tissue from AD cases and a mouse 
model of AD to correlate the extent and distribution of neuropathology with the PK11195 
binding. We also sought to determine if [11C](R)-PK11195 could image activated brain 
macrophages in the APP/PS1 transgenic mouse model of AD in vivo. We show that 
PK11195 binding is higher in AD tissue and significantly correlates with the distribution 
of activated brain macrophages in AD. Further, the extent of activated brain macrophages 
is significantly lower in APP/PS1 transgenic mice compared to AD tissue corresponding 
to moderate increases in PK11195 binding in vivo. 
 
3.3.3 Methods 
Animals 
All animals were housed and maintained according to standards of the 
Association for Assessment and Accreditation of Laboratory Animal Care, and 
experiments were approved by the University of Pittsburgh Institutional 
Animal Care and Use Committee. APPSwe/PSEN1-DeltaE9 transgenic (Tg, n=9) 
heterozygote and control wild type (n=6) animals on a B6C3 background between the 
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ages of 7-9 months were obtained from The Jackson Laboratory (Maine, USA). 4/9 Tg 
and 1/6 wild type mice were part of a failed immunization experiment. In this study 
APPSwe/PS1dE9 and wild type mice beginning at the age of nine months mice were 
immunized i.p. with 100µg of Aβ42 emulsified in complete Freund’s adjuvant, followed 
by a boost at 2 weeks with incomplete Freund’s adjuvant and monthly thereafter for the 
next 3 immunizations according to established protocols (218). We assayed for the 
production of antibodies against Aβ42 at 1, 2, 3 and 4 months after immunization. Levels 
of antibody production were very low and did not differ in animals that were immunized 
with Aβ42 versus animals that were sham immunized (data not shown). Further, 
histopathologic assessment of immunized versus sham immunized or non-immunized 
animals did not show any differences in Aβ plaque deposition, brain macrophage 
activation, or the extent of astrocytosis (data not shown). Since immunization failed in 
these animals, PET data derived from these animals were grouped along with data 
obtained from their non-immunized counterparts. 
PET imaging 
High specific activity [11C](R)-PK11195 ([N-methyl-11C]-PK11195) was produced at 
the UPMC PET Facility using methods similar to those previously described (245). 
Chemical and radiochemical purities were ≥95% with specific activities ≥2.0 Ci/µmol at 
the end of a 40 min synthesis. Typical end of synthesis yields of high purity [11C](R)-
PK11195 was in the range of 40-100 mCi.  
APPSwe/PS1dE9 (Tg) (n=9) and control wild type (n=6) mice were imaged using 
microPET with [11C](R)-PK11195 between ages 14-20 months. Data were reconstructed 
using the 3D Ordered Subsets Expectation Maximum (OSEM) algorithm for maximal 
image quality and image resolution. Regional brain radioactivity concentration were 
summed over the scan frames at various time points was normalized to both the injected 
dose of [11C](R)-PK11195 and the body mass of the animal (%ID/Kg*g) to represent a 
semi-quantitative measure of [11C](R)-PK11195 binding. Regions-of-interest (ROI) were 
defined on summed PET images and applied to the dynamic PET images to generate 
time-activity curves for both transgenic and control animals.  Due to the spatial resolution 
limitations of microPET, it is not practical to define ROIs on small structures such as the 
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hippocampus within the mouse brain. Hence ROI parameters were defined in regions 
approximating the frontal cortex of the mouse brain and applied to all Tg and control 
animals.  
Human Tissue 
Brain tissue from the frontal cortex and the cerebellum of six AD postmortem cases and 
six age-matched controls were derived from the University of Pittsburgh Alzheimer’s 
disease research center brain bank. 
Tissue processing 
After PET scans both transgenic and control animals were sacrificed to compare time 
activity curves for [11C](R)-PK11195 with the extent of activated brain macrophages, 
astrocytes and amyloid burden as determined by histopathology. After PET imaging, the 
brain was removed and the left hemisphere was fixed while the right hemisphere was 
frozen. Histopathology including amyloid burden and the extent of astrocytosis and brain 
macrophage activation was assessed using semi-quantitative laser confocal microscopy in 
the left hemisphere as described below. The right hemisphere was used to determine 
[3H](R)-PK11195 binding in six (3 Tg and 3 control) animals.  
Filtration radioligand binding assays 
Brain tissue from the frontal cortex and the cerebellum from AD cases and age-matched 
controls, and from the frontal cortex of 3 Tg and 3 control animals were dissected, 
weighed and homogenized in ice-cold 50 mM HEPES buffer (pH 7.4). Homogenates 
were washed four times by centrifugation at 40,000 g for 20 min at 40C. Saturation 
binding experiments were performed by incubating tissue (total protein concentration 
ranging from 150 to 200 µg determined using the BCA protein assay kit; Pierce, 
Rockford, IL) with 0.5-64 nM [3H](R)-PK11195 (sp. Act., 89.9 Ci/mmol; NEN Life 
Sciences Products, Boston, MA) at 40C for 2 hr in a final volume of 250 µl of HEPES. 
Nonspecific binding was determined by the inclusion of 10 µM PK11195. The reaction 
was terminated by the addition of ice-cold buffer in a vacuum cell harvester (Brandel, 
Gaithersburg, MD). All samples were run in duplicate. Bmax in fmoles per mg protein 
and kd in nM were determined using PRISM software (Graphpad, San Diego, CA). 
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Immunohistochemical labeling and confocal microscopic quantification 
Immunostaining and laser confocal microscopic quantification was performed as 
described before (32, 126). Paraffin embedded sections obtained from transgenic mice 
and controls (whole brain sagital sections) or AD postmortem tissue and age-matched 
controls (sections from the frontal cortex) were stained with antibodies to GFAP (mouse 
monoclonal, DAKO, Carpinteria, CA) or Aβ (mouse monoclonal, DAKO, Carpinteria, 
CA) used at concentrations 1:1000, and 1:100 respectively. Brain macrophages were 
stained with F/4 80 (mouse monoclonal, DAKO) at a concentration of 1:1000 in mouse 
brain tissue or with CD68 (mouse monoclonal, DAKO) at a concentration of 1:100 in 
human tissue. Sections were then incubated with Cy5-conjugated goat anti-mouse or 
Cy3-conjugated anti-rabbit IgG at a concentration of 1:200 (Jackson Immunoresearch 
Laboratories Inc., West Grove, PA). The frontal cortex was identified using a dissection 
microscope and marked on the slides. Immunostained sections were scanned and 
quantified on a laser confocal microscope (LSM 150, Zeiss, Heidelberg, Germany). This 
scope is equipped with an argon laser with 458 nm, 477 nm, 488 nm and 514 nm primary 
emission lines. Each section was scanned along the z-axis to define the middle optical 
plane used in quantification (262,144 pixels/plane; 1 pixel= 0.25 µm2). Image analysis 
was performed on a Silicon Graphics computer (Windows NT 4.0 operating system, 
Microsoft, Redmond, Washington) using the LSM software (version 3.0, Zeiss). 
Scanning parameters such as laser power aperture, gain, and photomultiplier tube settings 
were kept constant for each wavelength.  
In each region, an individual blinded to the experimental design imaged 3 areas 
(40X) encompassing 106,100 µm2. For each cell phenotype scanned, contribution to 
signal intensity from autofluorescence was minimized using a threshold that was kept 
constant. In each area the average pixel fluorescence along with the pixel counts for a 
given cell phenotype marker that exceeded the threshold were enumerated. The average 
pixel fluorescence was multiplied by the total number of pixels to measure the total 
florescence for that cell phenotype marker in that area. The total fluorescence values 
determined from the 3 scanned areas in one brain region were averaged to represent a 
measure of the cell phenotype in that brain region.  
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Statistical analysis  
Data were analyzed using PRISM software (Graphpad, San Diego, CA). Student’s t tests 
or one-way ANOVA tests with post-test Bonferroni correction and 95% confidence 
intervals were used to analyze data. Correlations using 95% confidence intervals were 
performed to quantify the relationship between [11C](R)-PK11195 binding and age of Tg 
or control mice. Results from correlation analyses are represented by r, the Pearson’s 
coefficient. 
3.3.4 Results 
[3H](R)-PK11195 binding is higher in AD frontal cortex 
We used saturation filtration binding to compare [3H](R)-PK11195 specific binding in 
AD with age-matched controls. Brain tissue from the frontal cortex and the cerebellum 
were dissected from five AD cases and five age matched controls. Tissue was weighed, 
homogenized and protein values were determined using the BCA protein assay kit 
(Pierce, Rockford, IL). Homogenized tissue was incubated with 0.5-64 nM [3H](R)-
PK11195 to obtain total binding values. Nonspecific binding was determined in parallel 
by including 10µM PK11195. Specific binding at each given concentration of  [3H](R)-
PK11195 was defined as the difference between total binding and nonspecific binding. 
Bmax and kd values reflective of the total number of binding sites per mg protein and 
binding affinity of  [3H](R)-PK11195 to PBR respectively were determined using 
PRISM software.  
Bmax was significantly higher in the frontal cortex of AD brain tissue but did 
differ in the cerebellum (Figure 16 A and B, p=0.0002). This suggests that the increase 
in Bmax is specific to regions with pathology, as the cerebellum is not usually affected in 
AD until end stages of the disease (122). The affinity of [3H](R)-PK11195 to PBR 
reflected by the kd did not differ between AD and control brain tissue in either brain 
region (Figure 16 C).  
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[11C](R)-PK11195 PET imaging in APPSwe/PSEN1 (DeltaE9) transgenic mice  
PET imaging using [11C](R)-PK11195 was assessed in 9 APPSwe/PSEN1-DeltaE9 
transgenic mice (Tg) and 6 controls between the ages of 13 to 20 months. These mice 
show accelerated plaque deposition beginning at the age of 6 months (34). Both Tg and 
wild type control animals were injected i.v. with [11C](R)-PK11195. [11C](R)-PK11195 
binding was followed over time (in minutes, X axis) and represented as radioactivity 
concentrations summed over the scan frames and normalized to both the injected dose of 
[11C](R)-PK11195 and the body mass of the animal (%ID/g*kg, y-axis).  Tg animals 
showed an age dependent increase in retention of [11C](R)-PK11195 in the brain 
compared to controls in that, only Tg animals between the ages of 17-20 months showed 
increases in [11C](R)-PK11195 binding compared to controls (p=0.001) (Figure 17).  
This is consistent with the age-dependent progression of pathology in APP/PS1 and other 
Tg mice with age  (34, 130). 
 
Figure 16 [3H](R)-PK11195 is higher in the AD frontal cortex 
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Filtration binding with [3H](R)-PK11195 was assessed in the frontal cortex (FC), cerebellum (CB) of 5 
Alzheimer’s disease (AD) and 5 age-matched controls (Con). Data was analyzed using one-way ANOVA 
with 95% confidence intervals. 
(A) Shows representative curves from filtration [3H](R)-PK11195 binding experiments with brain tissue 
obtained from the frontal cortex (FC) and the cerebellum (CB) of AD and control cases. Frontal cortex 
(FC) brain tissue from AD showed significantly higher specific binding (per mg protein) than brain 
tissue obtained the cerebellum of AD cases, frontal cortical and cerebellar brain tissue obtained from 
controls.  
(B) Bmax (reflective of the total number of binding sites) with [3H](R)-PK11195 was significantly higher 
in AD frontal cortical tissue compared with AD cerebellar tissue, frontal cortical and cerebellar tissue 
obtained from controls.  (p=0.0002).  
(C) The kd (reflective of the binding affinity) was not significantly different in all the conditions 
(P=0.3187).  
 
Figure 17 PET imaging with [11C](R)-PK11195 shows an age-dependent increase in APP/PS1 (Tg) 
mice, but not controls. 
Time Activity curve of [11C](R)-PK11195 specific binding in APP/PS1 (Tg) and control (Con) 
represented as radioactivity concentrations summed over the scan frames and normalized to both the 
injected dose of [11C](R)-PK11195 and the body mass of the animal (%ID/g*kg, Y-axis) and is plotted 
against time in minutes (X-axis). Tg and control animals were divided into the age groups of 13-16 and 17-
20 months (n shown in brackets). [11C](R)-PK11195 binding was not different between control and Tg 
mice in the 13-16 month age group. [11C](R)-PK11195 binding was higher in Tg mice compared to 
controls in the 17-20 month age group (p=0.001). Data was analyzed using one-way ANOVA with 95% 
confidence intervals. 
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[3H](R)-PK11195 binding in APPSwe/PSEN1 (DeltaE9) transgenic mice 
We used saturation filtration binding to compare [3H](R)-PK11195 specific binding in 
TG with controls. Brain tissue from the frontal cortex was dissected from 3 Tg and 3 age 
wild type controls based on tissue availability. The ages of the Tg and control mice were 
9, 11 and 19 months. [3H](R)-PK11195 and [11C](R)-PK11195 binding in Tg mice 
showed similar trends. Overall, the Bmax was moderately increased in the frontal cortex, 
but not significantly different in Tg mice compared to controls (Figure 18 A & B). 
However, the increase in [3H](R)-PK11195 binding was age dependent with 45%, 23% 
and 13% increases from controls in the 19, 11 and 9 month old Tg mice. The affinity of 
[3H](R)-PK11195 to PBR reflected by the kd did not differ between Tg and control brain 
tissue (Figure 18 C).  
The extent of neuroinflammation is significantly higher in AD compared to Tg mice 
After PET imaging, the animals were sacrificed and histopathology including amyloid 
burden, abundance of astrocyte activation and the extent of macrophage activation was 
assessed and measured using semi-quantitative laser confocal microscopy. Astrocytes, 
amyloid deposits and activated brain macrophages were immunostained for GFAP, Aβ 
and F4/80 respectively, and quantified in the frontal cortex of Tg and control brain tissue 
using laser confocal microscopy by an individual blinded to the experimental design. In 
Tg mice, GFAP and F4/80 staining was quantified in regions containing plaques as well 
as regions devoid of plaques. GFAP staining was significantly increased from controls in 
Tg mice in regions containing plaques, but did not differ from controls in regions devoid 
of plaques (Figure 19 D-F and Figure 20 D). Surprisingly, F4/80 staining for brain 
macrophages did not differ between Tg and controls in regions with or without plaque 
deposition (Figure 19 D-F and Figure 20 C). 
Similarly, the abundance of GFAP staining, brain macrophage activation (as 
assessed by CD68 staining) and amyloid burden (by staining for Aβ) was assessed in the 
frontal cortex of AD postmortem tissue and age-matched controls. In contrast to the Tg 
mice, activated brain macrophages were significantly increased in AD in areas 
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surrounding plaques compared to areas with no plaques and age-matched controls 
(Figure 19 A-C and Figure 20 A). GFAP staining was also significantly higher in 
regions with plaques compared to plaque free areas and control brain tissue (Figure 19 
A-C and Figure 20 B).  
Increased PK11195 binding correlates with brain macrophages in AD postmortem 
tissue but not in Tg mice 
We then determined the relationship between PK11195 binding and the abundance of 
activated brain macrophages and astrocytes. In Tg brain tissue, [11C](R)-PK11195 
binding correlated poorly with the distribution of both brain macrophages and astrocytes, 
corresponding to moderate increases in PK11195 binding in these animals (Table 4). In 
contrast, [3H](R)-PK11195 binding correlated significantly with the abundance of brain 
macrophages and to a lesser extent the distribution of astrocytes in the frontal cortex of 
AD postmortem tissue (Table 4). 
 
Figure 18 [3H](R)-PK11195 binding in APP/PS1 (Tg) mice. 
Filtration binding with [3H](R)-PK11195 was assessed in the frontal cortex of 3 APP/PS1 (Tg) mice and 
3age-matched controls (Con) aged 19, 11 and 9 months depending on tissue availability.  
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(A) Shows representative curves from filtration [3H](R)-PK11195 binding experiments in Tg and control 
cases. Brain tissue obtained from the frontal cortex of Tg showed moderately higher specific binding 
(per mg protein) than controls. 
(B) Bmax (reflective of the total number of binding sites) with [3H](R)-PK11195 was higher, but not 
significantly different (p=0.1265) in Tg frontal cortical tissue compared with controls. However, the 
increase in [3H](R)-PK11195 binding was age dependent with 45%, 23% and 13% increases from 
controls in the 19, 11 and 9 month old Tg mice.  Data analyzed using student’s t test.  
(C) The kd (reflective of the binding affinity) was not significantly different in all the conditions 
(P=0.2355). Data analyzed using student’s t test. 
 
 
 
Figure 19 Immunohistochemical evaluation of neuroinflammation in AD and Tg mice 
 
(A-C) Frontal tissue from AD and age-matched controls were stained for Aβ (red) brain macrophages 
(CD68, green) and astrocytes (GFAP, blue). In AD tissue, regions containing plaques (A) and 
plaque free areas (B) were compared with age matched controls (C). 
(D-F) Frontal tissue from APP/PS1 (Tg) and control, wild type mice were stained for Aβ (red) brain 
macrophages (F 4/80, green) and astrocytes (GFAP, blue). In Tg tissue, regions containing plaques 
(D) and plaque free areas (E) were compared with age matched controls (F). 
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 Figure 20 The extent of neuroinflammation is higher in AD in comparison to Tg brain tissue 
(A-B) Frontal tissue from AD and age-matched controls were stained and quantified for brain macrophages 
(CD68) and astrocytes (GFAP). In AD tissue, regions containing plaques had significantly higher 
brain macrophages (A) and astrocytes (B) than regions without plaques and age matched controls. 
(C-D) Frontal tissue from APP/PS1 Tg and wild type controls were stained and quantified for brain 
macrophages (F4/80) and astrocytes (GFAP). In Tg brain tissue, regions containing plaques had 
significantly higher astrocytes (D) but not macrophages (C) than regions without plaques and age 
matched controls. 
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Table 4 [3H](R)-PK11195 binding correlates best with brain macrophages in AD 
 
Pearson’s coefficient (r) with 
[3H](R)-PK11195 
binding in AD post 
mortem tissue. 
Pearson’s coefficient (r) with 
[11C](R)-PK11195 
binding in APP/PS1 in 
vivo. 
Variable 
r value r value 
Astrocytes 
(GFAP) 0.6736* 0.4937 
Brain macrophage 
 (CD68 or F4/80) 0.8432** 0.6062 
 
Activated macrophages and astrocytes were quantified by immunostaining for CD68 or F4/80 in AD and 
Tg tissue respectively, or GFAP (astrocytic marker) in the frontal cortical tissue using confocal laser 
microscopy. Each cell phenotype marker was then correlated with [3H](R)-PK11195 binding in post 
mortem tissue in AD or [11C](R)-PK11195 PET binding in vivo in Tg mice in the corresponding brain 
regions in the same cases. PK11195 binding in post mortem tissue in AD correlated best with brain 
macrophages and did not correlate with either marker in Tg tissue, **p=0.002, *p=0.03. 
 
3.3.5 Discussion 
We sought to determine if [3H](R)-PK11195 could detect neuroinflammation in 
Alzheimer’s disease. We first compared [3H](R)-PK11195 binding in Alzheimer’s 
disease post mortem tissue with age-matched controls. We found increased [3H](R)-
PK11195 binding in the frontal cortex but not the cerebellum, suggesting that the increase 
in [3H](R)-PK11195 binding was specific to regions of AD pathology. We then 
investigated the feasibility of [11C](R)-PK11195 to detect neuroinflammtion in vivo. We 
imaged mice expressing the APPSwe/PSEN1-DeltaE9 mutations with [11C](R)-
PK11195 using PET. We found an age dependent increase in [11C](R)-PK11195 binding 
in Tg mice compared with controls. Immunohistochemical examination of brain tissue 
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from transgenic mice and AD showed significant differences in extent of 
neuroinflammation. AD postmortem tissue showed an increase in both brain 
macrophages and astrocytes, while brain tissue from Tg mice showed an increase in 
mainly astrocytes. This suggests that PK11195 binding in AD postmortem tissue may 
detect both activation of astrocytes and brain macrophages, while mainly labeling 
astrocytes in our Tg model of AD. 
Alternatively, it is also possible that our microglial staining procedure in Tg mice 
using the F4/80 marker is not optimal. Our results suggest that activation of brain 
macrophages in mice expressing the APPSwe/PSEN1-DeltaE9 mutations is not different 
from control mice. While the deposition of Aβ has been well documented, the data 
suggesting activation of brain macrophages is in mice models is not so clear (72). Mice 
that model AD differ substantially with respect to the type and extent of transgene(s) 
overexpressed, which is further complicated by inconsistent results obtained from the 
various histologic markers currently available to detect activated brain macrophages in 
mice (reviewed in)(172). Some studies suggest that the extent of activation of brain 
macrophages in Tg mice is lower than that seen in the human disease, while other suggest 
comparable extent of brain macrophage activation. We utilized F4/80, a marker 
expressed on mature brain macrophages (118). Gordon et.al. suggest that that F4/80 is 
upregulated on brain macrophages in APP/PS1 Tg mice, but decreases with age, reaching 
levels comparable to controls in 15 month old Tg mice (103, 172). Sasaki et. al. also 
report low levels of brain macrophage activation using F4/80 in Tg2576 (APP) mice  
(215). Our F4/80 staining data in APP/PS1 mice are in agreement with these two studies. 
In contrast, other studies report robust brain macrophage activation in APP/PS1 mice 
utilizing markers such as Iba-1 (224), an actin cross linking protein in brain macrophages 
(127, 216). It is possible that different markers are expressed in brain macrophages in a 
time dependent manner in Tg mice and that we may be able to detect increases in brain 
macrophage staining in APP/PS1 Tg mice with other markers. We were unable to label 
brain macrophages using Iba1 in Tg mice tissue due to technical difficulties and are 
currently trouble-shooting the staining procedure.  
Irrespective of the histologic detection of brain macrophages, the extent of 
PK11195 binding in APP/PS1 mice (~2 fold) was lower than that seen in AD (~4 fold). 
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This suggests that the extent of brain macrophage activation in Tg mice may be lower 
than seen in AD. APP/PS1 mice also show decreased retention of the PIB-amyloid PET 
ligand as compared to human AD subjects, which may be due to differences in the 
secondary structure of the deposited Aβ (133). It is possible that these differences in Aβ 
deposition and secondary structure may result in a lower degree of brain macrophage 
activation in APP/PS1 mice as compared to AD. While, genetically manipulated mice 
may have several advantages as model systems in AD and other neurodegenerative 
disorders, they may not be suitable in AD related PET studies.  
PET imaging with [11C](R)-PK11195 shows increased ligand binding in 8 
subjects with AD (41). Brain regions such as the temporal gyri, the cingulated cortex and 
the entorhinal cortex show increased [11C](R)-PK11195 retention. However, this study 
also reported high levels of [11C](R)-PK11195 binding in regions traditionally not 
involved in AD such as the thalamus and the brainstem (41). The authors interpret these 
findings arising due to a mechanism called “synaptic stripping” that may be the result of 
increased brain macrophage activation in regions connected by synapses to areas of 
pathology. It is also possible that these signals may arise from non-specific [11C](R)-
PK11195 binding. In such cases it is vital that PET findings be compared to 
histopathology to confirm the presence of activated brain macrophages. It is obviously 
not possible to conduct such comparisons in human in vivo PET studies, which 
emphasize the need to compare human histopathologic data with ligand binding studies to 
determine if the underlying neuropathology corresponds to ligand binding. 
The role of activated brain macrophages in AD is still not clearly understood 
(reviewed in (16, 219)). The neurotoxic role of brain macrophages draws support from 
several in vitro studies (reviewed in (27, 102)), while other studies suggest a beneficial 
role to brain macrophages in promoting phagocytosis of Aβ (150, 224).  Moreover, 
clinical trials aimed at reducing the extent of neuroinflammation have suggested either 
reduction in the occurrence of the disease prior to the onset of AD (119, 233) or no 
effects in patients with mild-moderate AD (6). Brain macrophages may also play a role in 
immunization therapies by promoting phagocytosis of Aβ (22, 85, 179, 218). Detecting 
brain macrophages in vivo in AD may be of vital importance in defining the role of brain 
macrophages in progression of disease as well as the effectiveness of therapeutic 
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strategies targeted at modulating the immune system. Our studies suggest that PK11195 
may be one such tool, which may help delineate the role of brain macrophages in the 
treatment and pathology of AD. 
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 3.4 UTILITY OF THE PERIPHERAL BENZODIAZEPINE RECEPTOR 
LIGANDS DA1106 AND PK11195 TO IMAGE BRAIN MACROPHAGES IN RAT 
MODELS OF NEUROINFLAMMATION IN VIVO 
3.4.1 Abstract 
Activation of brain macrophages is seen in several neurological disorders and is thought 
to contribute to disease progression. Activated brain macrophages can be imaged in vivo 
using PET by taking advantage of increased expression of the peripheral benzodiazepine 
receptor in these cells in neuroinflammation. PK11195 is a ligand that binds specifically 
to the peripheral benzodiazepine receptor and has been used to image activated brain 
macrophages in a number of neuroinflammatory conditions. DAA1106 is a newer ligand 
that has been reported to bind to the peripheral benzodiazepine receptor with a higher 
affinity than PK11195. We compared the binding characteristics of both these ligands in 
normal brain tissue as well as rat models of neuroinflammation. [3H]-DAA1106 showed 
higher binding affinities compared with [3H](R)-PK11195 in brain tissue derived from 
normal rats and humans. [3H]-DAA1106 also bound with higher affinity when compared 
with [3H](R)-PK11195 in brain tissue derived from rats injected with 6-
hydroxydopamine. Ex-vivo autoradiography showed greater retention of [11C]-
DAA1106 compared to [11C](R)-PK11195 in the brains of rats injected with 
lipopolysaccaride. Further, PET imaging of rats lesioned with 6-hydroxydopamine 
showed increased retention of [11C]-DAA1106 compared to controls in vivo. These 
results indicate that DAA1106 binds with higher affinities to the site of lesion in animal 
models of neuroinflammation when compared with PK11195, suggesting that DAA1106 
may be a better ligand to image activated brain macrophages in vivo.  
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3.4.2 Introduction 
Activation of brain macrophages is a significant component of several neurodegenerative 
disorders. Phagocytic functions of these cells help in clearing debris at sites of neuronal 
death and damage (135). However, activated brain macrophages are also hypothesized to 
promote neurodegenerative in several disorders such as Alzheimer’s disease, HIV 
associated dementia and Parkinson’s diseases (102). On activation, brain macrophages 
are hypothesized to secrete neurotoxins such as interleukins (96, 208), tumor necrosis 
factor α (53), free radicals (52), nitric oxide (51), proteinases (61) and eicosanoids (114) 
which are thought to trigger various cellular processes including cell death cascades in 
neurons (235). In several of these disorders, therapeutic strategies are aimed at 
modulating the inflammatory process (132). If brain macrophage activation could be 
evaluated during life, it would be possible to identify developing neuroinflammatory 
damage and monitor efficacy of therapies targeted at decreasing neuroinflammation. 
Several studies suggest that brain macrophages can be imaged in vivo using 
positron emission tomography with ligands specific to the peripheral benzodiazepine 
receptor (PBR) (17). Unlike the central benzodiazepine receptor, PBR is expressed at 
relatively low levels in the normal brain on resting brain macrophage and astrocytes (42, 
45). Ex vivo autoradiography and in vitro studies show increased expression of PBR in 
activated brain macrophages in neurological diseases such as multiple sclerosis and 
experimental autoimmune encephalitis (20, 246), stroke (231) and in brain trauma (204).  
Various ligands have been synthesized that bind specifically to PBR. Labeling 
these ligands with 3H and 11C has enabled their use in autoradiography and PET 
respectively. Of these ligands PK11195, a lipid soluble isoquinoline carboxamide shows 
rapid uptake into the central nervous system across the blood brain barrier and has been 
extensively characterized (17). [11C](R)-PK11195 has been used to label activated brain 
macrophage in patients with multiple sclerosis (20, 69) Rasmussen’s encephalitis (18), 
stroke (206), Herpes encephalitis (43), gliomas (191), Multiple System Atrophy (95), 
animal models of HIV encephalitis (245) and AD (41). 
A newer ligand, DAA1106 [N-(2,5-dimethoxybenzyl)-N-(4-uoro-2-
phenoxyphenyl) acetamide] is an aryloxyanilide derivative, that binds selectively and 
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with higher affinity to PBR compared to PK11195 (47). This is reflected by its low 
dissociation constant (kd) assessed in mitochondrial fractions derived from the rat 
cerebral cortex (47). Due to high affinity, DAA1106 may serve as a more efficient ligand 
to label PBR in the brain in neuroinflammtion (149, 262). In this report our goal is to 
determine the utility of DAA1106 to image activated brain macrophages activation in 
animal models of neuroinflammation in vivo. 
We first compare binding characteristics of [3H]-labeled PK11195 and DAA1106 
in tissues using filtration binding techniques followed by in vivo binding comparisons 
utilizing [11C] labeled ligands. We report that DAA1106 displays higher binding affinity 
to PBR in comparison with PK11195 in normal brain tissue and brain tissue obtained 
from rats injected with either lipopolysaccharide (LPS) or 6-hydroxydopamine (6-
OHDA). Ex vivo autoradiography showed that [11C]-DAA1106 was retained at higher 
levels compared to [11C](R)-PK11195 at the site of lesion in LPS-injected rats. PET 
imaging in 6-OHDA lesioned rats showed increased [11C]-DAA1106 compared to 
controls in vivo. These data suggest that DAA1106 binds to PBR with higher affinity 
compared to PK11195 and may be a better ligand in imaging brain macrophages in vivo 
with PET.  
3.4.3 Methods 
Animals 
All animals were housed and maintained according to standards of the 
Association for Assessment and Accreditation of Laboratory Animal Care, and 
experiments were approved by the University of Pittsburgh Institutional 
Animal Care and Use Committee. Male Sprague-Dawley rats (300-350g) were injected 
with either 50µg lipopolysaccaride (LPS, Sigma, St Louis, MO) or 20µg 6-
hydroxydopamine (6-OHDA, Sigma, St Louis, MO) into the striatum. Surgical 
procedures were conducted as described earlier (113). Briefly, animals were anesthetized 
with Equithesin [3.0 mg/kg; 258 mM chloral hydrate/20% (vol/vol) propylene glycol/86 
mM MgSO4/20% (wt/vol) Nembutal (sodium pentobarbital)] and were injected 
sterotaxically with either 6-OHDA or LPS into the striatum with the help of a cannula 
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(coordinates: +0.8 mm anterior-posterior; +2.7 mm medial-lateral from bregma; -5.0 mm 
dorsal-ventral from dura). Animals were allowed to recover after surgery and were 
housed for 4 days following LPS injections or 21 days following 6-OHDA injections, 
following which they were imaged with PET.  
Tissue processing 
Following PET scans, animals were sacrificed and the brain was removed. Brian tissue 
was either processed to obtain frozen sections for autoradiography or paraffin sections for 
immunohistochemistry. Brain tissue from the cerebellum, occipital cortex and basal 
ganglia was dissected out from three control/normal rats. Similarly, tissue from the 
frontal cortex, cerebellum and basal ganglia was dissected out from three control/normal 
human brains obtained from the University of Pittsburgh Brain bank. In three animals 
injected with LPS and three animals injected with 6-OHDA the ipsilateral and 
contralateral striatum was dissected out. Brain tissue from each of these cases was then 
weighed and homogenized in ice-cold 50 mM HEPES buffer (pH 7.4). Homogenates 
were washed four times by centrifugation at 40,000 g for 20 min at 40C and protein 
values were estimated using the BCA protein assay kit before using homogenates in 
filtration binding experiments (Pierce, Rockford, IL).  
Filtration radioligand binding assays 
Tissue samples (total protein concentration ranging from 150 to 200 µg) were incubated 
with either 0.5-64 nM [3H](R)-PK11195 (sp. Act., 89.9 Ci/mmol; NEN Life Sciences 
Products, Boston, MA) or [3H]-DAA1106 (sp. Act., 80 Ci/mmol; American Radiolabeled 
Chemical, St Lousi, MO)  at 40C for 2 hr in a final volume of 250 µl of HEPES. This was 
defined as total binding. Nonspecific binding was determined by the inclusion of 10 µM 
PK11195 or 10 µM DAA11106 respectively. The reaction was terminated by filtration 
through glass fiber filters harvester (Brandel, Gaithersburg, MD) presoaked in 0.3% 
polyethyleneimine by the addition of ice-cold HEPES in a vacuum cell harvester 
(Brandel, Gaithersburg, MD). Filter bound radioactivity was counted in a liquid 
scintillation spectrometer (Tricarb liquid scintillation counter, Perkin Elmer life sciences, 
Wellesley, MA) after the addition of 6 mls of liquid scintillation fluid (Perkin Elmer life 
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sciences, Wellesley, MA). Specific binding at each concentration of [3H]-ligand was 
defined as the difference between total binding and nonspecific binding and ranged from 
80-90% of total binding. All samples were run in duplicate. Bmax in fmoles per mg 
protein and kd in nM were determined using PRISM software (Graphpad, San Diego, 
CA).  
Immunohistochemistry 
Immunostaining and laser confocal microscopic imaging was performed as described 
before (245). Paraffin embedded sections obtained from transgenic mice and controls 
were stained with antibodies to GFAP (mouse monoclonal, DAKO, Carpinteria, CA), or 
ED1 (anti-rat CD68, mouse monoclonal, Serotec, Raleigh, NC), or tyrosine hydroxylase 
(rabbit polyclonal, Covance research products, Denver, PA) used at concentrations 
1:1000, 1:100 and 1:1000 respectively. Sections were then incubated with Cy5-
conjugated goat anti-mouse or Cy3-conjugated anti-rabbit IgG at a concentration of 1:200 
(Jackson Immunoresearch Laboratories Inc., West Grove, PA). Immunostained sections 
were then scanned on a laser confocal microscope (LSM 150, Zeiss, Heidelberg, 
Germany). 
Ex-vivo autoradiography 
Rats injected with LPS were anesthetized and injected intravenously with either of [11C]-
DAA1106 or [11C](R)-PK11195 (1-2 mCi). The animals were sacrificed 30 minutes later 
and the brain was rapidly removed. The cortex was sectioned coronally into 2mm 
sections and mounted on a plastic film and apposed to a phosphor screen 
(PhosphorImager SI system, Molecular Dynamics, Sunnyvale, CA) for 20 minutes and 
then imaged on a phosphorimager (PhosphorImager SI system, Molecular Dynamics, 
Sunnyvale, CA). Brain sections were then fixed and processed for 
immunohistochemistry. 
PET imaging 
High specific activity [11C](R)-PK11195 ([N-methyl-11C]-PK11195) and [11C]-
DAA1106 ([N-methyl-11C]-DAA1106) were produced at the UPMC PET Facility using 
methods similar to those previously described (245, 262). Chemical and radiochemical 
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purities were ≥95% with specific activities ≥2.0 Ci/µmol at the end of a 40 min synthesis. 
Typical end of synthesis yields of high purity [11C](R)-PK11195 was in the range of 40-
100 mCi. 
Rats were imaged using microPET with [11C](R)-PK11195 and [11C]-DAA1106 
in succession. In ligand displacement studies, some animals were injected with a 
displacing dose of unlabeled DAA1106 (1.0 mg/kg) 15 min after injection of [11C](R)-
PK11195 or [11C]-DAA1106. Data were reconstructed using the 3D Ordered Subsets 
Expectation Maximum (OSEM) algorithm for maximal image quality and image 
resolution. Regional brain radioactivity concentration were summed over the scan frames 
at various time points was normalized to both the injected dose of [11C]-ligand and the 
body mass of the animal (%ID/Kg*g) to represent a semi-quantitative measure of [11C]-
ligand binding. Regions-of-interest (ROI) were defined on summed PET images and 
applied to the dynamic PET images to generate time-activity curves.  
Autoradiography 
Autoradiography was performed as described earlier (245). Briefly, 15 µm thick frozen 
brain sections were placed on SuperfrostTm glass slides (Sigma, St Louis, MO) and 
incubated in ice-cold 50 mM TRIS-HEPES (pH 7.4) containing 1 nM [3H](R)-PK11195 
(sp. Act., 89.9 Ci/mmol; NEN Life Sciences Products, Boston, MA) or 1 nM [3H]-
DAA1106 for 30 min. Specificity of binding was ensured by the inclusion of 10 µM 
PK11195 (Sigma, St Louis, MO)  or 10 µM DAA1106 in parallel sections. The sections 
were mounted with a layer of autoradiographic LM-1 emulsion (Amersham, UK), were 
developed after 4 weeks and imaged on the confocal microscope.  
Statistical analysis  
Data were analyzed using PRISM software (Graphpad, San Diego, CA). Student’s t tests 
or one-way ANOVA tests with post-test Bonferroni correction and 95% confidence 
intervals were used to analyze data.  
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3.4.4 Results 
[3H]-DAA1106 shows higher binding affinity compared to [3H](R)-PK11195 in 
normal human and rat brain tissue. 
We used saturation filtration binding to compare [3H]-DAA1106 specific binding with 
that of [3H](R)-PK11195 in normal human (n=3) and rat (n=3) brain tissue. Brain tissue 
from the frontal cortex, cerebellum and basal ganglia were dissected from three 
postmortem samples of patients with no CNS pathology. Brain tissue from cerebellum, 
basal ganglia and the occipital cortex of three adult rats was dissected out. Tissue was 
weighed, homogenized in 50 mM HEPES (pH 7.4) and protein values were determined 
using the BCA protein assay kit. Homogenized tissue was incubated with either 0.5-64 
nM [3H](R)-PK11195 or 0.2 to 20 nM [3H]-DAA1106 to obtain total binding values. 
Nonspecific binding was determined in parallel by including 10µM PK11195 or 10µM 
DAA1106 respectively. Specific binding at each given concentration of  [3H]-ligand was 
defined as the difference between total binding and nonspecific binding. Bmax and kd 
values reflective of the total number of binding sites per mg protein and binding affinity 
of the ligand to PBR respectively were determined using PRISM software.  
We first compared the affinity of binding of these two ligands to PBR reflected by 
an inverse proportionality to the dissociation constant kd. Binding affinity for [3H]-
DAA1106 compared to [3H](R)-PK11195 was significantly higher reflected by a five to 
six fold lower kd in all brain regions assessed in normal human and rat brain tissue in 
(Figure 21 B and D). Bmax values were uniformly lower with [3H]-DAA1106 
compared to [3H](R)-PK11195 in both human and rat brain tissue but did not approach 
statistical significance (Figure 21 A and C).  
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Figure 21 [3H]-DAA1106 shows higher binding affinity to PBR when compared with 
[3H](R)-PK11195 
Filtration binding was assessed in normal human brain tissue (n=3, top panel) and normal rat brain tissue 
(n=3, lower panel) using [3H]-DAA1106 and [3H](R)-PK11195. The Bmax (fmols/mg), reflective of the 
total number of binding sites was calculated for both ligands is shown in the left panel (A & C) and the kd 
(nM) reflective of the binding affinity of the ligands to PBR is shown in the right panel (B & D). 
CB=Cerebellum, FC=Frontal Cortex, BG=Basal Ganglia, and OC=Occipital Cortex. Data analyzed using 
student’s t test. 
 (A, C) Bmax with [3H]-DAA1106 assessed in normal human (A) and rat (C) brain tissue was uniformly 
lower than [3H](R)-PK11195 but did not approach statistical significance. 
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(B, D) kd with [3H]-DAA1106 was significantly lower with [3H]-DAA1106 than [3H](R)-PK11195 in all 
brain regions of both human (B) and rat (D) brain tissue , ***p<0.0001, **p<0.001, *p<0.01. 
 
Figure 22 Rat models of neuroinflammation show increased [3H]-DAA1106 and  
[3H](R)-PK11195 
(A-D) Rats were injected with either 20µg of 6-OHDA (A-C) or 50µg of LPS into the striatum (D). Brain 
sections were then stained with tyrosine hydroxylase (TH, marker for dopaminergic terminals, A & 
B) or CD68 (ED1, marker for rat brain macrophages, C&D). Rats injected with 6-OHDA showed a 
decrease in tyrosine hydroxylase staining in the ipsilateral (B) compared to contralateral side (A). 
Rats injected with 6-OHDA (C) and LPS (D) showed activated brain macrophages in the striatum. 
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(E-F) Brain sections obtained from 6-OHDA injected rats were incubated with 1nM [3H]-DAA1106 either 
without (E) or with 1µM DAA1106 (F). [3H]-DAA1106 binds to the lesioned area (E) and is 
competed out by DAA1106 (F), indicating that the binding is specific. 
(G-H) Brain sections obtained from 6-OHDA injected rats were incubated with 1nM [3H](R)-PK11195 
either without (G) or with 1µM PK11195 (H). [3H](R)-PK11195 binds to the lesioned area (G) and 
is competed out by DAA1106 (H), indicating that the binding is specific. 
Rat models of neuroinflammation 
PK11195 binding is higher in CNS tissue in response to neuroinflammatory lesions (17). 
We sought to determine if DAA1106 similarly shows an increase in specific binding in 
neuroinflammation. We also wanted to determine if the high binding affinity of 
DAA1106 observed in normal human tissue is seen in neuroinflammation. We used two 
well-characterized rat models of neuroinflammation. Rats were injected with 20 µg of 6-
hydroxydopamine (6-OHDA) (as a model for Parkinson’s disease) or 50 µg of 
lipopolysaccaride (LPS) into the striatum. Rats were sacrificed 3 weeks and 4 days post 
injection respectively, as maximal neuroinflammation was seen at these time points in 
each of the two models (data not shown). In 6-OHDA lesioned animals, tyrosine 
hydroxylase staining was significantly decreased  (Figure 22 A and B) along with 
increased staining for the brain macrophage marker (rat CD68) on the ipsilateral side 
compared to the contralateral side (Figure 22 C). LPS injected rats showed increased 
staining for the activated brain macrophage marker (rat CD68) on the ipsilateral side 
compared to the contralateral side (Figure 22 D). PK11195 and DAA1106 binding 
characteristics were then compared in each of these two models. 
[3H]-DAA1106 shows higher binding affinity compared to [3H](R)-PK11195 in 
brain tissue obtained from rats lesioned with 6-OHDA. 
We assessed Bmax and kd values for each ligand in the ipsilateral and contralateral side 
of rats lesioned with 6-OHDA (n=3). Bmax values were significantly higher on the 
ipsilateral side compared with the contralateral side with either [3H]-DAA1106 or 
[3H](R)-PK11195 (Figure 23 A). On comparing the two ligands with each other, Bmax 
values did not differ significantly in the same brain region, but kd values were 
significantly lower with [3H]-DAA1106 (Figure 23 A and B). These results were 
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confirmed with autoradiography in frozen sections that showed specific binding of [3H]-
DAA1106 (Figure 22 E and F) and [3H](R)-PK11195 at the site of the lesion in 6-
OHDA lesioned rats (Figure 22 G and H).  These results suggest that [3H]-DAA1106 
binding sites (Bmax) increase in sites of brain inflammation similar to [3H](R)-PK11195. 
Further, [3H]-DAA1106 displays higher binding affinity compared with [3H](R)-
PK11195 in neuroinflammation. 
 
Figure 23 [3H]-DAA1106 shows higher affinity binding compared with [3H](R)-PK11195 in 
6-OHDA injected rats. 
Filtration binding was assessed in rat striatal brain tissue injected with 20µg 6-OHDA (n=3) using [3H]-
DAA1106 and [3H](R)-PK11195.  
(A) The Bmax (fmols/mg), reflective of the total number of binding sites was significantly higher in 
the area ipsilateral to the lesion compared with the area contralateral to the lesion with [3H]-
DAA1106 and [3H](R)-PK11195. [3H]-DAA1106 and [3H](R)-PK11195 Bmax did not differ 
within the same area. 
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(B) The kd (nM), reflective of the ligand binding affinity was not different between the ipsilateral and 
the contralateral regions with the same ligand. However, the kd with [3H]-DAA1106 was 
significantly lower than with [3H](R)-PK11195 in both ipsillateral and contralateral regions. 
Ex-vivo binding analysis shows increased brain retention of [11C]-DAA1106 
compared to [11C](R)-PK11195 in rats lesioned with LPS. 
 [11C]-DAA1106 or [11C](R)-PK11195 (1-2mCi) was injected intravenously into rats 
lesioned with LPS (n=3, each). After a 30-minute uptake the animals were sacrificed, the 
brain was rapidly and sectioned coronally (2mm thick) and imaged on a phosphorimager. 
While both ligands showed retention, [11C]-DAA1106 binding was higher compared to 
[11C](R)-PK11195 at the site of the lesion (Figure 24 A-D). These results are consistent 
with the filtration binding studies suggesting that DAA1106 has higher binding affinity 
compared to PK11195 in neuroinflammation. 
 
 
Figure 24 Ex vivo autoradiography shows higher [11C]-DAA1106 retention compared to 
[11C](R)-PK11195 in rats lesioned with LPS. 
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Rats (n=3) lesioned with 50µg LPS were injected with either [11C]-DAA1106 or [11C](R)-PK11195 (1-
2mCi) intravenously. Brain sections were obtained after a 30-minute uptake and imaged on a 
phosphorimager. 
(A & C) [11C]-DAA1106 retention was observed in lesioned area, but not the contralateral area. 
(B & D) [11C](R)-PK11195 retention was also observed in lesioned area, but at lower levels when 
compared with [11C]-DAA1106. 
PET imaging in with [11C]-DAA1106 in normal rats 
We conducted a series of PET imaging experiments in normal rats to compare the kinetic 
behavior of [11C]-DAA1106 with [11C](R)-PK11195. We injected either [11C]-
DAA1106 or [11C](R)-PK11195 into anesthetized animals and positioned them in the 
microPET scanner to image the brain, heart and lung. To demonstrate specific binding, 
we injected a displacing dose of unlabeled DAA1106 (1.0 mg/kg) 15 min after injection 
of [11C](R)-PK11195 or [11C]-DAA1106.  Time-activity curves of radioactivity 
concentrations were expressed as percent-injected dose per gram normalized by body 
mass (%ID*kg/g, Y-axis) (Figure 25).  
In rat myocardium where PBR sites are known to be abundant, kinetics of 
[11C](R)-PK11195 and [11C]-DAA1106 were similar and both were effectively 
displaced by unlabeled DAA1106 (Figure 25 B, black and red triangles).  Clearance of 
[11C](R)-PK11195 from lung was much faster than [11C]-DAA1106, though both were 
displaced by unlabeled DAA1106 (Figure 25 B, black and red circles). In the rat brain 
[11C]-DAA1106 was effectively displaced by unlabeled DAA1106 (Figure 25 A, red 
triangles). [11C](R)-PK11195 showed an initial displacement followed by brief upswing 
before renewed clearance from brain (Figure 25 A, black triangles). This upswing may 
be the result of recirculation of [11C](R)-PK11195 displaced from peripheral tissues, 
such as the heart and lung (Figure 25 B, black triangles and circles) by the high affinity 
DAA1106 ligand. These studies complement blocking studies of [11C]-DAA1106 with 
unlabeled DAA1106 (1.0 mg/kg) and higher doses (5-10 mg/kg) of unlabeled PK11195 
(149).  
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PET imaging with [11C]-DAA1106 shows increased brain retention compared to 
[11C](R)-PK11195 in 6-OHDA lesioned rats 
[11C]-DAA1106 and [11C](R)-PK11195 were then used sequentially to image rats 
lesioned with 6-OHDA (n=2). When compared with  [11C](R)-PK11195, [11C]-
DAA1106 showed increased brain retention in 6-OHDA lesioned animals as compared to 
normal rats (Figure 26). However, due to limited resolution with PET imaging and the 
small size of the rat brain compared to the human brain, both ligands were unable to 
distinguish between the lesioned and the non-lesioned brain hemispheres in the same 
animal. However, ligand retention was significantly higher in the lesioned animals 
compared to controls. Further, [11C]-DAA1106 showed increased retention compared to 
[11C](R)-PK11195, consistent with our filtration binding and ex-vivo autoradiography 
results suggesting that DAA1106 shows higher affinity to PBR and hence, significantly 
higher retention at sites of neuroinflammation. 
 
Figure 25 [11C]-DAA1106 specific binding in normal rats 
The kinetics of [11C]-DAA1106 or [11C](R)-PK11195 injected in normal rats was followed in the brain, 
heart and lungs in vivo using PET. A displacing does of 1mg/ kg DAA1106 was injected 15 minutes 
(indicated by the dotted black line) after initial the [11C]-ligand administration. Time-activity curves of 
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radioactivity concentrations are expressed as percent-injected dose per gram normalized by body mass 
(%ID*kg/g, Y-axis) plotted against time (minutes, X-axis). 
(A) PET imaging of the brain revealed [11C]-DAA1106 retention (red open squares), which was 
displaced by DAA1106 (red triangles), indicating that [11C]-DAA1106 binding was specific. 
[11C](R)-PK11195 binding showed an initial displacement followed by brief upswing before 
renewed clearance from brain. 
(B) [11C]-DAA1106 retention in the lung (red circles) and myocardium (red triangles) were displaced 
by DAA1106 indicating specific binding in both these organs. Similarly, [11C](R)-PK11195 
binding was displaced by DAA1106 in both the lung (black circles) and myocardium (black 
triangles). 
 
Figure 26 [11C]-DAA1106 binding is higher in 6-OHDA lesioned animals compared to 
controls 
Rats lesioned with 6-OHDA were imaged sequentially with [11C]-DAA1106 and [11C](R)-PK11195 (n=2) 
and compared with control non-injected rats (n=1). [11C]-DAA1106 binding was significantly higher in 6-
OHDA lesioned rats (red squares) compared to the control (red circles). 
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3.4.5 Discussion 
PK11195 is a ligand that specifically binds to PBR expressed in low levels in the normal 
brain and is enriched in brain macrophages in neurological disorders (41, 45). PK11195 
has been used to label brain macrophages in a number of neurodegenerative disorders 
(reviewed in (42)). In this study, we compared the binding characteristics of a newer PBR 
ligand DAA1106 with PK11195 in brain tissues and in rat models of neuroinflammation 
in vivo. We first used filtration binding analyses to compare the pharmacologic properties 
of DAA1106 with PK11195 in normal human and rat brain tissues, followed by binding 
studies in brain tissues obtained from rats lesioned with either LPS or 6-OHDA. In all the 
filtration binding experiments using [3H] labeled ligands, the binding affinity of 
DAA1106 to PBR was significantly higher than PK11195, reflected by a 5-6 fold lower 
dissociation constant (kd). The Bmax, reflective of the number of binding sites, was 
uniformly lower with DAA1106 but was not significantly different from PK11195. Ex-
vivo autoradiography experiments utilizing [11C] labeled ligands, showed increased 
brain retention of DAA1106 compared to PK11195. DAA1106 thus shows similar 
properties as PK11195 and rapidly penetrates the blood brain barrier to enter the CNS. 
Further, [11C]-DAA1106 was displaced by DAA1106 in the brain suggesting [11C]-
DAA1106 binding was specific. Finally, [11C]-DAA1106 showed increased retention in 
6-OHDA lesioned animals compared to [11C](R)-PK11195 binding and controls.  These 
data suggest that DAA1106 binds to PBR with higher affinity and can detect 
neuroinflammation in vivo using PET. 
Our results showing higher PBR-ligand binding in rats injected with either LPS or 
6-OHDA are consistent with previously published studies (31, 56, 212). However, 
Cicchetti et. al. report the ability to distinguish between the ipsilateral and contralateral 
regions of 6-OHDA lesioned animals using PET with [11C](R)-PK11195 (56). In our 
experience, the resolution of PET along with the small size of the rat brain did not enable 
us to distinguish between ipsilateral and contralateral regions with either [11C](R)-
PK11195 or [11C]-DAA1106. However, animals lesioned with 6-OHDA showed 
increased brain retention of both ligands compared to controls. This binding was specific 
as it was displaced by cold DAA1106 in control animals. 
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[11C](R)-PK11195 has been used extensively to image neuroinflammation in 
vivo using PET (42). Studies in AD patients showed high [11C](R)-PK11195 binding in 
the entorhinal, temporoparietal and cingulate cortex, which are brain regions that show 
the highest degree of AD pathology (41). However, this study also reported high levels of 
[11C](R)-PK11195 binding in regions not involved in AD such as the thalamus and the 
brainstem (41). The authors interpret these findings arising due to a mechanism called 
“synaptic stripping” that may be the result of increased brain macrophage activation in 
regions synaptically connected to areas of pathology. It is also possible that these signals 
may arise from non-specific [11C](R)-PK11195 binding. Similarly, a recent report using 
[11C](R)-PK11195 to image activated brain macrophages in ALS patients showed high 
binding in the occipital cortex, regions of the prefrontal cortex, and the thalamus, which 
are areas that are not traditionally implicated in ALS pathology (238). Both these studies 
were not followed up by neuropathologic assessments with filtration binding analyses (to 
determine ligand-receptor binding characteristics), and the presence of activated brain 
macrophages in regions traditionally not involved in the disease pathology cannot be 
ruled out. However, these findings may be attributed to some degree of non-specific 
binding of PK11195, underscoring the importance of using a ligand with high specific 
binding to PBR. The higher affinity of DAA1106 to PBR may be able to address some of 
these concerns.  
In conclusion, DAA1106 shows higher affinity to PBR, reflected by a 5-6 fold 
lowers kd, in comparison to PK11195 in both human and rat brain tissues. DAA1106 was 
also effectively crossed the blood brain barrier and was retained at higher levels in rats 
lesioned with either LPS or 6-OHDA. These results suggest that DAA1106 may be a 
better ligand than PK11195 to image neuroinflammation in vivo using PET. 
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4.0  OVERALL DISCUSSION  
4.1.1 Summary 
Neuroinflammation is seen in several neurodegenerative disorders and constitutes a 
significant component of the underlying pathology. In this body of work, we take 
advantage of increased PBR expression on brain macrophages to image these cells in 
vivo utilizing PET. We utilize two specific PBR ligands, PK11195 and DAA1106, to 
compare ligand binding in (1) human postmortem brain tissue and animal models of 
neuroinflammation (2) cell culture systems to dissect out relative contributions to ligand 
binding from macrophages and astrocytes and (3) animal models of disease utilizing 
PET.  
Specifically, we found that SIV infected macaques that show higher levels of 
[11C](R)-PK11195 binding corresponded to the presence of SIV encephalitis on post 
mortem examination. Macaques that did not show an increase in [11C](R)-PK11195 
binding did not exhibit SIVE. Brain post mortem [3H](R)-PK11195 binding was 
significantly higher in SIVE macaques from controls due to an increase in the number of 
binding sites (Bmax) with no significant changes in binding affinity (Kd) and correlated 
with in vivo binding measured with PET. Brain regions with elevated PK11195 binding 
on PET and filtration assays correlated with abundant activated macrophages but not with 
activated astrocytes or neurons quantified by laser confocal microscopy. Finally, 
combined autoradiography and immunostaining identified macrophages, but not 
astrocytes as the cells with highest [3H](R)-PK11195 binding. 
HIV encephalitic brain tissue showed a significant increase in binding with both 
PK11195 and DAA1106 compared to HIV infected, non-encephalitic controls and non-
infected brain tissue. We also saw an increase in [3H]-DAA1106 binding in SIVE tissue 
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compared to SIV infected, non-encephalitic and non-infected tissue. Increased expression 
was specific to macrophages as determined by combined immunohistochemistry and 
autoradiography in SIVE tissue. In tissue culture experiments, we found increased 
[3H](R)-PK11195 binding in macrophages activated with LPS or INF-γ compared to 
unactivated macrophages, astrocytes activated with dCAMP and unactivated astrocytes. 
Similar results were seen in mitochondrial fractions harvested from activated and 
unactivated macrophages and astrocytes using [3H]-DAA1106. Increase in [3H](R)-
PK11195 binding was also seen in macrophages infected with HIV-1 ADAM, peaking at 
14 days post infection and reaching a plateau by 21 days post infection. Astrocytes 
treated with supernatants derived from HIV-1 ADMA infected macrophages did not 
show a significant increase in [3H](R)-PK11195 binding compared to untreated cultures. 
The increase in [3H](R)-PK11195 binding in LPS treated macrophages was reversed 
using inhibitors of PI3-kinase, but not a MEK-1/2 inhibitor. 
In postmortem brain tissue obtained from AD subjects we found increased 
[3H](R)-PK11195 binding in the frontal cortex but not the cerebellum, suggesting that 
the increase in [3H](R)-PK11195 binding was specific to regions of AD pathology. Mice 
expressing the APPSwe/PSEN1-DeltaE9 mutations showed an in vivo, age-dependent 
moderate increase in [11C](R)-PK11195 binding compared with controls. 
Immunohistochemical examination of brain tissue from transgenic mice and AD showed 
significant differences in extent of neuroinflammation. AD postmortem tissue showed an 
increase in both brain macrophages and astrocytes, while brain tissue from Tg mice 
showed an increase in mainly astrocytes.  
On comparing the pharmacologic characteristics of DAA1106 with PK11195, we 
found that the binding affinity of DAA1106 to PBR was significantly higher than 
PK11195, reflected by a 5-6 fold lower dissociation constant (kd). The Bmax, reflective 
of the number of binding sites, was uniformly lower with DAA1106 but was not 
significantly different from PK11195. Ex-vivo autoradiography experiments utilizing 
[11C] labeled ligands, showed increased brain retention of DAA1106 compared to 
PK11195. In PET experiments, [11C]-DAA1106 was displaced by DAA1106 in the brain 
suggesting that in vivo [11C]-DAA1106 binding was specific. Finally, [11C]-DAA1106 
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showed increased retention in 6-OHDA lesioned animals compared to [11C](R)-
PK11195 binding and controls. 
These results taken together suggest that ligands to PBR specifically label brain 
macrophages and can be used to image these cells in vivo using PET in 
neuroinflammation. 
4.1.2 Discussion and future directions 
PBR can be used to label brain macrophages in vivo in neuroinflammation 
We have shown that ligands to PBR can label brain macrophages in many 
neurodegenerative disorders including HIV encephalitis, Alzheimer’s disease and animal 
models of Parkinson’s disease. These data taken together suggest that increased 
expression of PBR is a common aspect of neuroinflammation and can be used to image 
brain macrophages in vivo. Our findings support the hypothesis that PBR-ligand binding 
may be a surrogate marker of activated brain macrophages and active loci of 
neuroinflammation in neurodegenerative disease. Although, the pathogenesis of these 
various diseases differ enormously, the common finding that PBR is expressed in brain 
macrophages in these diseases suggests that mechanisms and pathways responsible for 
brain macrophage activation are similar in these diseases.  
In future experiments, we will expand on determining the biochemical processes 
that link PBR expression with brain macrophage activation. Our initial results suggest 
that PBR expression is mediated by the activation of the PI3K/Akt pathway. We will 
utilize cell culture systems to dissect out this pathway in relation to both brain 
macrophage activation and PBR expression in more detail.  
What is the function of PBR in activated brain macrophages? 
The functional significance of increased PBR in activated brain macrophages is not 
known.  It is part of a hetero-oligomeric complex comprised of the voltage-dependent 
anion channel and an adenine nucleotide carrier forming the mitochondrial permeability 
transition pore (160). It is thought to be involved in neurosteroid synthesis by serving to 
transport cholesterol from the outer to the inner mitochondrial membranes (190). As a 
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constituent of the mitochondrial permeability transition pore it is thought to regulate cell 
death (160) and mitochondrial respiration (117). PBR overexpression in many cell types 
has also been shown to protect against various apoptotic insults including the cytopathic 
effects of sindbis and myxoma viral infections (80, 125). Forced PBR expression in 
neurons in vivo and jurkat cells in vitro protects these cells against apoptosis (125, 234). 
PBR upregulation in testicular leydig cells protects them from cytokine-induced toxicity 
(20, 237). This is also seen in blood phagocytic cells where PBR protects against oxidant 
induced cell death (44). 
Several proteins involved in apoptosis including Bcl-2, Bcl-Xl and Bax have also 
been shown to physically interact with the voltage dependent anion channel and the 
adenine nucleotide carrier (62, 112). PBR can thus influence the cell death processes 
either by directly affecting the molecular components of the pore or through indirect 
effects by interfering with interactions of the voltage dependent anion channel and the 
adenine nucleotide carrier with pro-apoptotic proteins like Bax (46). These hypotheses 
draw support from kainic acid-injected rats, where hippocampal PBR is increased by 20 
fold with no significant increases in either the voltage dependent anion channel or the 
adenine nucleotide carrier (244). Increases in only the PBR component of the pore might 
result in altering both the channel properties and altering interactions of other pore 
proteins with pro-apoptotic mediators.  
The biochemical mechanisms by which selective increase in expression of PBR in 
activated brain macrophages in several of these CNS diseases is not understood (91). In 
pancreatic islet cells, testicular leydig cells, the cytokines TNF-α, IFN-γ and IL-1β 
caused an increase in mitochondrial PBR mRNA and [3H](R)-PK11195 binding in a 
transcription dependent manner (20, 237). In the CNS, rats injected with IL-1, or TNF-α , 
or LPS resulted in increased [3H](R)-PK11195 binding to brain macrophages (31, 35). 
IL-1 and TNF-α also increase [3H](R)-PK11195 binding in cultured astrocytes (65). 
Finally, in Experimental Autoimmune Encephalitis, IL-6 and TNF-α expression profiles 
correlate with increase in spinal cord [3H](R)-PK11195 binding (5). These data suggest 
that cytokines increase PBR expression in various cell types including macrophages. 
However, the mechanisms mediating this increase are not known. Cellular upregulation 
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of PBR in these systems may serve as a protective strategy against cytokine toxicity by 
altering mitochondrial permeability transition and consequent cell death.  
Since brain macrophages are themselves sources of cytokines and several other 
toxic products, it is possible that the function of PBR in activated brain macrophages is to 
protect them from self-generated toxins by influencing mitochondrial permeability 
transition and preventing apoptosis of these cells in the CNS. We hypothesize that PBR 
expression in brain macrophages prevents these cells from undergoing toxin-induced cell 
death in neurodegenerative disorders.  
To test this hypothesis, we will first determine the effects of increased PBR 
expression on mitochondrial permeability transition. We will also utilize RNA inhibition 
(RNAi) technologies to knock down PBR in brain macrophages. A prediction of this 
hypothesis is that PBR knockdown will increase cell death in brain macrophages. We will 
compare mitochondrial potential changes and cell death in macrophages that have been 
treated with RNAi with control untreated cells. These studies will help us better 
understand the role of PBR in activated brain macrophages. It is also conceivable that a 
longer life span of brain macrophages would lead to exacerbation of neuroinflammation 
and subsequently the neurodegenerative process. If PBR regulates cell survival in brain 
macrophages, it may prove a suitable target to decrease the viability of these cells in 
neuroinflammation. 
Implications of detecting neuroinflammation in vivo 
The clinical diagnosis of neurodegenerative disorders requires the presence of irreversible 
clinical symptoms and signs. Traditional imaging studies such as CT and MRI have not 
been of much assistance in the diagnosis of dementia in general (66). Current 
methodologies, such as structural MRI assessment of brain volume are insensitive late 
measures of neurological damage and the diagnosis by neurocognitive tests is possible 
only after irreversible neuronal damage has occurred. Effective therapy requires early 
intervention at the onset of neuronal injury prior to the appearance of irreversible signs 
and symptoms. PET imaging of brain macrophages in neurodegenerative may enable 
early diagnosis and therapeutic interventions. 
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To design therapies for neurodegenerative disorders, it is critical to be able to 
monitor their success in arresting the progression of neurological disease. Monitoring 
therapeutic efficacy of any such treatments is also complicated by the fact that one can 
only assess absence of disease progression and not recovery of function. Any attempt to 
develop therapy targeted at neuroinflammation for diseases such as AIDS dementia, 
Alzheimer’s disease or Multiple Sclerosis will require some means of monitoring the 
inflammatory pathogenic process, activated brain macrophages. Imaging brain 
macrophages may provide a better index of disease progression during treatment with 
antiinflammatory and other potentially neuroprotective drugs. PET imaging of brain 
macrophages with PBR ligands may be able to help in the early prediction of 
neuroinflammation, monitor the severity and progression of the disease, and help 
evaluate the effectiveness of CNS therapies aimed at decreasing neuroinflammation. 
 
 
 
 120 
BIBLIOGRAPHY 
1. 1996. Clinical confirmation of the American Academy of Neurology algorithm for HIV-
1-associated cognitive/motor disorder. The Dana Consortium on Therapy for HIV 
Dementia and Related Cognitive Disorders. Neurology 47:1247-53. 
2. Achim, C. L., M. P. Heyes, and C. A. Wiley. 1993. Quantitation of human 
immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains. 
J Clin Invest 91:2769-75. 
3. Adamson, D. C., J. C. McArthur, T. M. Dawson, and V. L. Dawson. 1999. Rate and 
severity of HIV-associated dementia (HAD): correlations with Gp41 and iNOS. Mol Med 
5:98-109. 
4. Adamson, D. C., B. Wildemann, M. Sasaki, J. D. Glass, J. C. McArthur, V. I. 
Christov, T. M. Dawson, and V. L. Dawson. 1996. Immunologic NO synthase: 
elevation in severe AIDS dementia and induction by HIV-1 gp41. Science 274:1917-21. 
5. Agnello, D., L. Carvelli, V. Muzio, P. Villa, B. Bottazzi, N. Polentarutti, T. Mennini, 
A. Mantovani, and P. Ghezzi. 2000. Increased peripheral benzodiazepine binding sites 
and pentraxin 3 expression in the spinal cord during EAE: relation to inflammatory 
cytokines and modulation by dexamethasone and rolipram. J Neuroimmunol 109:105-11. 
6. Aisen, P. S., K. A. Schafer, M. Grundman, E. Pfeiffer, M. Sano, K. L. Davis, M. R. 
Farlow, S. Jin, R. G. Thomas, and L. J. Thal. 2003. Effects of rofecoxib or naproxen 
vs placebo on Alzheimer disease progression: a randomized controlled trial. Jama 
289:2819-26. 
7. Akiyama, H., C. Schwab, H. Kondo, H. Mori, F. Kametani, K. Ikeda, and P. L. 
McGeer. 1996. Granules in glial cells of patients with Alzheimer's disease are 
immunopositive for C-terminal sequences of beta-amyloid protein. Neurosci Lett 
206:169-72. 
8. Albert, M. S., and D. A. Drachman. 2000. Alzheimer's disease: what is it, how many 
people have it, and why do we need to know? Neurology 55:166-8. 
9. Alkhatib, G., C. Combadiere, C. C. Broder, Y. Feng, P. E. Kennedy, P. M. Murphy, 
and E. A. Berger. 1996. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a 
fusion cofactor for macrophage-tropic HIV-1. Science 272:1955-8. 
10. Anders, K. H., W. F. Guerra, U. Tomiyasu, M. A. Verity, and H. V. Vinters. 1986. 
The neuropathology of AIDS. UCLA experience and review. Am J Pathol 124:537-58. 
11. Aquaro, S., P. Bagnarelli, T. Guenci, A. De Luca, M. Clementi, E. Balestra, R. Calio, 
and C. F. Perno. 2002. Long-term survival and virus production in human primary 
macrophages infected by human immunodeficiency virus. J Med Virol 68:479-88. 
 1 
12. Aquaro, S., E. Balestra, A. Cenci, M. Francesconi, R. Calio, and C. F. Perno. 1997. 
HIV infection in macrophage: role of long-lived cells and related therapeutical strategies. 
J Biol Regul Homeost Agents 11:69-73. 
13. Autran, B., G. Carcelain, T. S. Li, C. Blanc, D. Mathez, R. Tubiana, C. Katlama, P. 
Debre, and J. Leibowitch. 1997. Positive effects of combined antiretroviral therapy on 
CD4+ T cell homeostasis and function in advanced HIV disease. Science 277:112-6. 
14. Avison, M. J., A. Nath, and J. R. Berger. 2002. Understanding pathogenesis and 
treatment of HIV dementia: a role for magnetic resonance? Trends Neurosci 25:468-73. 
15. Aylward, E. H., J. D. Henderer, J. C. McArthur, P. D. Brettschneider, G. J. Harris, 
P. E. Barta, and G. D. Pearlson. 1993. Reduced basal ganglia volume in HIV-1-
associated dementia: results from quantitative neuroimaging. Neurology 43:2099-104. 
16. Bamberger, M. E., and G. E. Landreth. 2001. Microglial interaction with beta-
amyloid: implications for the pathogenesis of Alzheimer's disease. Microsc Res Tech 
54:59-70. 
17. Banati, R. B. 2002. Visualising microglial activation in vivo. Glia 40:206-17. 
18. Banati, R. B., G. W. Goerres, R. Myers, R. N. Gunn, F. E. Turkheimer, G. W. 
Kreutzberg, D. J. Brooks, T. Jones, and J. S. Duncan. 1999. [11C](R)-PK11195 
positron emission tomography imaging of activated microglia in vivo in Rasmussen's 
encephalitis. Neurology 53:2199-203. 
19. Banati, R. B., R. Myers, and G. W. Kreutzberg. 1997. PK ('peripheral 
benzodiazepine')--binding sites in the CNS indicate early and discrete brain lesions: 
microautoradiographic detection of [3H]PK11195 binding to activated microglia. J 
Neurocytol 26:77-82. 
20. Banati, R. B., J. Newcombe, R. N. Gunn, A. Cagnin, F. Turkheimer, F. Heppner, G. 
Price, F. Wegner, G. Giovannoni, D. H. Miller, G. D. Perkin, T. Smith, A. K. 
Hewson, G. Bydder, G. W. Kreutzberg, T. Jones, M. L. Cuzner, and R. Myers. 2000. 
The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative 
in vivo imaging of microglia as a measure of disease activity. Brain 123 ( Pt 11):2321-
37. 
21. Bard, F., R. Barbour, C. Cannon, R. Carretto, M. Fox, D. Games, T. Guido, K. 
Hoenow, K. Hu, K. Johnson-Wood, K. Khan, D. Kholodenko, C. Lee, M. Lee, R. 
Motter, M. Nguyen, A. Reed, D. Schenk, P. Tang, N. Vasquez, P. Seubert, and T. 
Yednock. 2003. Epitope and isotype specificities of antibodies to beta -amyloid peptide 
for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S 
A 100:2023-8. 
22. Bard, F., C. Cannon, R. Barbour, R. L. Burke, D. Games, H. Grajeda, T. Guido, K. 
Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, I. Lieberburg, 
R. Motter, M. Nguyen, F. Soriano, N. Vasquez, K. Weiss, B. Welch, P. Seubert, D. 
Schenk, and T. Yednock. 2000. Peripherally administered antibodies against amyloid 
beta-peptide enter the central nervous system and reduce pathology in a mouse model of 
Alzheimer disease. Nat Med 6:916-9. 
23. Barre-Sinoussi, F., J. C. Chermann, F. Rey, M. T. Nugeyre, S. Chamaret, J. Gruest, 
C. Dauguet, C. Axler-Blin, F. Vezinet-Brun, C. Rouzioux, W. Rozenbaum, and L. 
Montagnier. 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for 
acquired immune deficiency syndrome (AIDS). Science 220:868-71. 
 2 
24. Baskin, G. B., M. Murphey-Corb, E. D. Roberts, P. J. Didier, and L. N. Martin. 
1992. Correlates of SIV encephalitis in rhesus monkeys. J Med Primatol 21:59-63. 
25. Bauer, J., T. Sminia, F. G. Wouterlood, and C. D. Dijkstra. 1994. Phagocytic activity 
of macrophages and microglial cells during the course of acute and chronic relapsing 
experimental autoimmune encephalomyelitis. J Neurosci Res 38:365-75. 
26. Bennett, D. A. 2000. Part II. Clinical diagnosis and course of Alzheimer's disease. Dis 
Mon 46:666-86. 
27. Benveniste, E. N., V. T. Nguyen, and G. M. O'Keefe. 2001. Immunological aspects of 
microglia: relevance to Alzheimer's disease. Neurochem Int 39:381-91. 
28. Benzing, W. C., J. R. Wujek, E. K. Ward, D. Shaffer, K. H. Ashe, S. G. Younkin, 
and K. R. Brunden. 1999. Evidence for glial-mediated inflammation in aged APP(SW) 
transgenic mice. Neurobiol Aging 20:581-9. 
29. Bergamini, A., E. Faggioli, F. Bolacchi, S. Gessani, L. Cappannoli, I. Uccella, F. 
Demin, M. Capozzi, R. Cicconi, R. Placido, S. Vendetti, G. M. Colizzi, and G. 
Rocchi. 1999. Enhanced production of tumor necrosis factor-alpha and interleukin-6 due 
to prolonged response to lipopolysaccharide in human macrophages infected in vitro with 
human immunodeficiency virus type 1. J Infect Dis 179:832-42. 
30. Bianca, V. D., S. Dusi, E. Bianchini, I. Dal Pra, and F. Rossi. 1999. beta-amyloid 
activates the O-2 forming NADPH oxidase in microglia, monocytes, and neutrophils. A 
possible inflammatory mechanism of neuronal damage in Alzheimer's disease. J Biol 
Chem 274:15493-9. 
31. Biegon, A., M. Alvarado, T. F. Budinger, R. Grossman, K. Hensley, M. S. West, Y. 
Kotake, M. Ono, and R. A. Floyd. 2002. Region-selective effects of neuroinflammation 
and antioxidant treatment on peripheral benzodiazepine receptors and NMDA receptors 
in the rat brain. J Neurochem 82:924-34. 
32. Bissel, S. J., G. Wang, M. Ghosh, T. A. Reinhart, S. Capuano, 3rd, K. Stefano Cole, 
M. Murphey-Corb, M. Piatak Jr, Jr., J. D. Lifson, and C. A. Wiley. 2002. 
Macrophages relate presynaptic and postsynaptic damage in simian immunodeficiency 
virus encephalitis. Am J Pathol 160:927-41. 
33. Bleich, S., J. Wiltfang, and J. Kornhuber. 2003. Memantine in moderate-to-severe 
Alzheimer's disease. N Engl J Med 349:609-10; author reply 609-10. 
34. Borchelt, D. R., T. Ratovitski, J. van Lare, M. K. Lee, V. Gonzales, N. A. Jenkins, N. 
G. Copeland, D. L. Price, and S. S. Sisodia. 1997. Accelerated amyloid deposition in 
the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor 
proteins. Neuron 19:939-45. 
35. Bourdiol, F., S. Toulmond, A. Serrano, J. Benavides, and B. Scatton. 1991. Increase 
in omega 3 (peripheral type benzodiazepine) binding sites in the rat cortex and striatum 
after local injection of interleukin-1, tumour necrosis factor-alpha and 
lipopolysaccharide. Brain Res 543:194-200. 
36. Bradbury, J. 2005. Hope for AD with NGF gene-therapy trial. Lancet Neurol 4:335. 
37. Brew, B. J. 1999. AIDS dementia complex. Neurol Clin 17:861-81. 
38. Brew, B. J., M. Rosenblum, K. Cronin, and R. W. Price. 1995. AIDS dementia 
complex and HIV-1 brain infection: clinical-virological correlations. Ann Neurol 38:563-
70. 
39. Budka, H. 1991. Neuropathology of human immunodeficiency virus infection. Brain 
Pathol 1:163-75. 
 3 
40. Budka, H., G. Costanzi, S. Cristina, A. Lechi, C. Parravicini, R. Trabattoni, and L. 
Vago. 1987. Brain pathology induced by infection with the human immunodeficiency 
virus (HIV). A histological, immunocytochemical, and electron microscopical study of 
100 autopsy cases. Acta Neuropathol (Berl) 75:185-98. 
41. Cagnin, A., D. J. Brooks, A. M. Kennedy, R. N. Gunn, R. Myers, F. E. Turkheimer, 
T. Jones, and R. B. Banati. 2001. In-vivo measurement of activated microglia in 
dementia. Lancet 358:461-7. 
42. Cagnin, A., A. Gerhard, and R. B. Banati. 2002. In vivo imaging of 
neuroinflammation. Eur Neuropsychopharmacol 12:581-6. 
43. Cagnin, A., R. Myers, R. N. Gunn, A. D. Lawrence, T. Stevens, G. W. Kreutzberg, 
T. Jones, and R. B. Banati. 2001. In vivo visualization of activated glia by [11C] (R)-
PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond 
the primary focal lesion. Brain 124:2014-27. 
44. Carayon, P., M. Portier, D. Dussossoy, A. Bord, G. Petitpretre, X. Canat, G. Le Fur, 
and P. Casellas. 1996. Involvement of peripheral benzodiazepine receptors in the 
protection of hematopoietic cells against oxygen radical damage. Blood 87:3170-8. 
45. Casellas, P., S. Galiegue, and A. S. Basile. 2002. Peripheral benzodiazepine receptors 
and mitochondrial function. Neurochem Int 40:475-86. 
46. Castedo, M., J. L. Perfettini, and G. Kroemer. 2002. Mitochondrial apoptosis and the 
peripheral benzodiazepine receptor: a novel target for viral and pharmacological 
manipulation. J Exp Med 196:1121-5. 
47. Chaki, S., T. Funakoshi, R. Yoshikawa, S. Okuyama, T. Okubo, A. Nakazato, M. 
Nagamine, and K. Tomisawa. 1999. Binding characteristics of [3H]DAA1106, a novel 
and selective ligand for peripheral benzodiazepine receptors. Eur J Pharmacol 371:197-
204. 
48. Chan, A., R. Seguin, T. Magnus, C. Papadimitriou, K. V. Toyka, J. P. Antel, and R. 
Gold. 2003. Phagocytosis of apoptotic inflammatory cells by microglia and its 
therapeutic implications: termination of CNS autoimmune inflammation and modulation 
by interferon-beta. Glia 43:231-42. 
49. Chang, L., T. Ernst, M. Leonido-Yee, I. Walot, and E. Singer. 1999. Cerebral 
metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor 
complex. Neurology 52:100-8. 
50. Chang, L., O. Speck, E. N. Miller, J. Braun, J. Jovicich, C. Koch, L. Itti, and T. 
Ernst. 2001. Neural correlates of attention and working memory deficits in HIV patients. 
Neurology 57:1001-7. 
51. Chao, C. C., S. Hu, T. W. Molitor, E. G. Shaskan, and P. K. Peterson. 1992. 
Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J 
Immunol 149:2736-41. 
52. Chao, C. C., S. Hu, and P. K. Peterson. 1995. Modulation of human microglial cell 
superoxide production by cytokines. J Leukoc Biol 58:65-70. 
53. Chao, C. C., S. Hu, W. S. Sheng, and P. K. Peterson. 1995. Tumor necrosis factor-
alpha production by human fetal microglial cells: regulation by other cytokines. Dev 
Neurosci 17:97-105. 
54. Chen, M. K., K. Baidoo, T. Verina, and T. R. Guilarte. 2004. Peripheral 
benzodiazepine receptor imaging in CNS demyelination: functional implications of 
anatomical and cellular localization. Brain 127:1379-92. 
 4 
55. Cherner, M., E. Masliah, R. J. Ellis, T. D. Marcotte, D. J. Moore, I. Grant, and R. 
K. Heaton. 2002. Neurocognitive dysfunction predicts postmortem findings of HIV 
encephalitis. Neurology 59:1563-7. 
56. Cicchetti, F., A. L. Brownell, K. Williams, Y. I. Chen, E. Livni, and O. Isacson. 2002. 
Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine 
degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J 
Neurosci 15:991-8. 
57. Cinque, P., P. Scarpellini, L. Vago, A. Linde, and A. Lazzarin. 1997. Diagnosis of 
central nervous system complications in HIV-infected patients: cerebrospinal fluid 
analysis by the polymerase chain reaction. Aids 11:1-17. 
58. Cinque, P., L. Vago, M. Mengozzi, V. Torri, D. Ceresa, E. Vicenzi, P. Transidico, A. 
Vagani, S. Sozzani, A. Mantovani, A. Lazzarin, and G. Poli. 1998. Elevated 
cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 
encephalitis and local viral replication. Aids 12:1327-32. 
59. Citron, M. 2004. Strategies for disease modification in Alzheimer's disease. Nat Rev 
Neurosci 5:677-85. 
60. Cleij MC, A. F., Baron JC, Clark JC. 2003. Presented at the 15th International 
Symposium on Radiopharmaceutical Chemistry. 
61. Colton, C. A., J. E. Keri, W. T. Chen, and W. L. Monsky. 1993. Protease production 
by cultured microglia: substrate gel analysis and immobilized matrix degradation. J 
Neurosci Res 35:297-304. 
62. Crompton, M. 1999. The mitochondrial permeability transition pore and its role in cell 
death. Biochem J 341 ( Pt 2):233-49. 
63. Czub, S., J. G. Muller, M. Czub, and H. K. Muller-Hermelink. 1996. Impact of 
various simian immunodeficiency virus variants on induction and nature of 
neuropathology in macaques. Res Virol 147:165-70. 
64. D'Aversa, T. G., K. M. Weidenheim, and J. W. Berman. 2002. CD40-CD40L 
interactions induce chemokine expression by human microglia: implications for human 
immunodeficiency virus encephalitis and multiple sclerosis. Am J Pathol 160:559-67. 
65. Dal Pan, G. J., J. H. McArthur, E. Aylward, O. A. Selnes, T. E. Nance-Sproson, A. 
J. Kumar, E. D. Mellits, and J. C. McArthur. 1992. Patterns of cerebral atrophy in 
HIV-1-infected individuals: results of a quantitative MRI analysis. Neurology 42:2125-
30. 
66. Das, P., V. Howard, N. Loosbrock, D. Dickson, M. P. Murphy, and T. E. Golde. 
2003. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-
/- knock-out mice. J Neurosci 23:8532-8. 
67. Davalos, D., J. Grutzendler, G. Yang, J. V. Kim, Y. Zuo, S. Jung, D. R. Littman, M. 
L. Dustin, and W. B. Gan. 2005. ATP mediates rapid microglial response to local brain 
injury in vivo. Nat Neurosci 8:752-8. 
68. Davis, L. E., B. L. Hjelle, V. E. Miller, D. L. Palmer, A. L. Llewellyn, T. L. Merlin, 
S. A. Young, R. G. Mills, W. Wachsman, and C. A. Wiley. 1992. Early viral brain 
invasion in iatrogenic human immunodeficiency virus infection. Neurology 42:1736-9. 
69. Debruyne, J. C., J. Versijpt, K. J. Van Laere, F. De Vos, J. Keppens, K. 
Strijckmans, E. Achten, G. Slegers, R. A. Dierckx, J. Korf, and J. L. De Reuck. 
2003. PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. 
Eur J Neurol 10:257-64. 
 5 
70. Del Rio Hortega, P. 1932. Cytology and Cellular Pathology of the Nervous system, 
Penfield, W., ed. ed. Hoeber, New York. 
71. DeMattos, R. B., K. R. Bales, D. J. Cummins, J. C. Dodart, S. M. Paul, and D. M. 
Holtzman. 2001. Peripheral anti-A beta antibody alters CNS and plasma A beta 
clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. 
Proc Natl Acad Sci U S A 98:8850-5. 
72. Dickson, D. W. 1999. Microglia in Alzheimer's disease and transgenic models. How 
close the fit? Am J Pathol 154:1627-31. 
73. Doody, R. S. 1999. Therapeutic standards in Alzheimer disease. Alzheimer Dis Assoc 
Disord 13 Suppl 2:S20-6. 
74. Dore, G. J., P. K. Correll, Y. Li, J. M. Kaldor, D. A. Cooper, and B. J. Brew. 1999. 
Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. 
Aids 13:1249-53. 
75. Dragic, T., V. Litwin, G. P. Allaway, S. R. Martin, Y. Huang, K. A. Nagashima, C. 
Cayanan, P. J. Maddon, R. A. Koup, J. P. Moore, and W. A. Paxton. 1996. HIV-1 
entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 
381:667-73. 
76. Du, Y., Z. Ma, S. Lin, R. C. Dodel, F. Gao, K. R. Bales, L. C. Triarhou, E. Chernet, 
K. W. Perry, D. L. Nelson, S. Luecke, L. A. Phebus, F. P. Bymaster, and S. M. Paul. 
2001. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP 
model of Parkinson's disease. Proc Natl Acad Sci U S A 98:14669-74. 
77. Ekdahl, C. T., J. H. Claasen, S. Bonde, Z. Kokaia, and O. Lindvall. 2003. 
Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci U S A 
100:13632-7. 
78. Ernst, T., L. Chang, and S. Arnold. 2003. Increased glial metabolites predict increased 
working memory network activation in HIV brain injury. Neuroimage 19:1686-93. 
79. Everall, I. P., R. K. Heaton, T. D. Marcotte, R. J. Ellis, J. A. McCutchan, J. H. 
Atkinson, I. Grant, M. Mallory, and E. Masliah. 1999. Cortical synaptic density is 
reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. 
HNRC Group. HIV Neurobehavioral Research Center. Brain Pathol 9:209-17. 
80. Everett, H., M. Barry, X. Sun, S. F. Lee, C. Frantz, L. G. Berthiaume, G. 
McFadden, and R. C. Bleackley. 2002. The myxoma poxvirus protein, M11L, prevents 
apoptosis by direct interaction with the mitochondrial permeability transition pore. J Exp 
Med 196:1127-39. 
81. Everett, H., and G. McFadden. 2001. Viruses and apoptosis: meddling with 
mitochondria. Virology 288:1-7. 
82. Fauci, A. S., G. Pantaleo, S. Stanley, and D. Weissman. 1996. Immunopathogenic 
mechanisms of HIV infection. Ann Intern Med 124:654-63. 
83. Fedoroff, S., R. Zhai, and J. P. Novak. 1997. Microglia and astroglia have a common 
progenitor cell. J Neurosci Res 50:477-86. 
84. Feng, Y., C. C. Broder, P. E. Kennedy, and E. A. Berger. 1996. HIV-1 entry cofactor: 
functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 
272:872-7. 
85. Ferrer, I., M. Boada Rovira, M. L. Sanchez Guerra, M. J. Rey, and F. Costa-Jussa. 
2004. Neuropathology and pathogenesis of encephalitis following amyloid-beta 
immunization in Alzheimer's disease. Brain Pathol 14:11-20. 
 6 
86. Fetler, L., and S. Amigorena. 2005. Neuroscience. Brain under surveillance: the 
microglia patrol. Science 309:392-3. 
87. Frackowiak, J., H. M. Wisniewski, J. Wegiel, G. S. Merz, K. Iqbal, and K. C. Wang. 
1992. Ultrastructure of the microglia that phagocytose amyloid and the microglia that 
produce beta-amyloid fibrils. Acta Neuropathol (Berl) 84:225-33. 
88. Frautschy, S. A., G. M. Cole, and A. Baird. 1992. Phagocytosis and deposition of 
vascular beta-amyloid in rat brains injected with Alzheimer beta-amyloid. Am J Pathol 
140:1389-99. 
89. Frautschy, S. A., F. Yang, M. Irrizarry, B. Hyman, T. C. Saido, K. Hsiao, and G. M. 
Cole. 1998. Microglial response to amyloid plaques in APPsw transgenic mice. Am J 
Pathol 152:307-17. 
90. Garaci, E., M. C. Caroleo, L. Aloe, S. Aquaro, M. Piacentini, N. Costa, A. 
Amendola, A. Micera, R. Calio, C. F. Perno, and R. Levi-Montalcini. 1999. Nerve 
growth factor is an autocrine factor essential for the survival of macrophages infected 
with HIV. Proc Natl Acad Sci U S A 96:14013-8. 
91. Gavish, M., I. Bachman, R. Shoukrun, Y. Katz, L. Veenman, G. Weisinger, and A. 
Weizman. 1999. Enigma of the peripheral benzodiazepine receptor. Pharmacol Rev 
51:629-50. 
92. Gehlert, D. R., D. T. Stephenson, D. A. Schober, K. Rash, and J. A. Clemens. 1997. 
Increased expression of peripheral benzodiazepine receptors in the facial nucleus 
following motor neuron axotomy. Neurochem Int 31:705-13. 
93. Gehrmann, J., Y. Matsumoto, and G. W. Kreutzberg. 1995. Microglia: intrinsic 
immuneffector cell of the brain. Brain Res Brain Res Rev 20:269-87. 
94. Geraci, A. P., and D. M. Simpson. 2001. Neurological manifestations of HIV-1 
infection in the HAART era. Compr Ther 27:232-41. 
95. Gerhard, A., R. B. Banati, G. B. Goerres, A. Cagnin, R. Myers, R. N. Gunn, F. 
Turkheimer, C. D. Good, C. J. Mathias, N. Quinn, J. Schwarz, and D. J. Brooks. 
2003. [(11)C](R)-PK11195 PET imaging of microglial activation in multiple system 
atrophy. Neurology 61:686-9. 
96. Giulian, D., T. J. Baker, L. C. Shih, and L. B. Lachman. 1986. Interleukin 1 of the 
central nervous system is produced by ameboid microglia. J Exp Med 164:594-604. 
97. Glass, J. D., H. Fedor, S. L. Wesselingh, and J. C. McArthur. 1995. 
Immunocytochemical quantitation of human immunodeficiency virus in the brain: 
correlations with dementia. Ann Neurol 38:755-62. 
98. Glass, J. D., S. L. Wesselingh, O. A. Selnes, and J. C. McArthur. 1993. Clinical-
neuropathologic correlation in HIV-associated dementia. Neurology 43:2230-7. 
99. Goedert, M. 1993. Tau protein and the neurofibrillary pathology of Alzheimer's disease. 
Trends Neurosci 16:460-5. 
100. Gold, M. R., V. Duronio, S. P. Saxena, J. W. Schrader, and R. Aebersold. 1994. 
Multiple cytokines activate phosphatidylinositol 3-kinase in hemopoietic cells. 
Association of the enzyme with various tyrosine-phosphorylated proteins. J Biol Chem 
269:5403-12. 
101. Gonzalez, E., B. H. Rovin, L. Sen, G. Cooke, R. Dhanda, S. Mummidi, H. Kulkarni, 
M. J. Bamshad, V. Telles, S. A. Anderson, E. A. Walter, K. T. Stephan, M. Deucher, 
A. Mangano, R. Bologna, S. S. Ahuja, M. J. Dolan, and S. K. Ahuja. 2002. HIV-1 
infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to 
 7 
increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci U S A 
99:13795-800. 
102. Gonzalez-Scarano, F., and G. Baltuch. 1999. Microglia as mediators of inflammatory 
and degenerative diseases. Annu Rev Neurosci 22:219-40. 
103. Gordon, M. N., L. A. Holcomb, P. T. Jantzen, G. DiCarlo, D. Wilcock, K. W. Boyett, 
K. Connor, J. Melachrino, J. P. O'Callaghan, and D. Morgan. 2002. Time course of 
the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. 
Exp Neurol 173:183-95. 
104. Gorry, P. R., G. Bristol, J. A. Zack, K. Ritola, R. Swanstrom, C. J. Birch, J. E. Bell, 
N. Bannert, K. Crawford, H. Wang, D. Schols, E. De Clercq, K. Kunstman, S. M. 
Wolinsky, and D. Gabuzda. 2001. Macrophage tropism of human immunodeficiency 
virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent 
of coreceptor specificity. J Virol 75:10073-89. 
105. Gray, F., F. Chretien, A. V. Vallat-Decouvelaere, and F. Scaravilli. 2003. The 
changing pattern of HIV neuropathology in the HAART era. J Neuropathol Exp Neurol 
62:429-40. 
106. Gray, F., and C. Keohane. 2003. The neuropathology of HIV infection in the era of 
Highly Active AntiRetroviral Therapy (HAART). Brain Pathol 13:79-83. 
107. Grimaldi, L. M., G. V. Martino, D. M. Franciotta, R. Brustia, A. Castagna, R. 
Pristera, and A. Lazzarin. 1991. Elevated alpha-tumor necrosis factor levels in spinal 
fluid from HIV-1-infected patients with central nervous system involvement. Ann Neurol 
29:21-5. 
108. Gunn, R. N., A. A. Lammertsma, S. P. Hume, and V. J. Cunningham. 1997. 
Parametric imaging of ligand-receptor binding in PET using a simplified reference region 
model. Neuroimage 6:279-87. 
109. Gunn, R. N., P. A. Sargent, C. J. Bench, E. A. Rabiner, S. Osman, V. W. Pike, S. P. 
Hume, P. M. Grasby, and A. A. Lammertsma. 1998. Tracer kinetic modeling of the 5-
HT1A receptor ligand [carbonyl-11C]WAY-100635 for PET. Neuroimage 8:426-40. 
110. Hansen, L. A., and R. D. Terry. 1997. Position paper on diagnostic criteria for 
Alzheimer disease. Neurobiol Aging 18:S71-3. 
111. Hardy, J., and D. J. Selkoe. 2002. The amyloid hypothesis of Alzheimer's disease: 
progress and problems on the road to therapeutics. Science 297:353-6. 
112. Harris, M. H., and C. B. Thompson. 2000. The role of the Bcl-2 family in the 
regulation of outer mitochondrial membrane permeability. Cell Death Differ 7:1182-91. 
113. Hastings, T. G., D. A. Lewis, and M. J. Zigmond. 1996. Role of oxidation in the 
neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci U S A 
93:1956-61. 
114. Heyes, M. P., C. L. Achim, C. A. Wiley, E. O. Major, K. Saito, and S. P. Markey. 
1996. Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. 
Biochem J 320 ( Pt 2):595-7. 
115. Heyes, M. P., B. J. Brew, A. Martin, R. W. Price, A. M. Salazar, J. J. Sidtis, J. A. 
Yergey, M. M. Mouradian, A. E. Sadler, J. Keilp, and et al. 1991. Quinolinic acid in 
cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and 
neurological status. Ann Neurol 29:202-9. 
 8 
116. Hickey, W. F., K. Vass, and H. Lassmann. 1992. Bone marrow-derived elements in the 
central nervous system: an immunohistochemical and ultrastructural survey of rat 
chimeras. J Neuropathol Exp Neurol 51:246-56. 
117. Hirsch, J. D., C. F. Beyer, L. Malkowitz, B. Beer, and A. J. Blume. 1989. 
Mitochondrial benzodiazepine receptors mediate inhibition of mitochondrial respiratory 
control. Mol Pharmacol 35:157-63. 
118. Hirsch, S., J. M. Austyn, and S. Gordon. 1981. Expression of the macrophage-specific 
antigen F4/80 during differentiation of mouse bone marrow cells in culture. J Exp Med 
154:713-25. 
119. in t' Veld, B. A., A. Ruitenberg, A. Hofman, L. J. Launer, C. M. van Duijn, T. 
Stijnen, M. M. Breteler, and B. H. Stricker. 2001. Nonsteroidal antiinflammatory 
drugs and the risk of Alzheimer's disease. N Engl J Med 345:1515-21. 
120. Janus, C., J. Pearson, J. McLaurin, P. M. Mathews, Y. Jiang, S. D. Schmidt, M. A. 
Chishti, P. Horne, D. Heslin, J. French, H. T. Mount, R. A. Nixon, M. Mercken, C. 
Bergeron, P. E. Fraser, P. St George-Hyslop, and D. Westaway. 2000. A beta peptide 
immunization reduces behavioural impairment and plaques in a model of Alzheimer's 
disease. Nature 408:979-82. 
121. Jayakumar, A. R., K. S. Panickar, and M. D. Norenberg. 2002. Effects on free radical 
generation by ligands of the peripheral benzodiazepine receptor in cultured neural cells. J 
Neurochem 83:1226-34. 
122. Joachim, C. L., J. H. Morris, and D. J. Selkoe. 1989. Diffuse senile plaques occur 
commonly in the cerebellum in Alzheimer's disease. Am J Pathol 135:309-19. 
123. Joe, B. N., M. B. Fukui, C. C. Meltzer, Q. S. Huang, R. S. Day, P. J. Greer, and M. 
E. Bozik. 1999. Brain tumor volume measurement: comparison of manual and 
semiautomated methods. Radiology 212:811-6. 
124. Johnson, L. A., J. D. Pearlman, C. A. Miller, T. I. Young, and K. R. Thulborn. 1993. 
MR quantification of cerebral ventricular volume using a semiautomated algorithm. 
AJNR Am J Neuroradiol 14:1373-8. 
125. Johnston, C., W. Jiang, T. Chu, and B. Levine. 2001. Identification of genes involved 
in the host response to neurovirulent alphavirus infection. J Virol 75:10431-45. 
126. Jordan-Sciutto, K. L., G. Wang, M. Murphey-Corb, and C. A. Wiley. 2002. Cell 
cycle proteins exhibit altered expression patterns in lentiviral-associated encephalitis. J 
Neurosci 22:2185-95. 
127. Kanazawa, H., K. Ohsawa, Y. Sasaki, S. Kohsaka, and Y. Imai. 2002. 
Macrophage/microglia-specific protein Iba1 enhances membrane ruffling and Rac 
activation via phospholipase C-gamma -dependent pathway. J Biol Chem 277:20026-32. 
128. Kaul, M., G. A. Garden, and S. A. Lipton. 2001. Pathways to neuronal injury and 
apoptosis in HIV-associated dementia. Nature 410:988-94. 
129. Kim, W. K., S. Y. Hwang, E. S. Oh, H. Z. Piao, K. W. Kim, and I. O. Han. 2004. 
TGF-beta1 represses activation and resultant death of microglia via inhibition of 
phosphatidylinositol 3-kinase activity. J Immunol 172:7015-23. 
130. Kitazawa, M., S. Oddo, T. R. Yamasaki, K. N. Green, and F. M. LaFerla. 2005. 
Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-
dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J 
Neurosci 25:8843-53. 
 9 
131. Klatzmann, D., E. Champagne, S. Chamaret, J. Gruest, D. Guetard, T. Hercend, J. 
C. Gluckman, and L. Montagnier. 1984. T-lymphocyte T4 molecule behaves as the 
receptor for human retrovirus LAV. Nature 312:767-8. 
132. Klegeris, A., and P. L. McGeer. 2005. Non-steroidal anti-inflammatory drugs 
(NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative 
disease. Curr Alzheimer Res 2:355-65. 
133. Klunk, W. E., B. J. Lopresti, M. D. Ikonomovic, I. M. Lefterov, R. P. Koldamova, E. 
E. Abrahamson, M. L. Debnath, D. P. Holt, G. F. Huang, L. Shao, S. T. DeKosky, J. 
C. Price, and C. A. Mathis. 2005. Binding of the positron emission tomography tracer 
Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain 
but not in transgenic mouse brain. J Neurosci 25:10598-606. 
134. Kosik, K. S. 1990. Tau protein and Alzheimer's disease. Curr Opin Cell Biol 2:101-4. 
135. Kreutzberg, G. W. 1996. Microglia: a sensor for pathological events in the CNS. Trends 
Neurosci 19:312-8. 
136. Kuhlmann, A. C., and T. R. Guilarte. 2000. Cellular and subcellular localization of 
peripheral benzodiazepine receptors after trimethyltin neurotoxicity. J Neurochem 
74:1694-704. 
137. Lackner, A. A., M. O. Smith, R. J. Munn, D. J. Martfeld, M. B. Gardner, P. A. 
Marx, and S. Dandekar. 1991. Localization of simian immunodeficiency virus in the 
central nervous system of rhesus monkeys. Am J Pathol 139:609-21. 
138. Lammertsma, A. A., and S. P. Hume. 1996. Simplified reference tissue model for PET 
receptor studies. Neuroimage 4:153-8. 
139. Langford, T. D., S. L. Letendre, G. J. Larrea, and E. Masliah. 2003. Changing 
patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathol 13:195-
210. 
140. Lemere, C. A., A. Beierschmitt, M. Iglesias, E. T. Spooner, J. K. Bloom, J. F. 
Leverone, J. B. Zheng, T. J. Seabrook, D. Louard, D. Li, D. J. Selkoe, R. M. 
Palmour, and F. R. Ervin. 2004. Alzheimer's disease abeta vaccine reduces central 
nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol 
165:283-97. 
141. Levy, J. A. 1994. HIV and the Pathogenesis of AIDS, Washington D.C. 
142. Lewandowska, E., E. Bertrand, J. Kulczycki, W. Lipczynska-Lojkowska, W. 
Lechowicz, and J. Stankiewicz. 1999. Microglia and neuritic plaques in familial 
Alzheimer's disease induced by a new mutation of presenilin-1 gene. An ultrastructural 
study. Folia Neuropathol 37:243-6. 
143. Lim, G. P., F. Yang, T. Chu, P. Chen, W. Beech, B. Teter, T. Tran, O. Ubeda, K. H. 
Ashe, S. A. Frautschy, and G. M. Cole. 2000. Ibuprofen suppresses plaque pathology 
and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20:5709-14. 
144. Liu, H., H. Perlman, L. J. Pagliari, and R. M. Pope. 2001. Constitutively activated 
Akt-1 is vital for the survival of human monocyte-differentiated macrophages. Role of 
Mcl-1, independent of nuclear factor (NF)-kappaB, Bad, or caspase activation. J Exp 
Med 194:113-26. 
145. Lockhart, A., B. Davis, J. C. Matthews, H. Rahmoune, G. Hong, A. Gee, D. 
Earnshaw, and J. Brown. 2003. The peripheral benzodiazepine receptor ligand 
PK11195 binds with high affinity to the acute phase reactant alpha1-acid glycoprotein: 
 10 
implications for the use of the ligand as a CNS inflammatory marker(1). Nucl Med Biol 
30:199-206. 
146. Logan, J., J. S. Fowler, N. D. Volkow, G. J. Wang, Y. S. Ding, and D. L. Alexoff. 
1996. Distribution volume ratios without blood sampling from graphical analysis of PET 
data. J Cereb Blood Flow Metab 16:834-40. 
147. Loy, R., D. Heyer, M. Clagett-Dame, and P. S. DiStefano. 1990. Localization of NGF 
receptors in normal and Alzheimer's basal forebrain with monoclonal antibodies against 
the truncated form of the receptor. J Neurosci Res 27:651-64. 
148. Lue, L. F., D. G. Walker, and J. Rogers. 2001. Modeling microglial activation in 
Alzheimer's disease with human postmortem microglial cultures. Neurobiol Aging 
22:945-56. 
149. Maeda, J., T. Suhara, M. R. Zhang, T. Okauchi, F. Yasuno, Y. Ikoma, M. Inaji, Y. 
Nagai, A. Takano, S. Obayashi, and K. Suzuki. 2004. Novel peripheral benzodiazepine 
receptor ligand [11C]DAA1106 for PET: An imaging tool for glial cells in the brain. 
Synapse 52:283-91. 
150. Malm, T. M., M. Koistinaho, M. Parepalo, T. Vatanen, A. Ooka, S. Karlsson, and J. 
Koistinaho. 2005. Bone-marrow-derived cells contribute to the recruitment of microglial 
cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer 
mice. Neurobiol Dis 18:134-42. 
151. Mankowski, J. L., S. E. Queen, P. J. Tarwater, R. J. Adams, and T. R. Guilarte. 
2003. Elevated peripheral benzodiazepine receptor expression in simian 
immunodeficiency virus encephalitis. J Neurovirol 9:94-100. 
152. Mann, D. M. 1985. The neuropathology of Alzheimer's disease: a review with 
pathogenetic, aetiological and therapeutic considerations. Mech Ageing Dev 31:213-55. 
153. Masliah, E., C. L. Achim, N. Ge, R. DeTeresa, R. D. Terry, and C. A. Wiley. 1992. 
Spectrum of human immunodeficiency virus-associated neocortical damage. Ann Neurol 
32:321-9. 
154. Masliah, E., R. M. DeTeresa, M. E. Mallory, and L. A. Hansen. 2000. Changes in 
pathological findings at autopsy in AIDS cases for the last 15 years. Aids 14:69-74. 
155. Masliah, E., L. Hansen, A. Adame, L. Crews, F. Bard, C. Lee, P. Seubert, D. Games, 
L. Kirby, and D. Schenk. 2005. Abeta vaccination effects on plaque pathology in the 
absence of encephalitis in Alzheimer disease. Neurology 64:129-31. 
156. Masliah, E., R. K. Heaton, T. D. Marcotte, R. J. Ellis, C. A. Wiley, M. Mallory, C. L. 
Achim, J. A. McCutchan, J. A. Nelson, J. H. Atkinson, and I. Grant. 1997. Dendritic 
injury is a pathological substrate for human immunodeficiency virus-related cognitive 
disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol 
42:963-72. 
157. Masters, C. L., G. Multhaup, G. Simms, J. Pottgiesser, R. N. Martins, and K. 
Beyreuther. 1985. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of 
Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood 
vessels. Embo J 4:2757-63. 
158. McArthur, J. C. 1997. NeuroAIDS: diagnosis and management. Hosp Pract (Off Ed) 
32:73-4, 77-9, 84 passim. 
159. McArthur, J. C., A. J. Kumar, D. W. Johnson, O. A. Selnes, J. T. Becker, C. 
Herman, B. A. Cohen, and A. Saah. 1990. Incidental white matter hyperintensities on 
 11 
magnetic resonance imaging in HIV-1 infection. Multicenter AIDS Cohort Study. J 
Acquir Immune Defic Syndr 3:252-9. 
160. McEnery, M. W., A. M. Snowman, R. R. Trifiletti, and S. H. Snyder. 1992. Isolation 
of the mitochondrial benzodiazepine receptor: association with the voltage-dependent 
anion channel and the adenine nucleotide carrier. Proc Natl Acad Sci U S A 89:3170-4. 
161. McGeer, P. L., S. Itagaki, B. E. Boyes, and E. G. McGeer. 1988. Reactive microglia 
are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease 
brains. Neurology 38:1285-91. 
162. McGeer, P. L., S. Itagaki, H. Tago, and E. G. McGeer. 1988. Occurrence of HLA-DR 
reactive microglia in Alzheimer's disease. Ann N Y Acad Sci 540:319-23. 
163. McLaurin, J., R. Cecal, M. E. Kierstead, X. Tian, A. L. Phinney, M. Manea, J. E. 
French, M. H. Lambermon, A. A. Darabie, M. E. Brown, C. Janus, M. A. Chishti, P. 
Horne, D. Westaway, P. E. Fraser, H. T. Mount, M. Przybylski, and P. St George-
Hyslop. 2002. Therapeutically effective antibodies against amyloid-beta peptide target 
amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8:1263-
9. 
164. McManus, C. M., C. F. Brosnan, and J. W. Berman. 1998. Cytokine induction of 
MIP-1 alpha and MIP-1 beta in human fetal microglia. J Immunol 160:1449-55. 
165. Meda, L., M. A. Cassatella, G. I. Szendrei, L. Otvos, Jr., P. Baron, M. Villalba, D. 
Ferrari, and F. Rossi. 1995. Activation of microglial cells by beta-amyloid protein and 
interferon-gamma. Nature 374:647-50. 
166. Merrill, J. E., and I. S. Chen. 1991. HIV-1, macrophages, glial cells, and cytokines in 
AIDS nervous system disease. Faseb J 5:2391-7. 
167. Mesulam, M. M. 1999. Neuroplasticity failure in Alzheimer's disease: bridging the gap 
between plaques and tangles. Neuron 24:521-9. 
168. Minghetti, L., and G. Levi. 1998. Microglia as effector cells in brain damage and repair: 
focus on prostanoids and nitric oxide. Prog Neurobiol 54:99-125. 
169. Minshall, C., S. Arkins, G. G. Freund, and K. W. Kelley. 1996. Requirement for 
phosphatidylinositol 3'-kinase to protect hemopoietic progenitors against apoptosis 
depends upon the extracellular survival factor. J Immunol 156:939-47. 
170. Monje, M. L., H. Toda, and T. D. Palmer. 2003. Inflammatory blockade restores adult 
hippocampal neurogenesis. Science 302:1760-5. 
171. Morgan, D., D. M. Diamond, P. E. Gottschall, K. E. Ugen, C. Dickey, J. Hardy, K. 
Duff, P. Jantzen, G. DiCarlo, D. Wilcock, K. Connor, J. Hatcher, C. Hope, M. 
Gordon, and G. W. Arendash. 2000. A beta peptide vaccination prevents memory loss 
in an animal model of Alzheimer's disease. Nature 408:982-5. 
172. Morgan, D., M. N. Gordon, J. Tan, D. Wilcock, and A. M. Rojiani. 2005. Dynamic 
complexity of the microglial activation response in transgenic models of amyloid 
deposition: implications for Alzheimer therapeutics. J Neuropathol Exp Neurol 64:743-
53. 
173. Muhleisen, H., J. Gehrmann, and R. Meyermann. 1995. Reactive microglia in 
Creutzfeldt-Jakob disease. Neuropathol Appl Neurobiol 21:505-17. 
174. Murman, D. L., and C. C. Colenda. 2005. The economic impact of neuropsychiatric 
symptoms in Alzheimer's disease: can drugs ease the burden? Pharmacoeconomics 
23:227-42. 
 12 
175. Murphy, G. M., Jr., X. C. Jia, Y. Song, E. Ong, R. Shrivastava, V. Bocchini, Y. L. 
Lee, and L. F. Eng. 1995. Macrophage inflammatory protein 1-alpha mRNA expression 
in an immortalized microglial cell line and cortical astrocyte cultures. J Neurosci Res 
40:755-63. 
176. Myers, R., L. G. Manjil, B. M. Cullen, G. W. Price, R. S. Frackowiak, and J. E. 
Cremer. 1991. Macrophage and astrocyte populations in relation to [3H]PK 11195 
binding in rat cerebral cortex following a local ischaemic lesion. J Cereb Blood Flow 
Metab 11:314-22. 
177. Nath, A. 2002. Human immunodeficiency virus (HIV) proteins in neuropathogenesis of 
HIV dementia. J Infect Dis 186 Suppl 2:S193-8. 
178. Navia, B. A., E. S. Cho, C. K. Petito, and R. W. Price. 1986. The AIDS dementia 
complex: II. Neuropathology. Ann Neurol 19:525-35. 
179. Nicoll, J. A., D. Wilkinson, C. Holmes, P. Steart, H. Markham, and R. O. Weller. 
2003. Neuropathology of human Alzheimer disease after immunization with amyloid-
beta peptide: a case report. Nat Med 9:448-52. 
180. Nimmerjahn, A., F. Kirchhoff, and F. Helmchen. 2005. Resting microglial cells are 
highly dynamic surveillants of brain parenchyma in vivo. Science 308:1314-8. 
181. Nottet, H. S., Y. Persidsky, V. G. Sasseville, A. N. Nukuna, P. Bock, Q. H. Zhai, L. 
R. Sharer, R. D. McComb, S. Swindells, C. Soderland, and H. E. Gendelman. 1996. 
Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. J 
Immunol 156:1284-95. 
182. O'Neil, S. P., C. Suwyn, D. C. Anderson, G. Niedziela, J. Bradley, F. J. Novembre, J. 
G. Herndon, and H. M. McClure. 2004. Correlation of acute humoral response with 
brain virus burden and survival time in pig-tailed macaques infected with the 
neurovirulent simian immunodeficiency virus SIVsmmFGb. Am J Pathol 164:1157-72. 
183. Oddo, S., A. Caccamo, J. D. Shepherd, M. P. Murphy, T. E. Golde, R. Kayed, R. 
Metherate, M. P. Mattson, Y. Akbari, and F. M. LaFerla. 2003. Triple-transgenic 
model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic 
dysfunction. Neuron 39:409-21. 
184. Oh, Y. J., J. W. Francis, G. J. Markelonis, and T. H. Oh. 1992. Interleukin-1-beta and 
tumor necrosis factor-alpha increase peripheral-type benzodiazepine binding sites in 
cultured polygonal astrocytes. J Neurochem 58:2131-8. 
185. Okuyama, S., S. Chaki, R. Yoshikawa, S. Ogawa, Y. Suzuki, T. Okubo, A. 
Nakazato, M. Nagamine, and K. Tomisawa. 1999. Neuropharmacological profile of 
peripheral benzodiazepine receptor agonists, DAA1097 and DAA1106. Life Sci 64:1455-
64. 
186. Orandle, M. S., A. G. MacLean, V. G. Sasseville, X. Alvarez, and A. A. Lackner. 
2002. Enhanced expression of proinflammatory cytokines in the central nervous system is 
associated with neuroinvasion by simian immunodeficiency virus and the development of 
encephalitis. J Virol 76:5797-802. 
187. Osaki, M., M. Oshimura, and H. Ito. 2004. PI3K-Akt pathway: its functions and 
alterations in human cancer. Apoptosis 9:667-76. 
188. Padmanabhan, J., D. Clayton, and M. L. Shelanski. 1999. Dibutyryl cyclic AMP-
induced process formation in astrocytes is associated with a decrease in tyrosine 
phosphorylation of focal adhesion kinase and paxillin. J Neurobiol 39:407-22. 
 13 
189. Pantaleo, G., and A. S. Fauci. 1996. Immunopathogenesis of HIV infection. Annu Rev 
Microbiol 50:825-54. 
190. Papadopoulos, V., H. Amri, H. Li, N. Boujrad, B. Vidic, and M. Garnier. 1997. 
Targeted disruption of the peripheral-type benzodiazepine receptor gene inhibits 
steroidogenesis in the R2C Leydig tumor cell line. J Biol Chem 272:32129-35. 
191. Pappata, S., P. Cornu, Y. Samson, C. Prenant, J. Benavides, B. Scatton, C. Crouzel, 
J. J. Hauw, and A. Syrota. 1991. PET study of carbon-11-PK 11195 binding to 
peripheral type benzodiazepine sites in glioblastoma: a case report. J Nucl Med 32:1608-
10. 
192. Paresce, D. M., H. Chung, and F. R. Maxfield. 1997. Slow degradation of aggregates 
of the Alzheimer's disease amyloid beta-protein by microglial cells. J Biol Chem 
272:29390-7. 
193. Pascal, S., L. Resnick, W. W. Barker, D. Loewenstein, F. Yoshii, J. Y. Chang, T. 
Boothe, J. Sheldon, and R. Duara. 1991. Metabolic asymmetries in asymptomatic HIV-
1 seropositive subjects: relationship to disease onset and MRI findings. J Nucl Med 
32:1725-9. 
194. Paul, R., R. Cohen, B. Navia, and K. Tashima. 2002. Relationships between cognition 
and structural neuroimaging findings in adults with human immunodeficiency virus type-
1. Neurosci Biobehav Rev 26:353-9. 
195. Peluso, R., A. Haase, L. Stowring, M. Edwards, and P. Ventura. 1985. A Trojan 
Horse mechanism for the spread of visna virus in monocytes. Virology 147:231-6. 
196. Perry, V. H., and S. Gordon. 1991. Macrophages and the nervous system. Int Rev Cytol 
125:203-44. 
197. Persidsky, Y., M. Buttini, J. Limoges, P. Bock, and H. E. Gendelman. 1997. An 
analysis of HIV-1-associated inflammatory products in brain tissue of humans and SCID 
mice with HIV-1 encephalitis. J Neurovirol 3:401-16. 
198. Portegies, P., R. H. Enting, J. de Gans, P. R. Algra, M. M. Derix, J. M. Lange, and J. 
Goudsmit. 1993. Presentation and course of AIDS dementia complex: 10 years of 
follow-up in Amsterdam, The Netherlands. Aids 7:669-75. 
199. Post, M. J., B. E. Levin, J. R. Berger, R. Duncan, R. M. Quencer, and G. Calabro. 
1992. Sequential cranial MR findings of asymptomatic and neurologically symptomatic 
HIV+ subjects. AJNR Am J Neuroradiol 13:359-70. 
200. Post, M. J., L. G. Tate, R. M. Quencer, G. T. Hensley, J. R. Berger, W. A. 
Sheremata, and G. Maul. 1988. CT, MR, and pathology in HIV encephalitis and 
meningitis. AJR Am J Roentgenol 151:373-80. 
201. Power, C., P. A. Kong, T. O. Crawford, S. Wesselingh, J. D. Glass, J. C. McArthur, 
and B. D. Trapp. 1993. Cerebral white matter changes in acquired immunodeficiency 
syndrome dementia: alterations of the blood-brain barrier. Ann Neurol 34:339-50. 
202. Price, R. W., C. T. Yiannoutsos, D. B. Clifford, L. Zaborski, A. Tselis, J. J. Sidtis, B. 
Cohen, C. D. Hall, A. Erice, and K. Henry. 1999. Neurological outcomes in late HIV 
infection: adverse impact of neurological impairment on survival and protective effect of 
antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research 
Consortium study team. Aids 13:1677-85. 
203. Pulvirenti, J. J. 2005. Inpatient care of the HIV infected patient in the highly active 
antiretroviral therapy (HAART) era. Curr HIV Res 3:133-45. 
 14 
204. Raghavendra Rao, V. L., A. Dogan, K. K. Bowen, and R. J. Dempsey. 2000. 
Traumatic brain injury leads to increased expression of peripheral-type benzodiazepine 
receptors, neuronal death, and activation of astrocytes and microglia in rat thalamus. Exp 
Neurol 161:102-14. 
205. Raininko, R., I. Elovaara, A. Virta, L. Valanne, M. Haltia, and S. L. Valle. 1992. 
Radiological study of the brain at various stages of human immunodeficiency virus 
infection: early development of brain atrophy. Neuroradiology 34:190-6. 
206. Ramsay, S. C., C. Weiller, R. Myers, J. E. Cremer, S. K. Luthra, A. A. 
Lammertsma, and R. S. Frackowiak. 1992. Monitoring by PET of macrophage 
accumulation in brain after ischaemic stroke. Lancet 339:1054-5. 
207. Rey, C., C. Mauduit, O. Naureils, M. Benahmed, P. Louisot, and F. Gasnier. 2000. 
Up-regulation of mitochondrial peripheral benzodiazepine receptor expression by tumor 
necrosis factor alpha in testicular leydig cells. Possible involvement in cell survival. 
Biochem Pharmacol 60:1639-46. 
208. Righi, M., L. Mori, G. De Libero, M. Sironi, A. Biondi, A. Mantovani, S. D. Donini, 
and P. Ricciardi-Castagnoli. 1989. Monokine production by microglial cell clones. Eur 
J Immunol 19:1443-8. 
209. Rogers, J., and L. F. Lue. 2001. Microglial chemotaxis, activation, and phagocytosis of 
amyloid beta-peptide as linked phenomena in Alzheimer's disease. Neurochem Int 
39:333-40. 
210. Rosci, M. A., F. Pigorini, A. Bernabei, F. M. Pau, V. Volpini, D. E. Merigliano, and 
M. F. Meligrana. 1992. Methods for detecting early signs of AIDS dementia complex in 
asymptomatic HIV-1-infected subjects. Aids 6:1309-16. 
211. Sacktor, N., M. P. McDermott, K. Marder, G. Schifitto, O. A. Selnes, J. C. 
McArthur, Y. Stern, S. Albert, D. Palumbo, K. Kieburtz, J. A. De Marcaida, B. 
Cohen, and L. Epstein. 2002. HIV-associated cognitive impairment before and after the 
advent of combination therapy. J Neurovirol 8:136-42. 
212. Sanchez-Pernaute, R., A. Ferree, O. Cooper, M. Yu, A. L. Brownell, and O. Isacson. 
2004. Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in 
a rat model of Parkinson's disease. J Neuroinflammation 1:6. 
213. Sanders, V. J., C. A. Pittman, M. G. White, G. Wang, C. A. Wiley, and C. L. Achim. 
1998. Chemokines and receptors in HIV encephalitis. Aids 12:1021-6. 
214. Sargsyan, S. A., P. N. Monk, and P. J. Shaw. 2005. Microglia as potential contributors 
to motor neuron injury in amyotrophic lateral sclerosis. Glia 51:241-53. 
215. Sasaki, A., M. Shoji, Y. Harigaya, T. Kawarabayashi, M. Ikeda, M. Naito, E. 
Matsubara, K. Abe, and Y. Nakazato. 2002. Amyloid cored plaques in Tg2576 
transgenic mice are characterized by giant plaques, slightly activated microglia, and the 
lack of paired helical filament-typed, dystrophic neurites. Virchows Arch 441:358-67. 
216. Sasaki, Y., K. Ohsawa, H. Kanazawa, S. Kohsaka, and Y. Imai. 2001. Iba1 is an 
actin-cross-linking protein in macrophages/microglia. Biochem Biophys Res Commun 
286:292-7. 
217. Schenk, D. 2002. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the 
beginning. Nat Rev Neurosci 3:824-8. 
218. Schenk, D., R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. 
Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, Z. Liao, I. Lieberburg, 
R. Motter, L. Mutter, F. Soriano, G. Shopp, N. Vasquez, C. Vandevert, S. Walker, 
 15 
M. Wogulis, T. Yednock, D. Games, and P. Seubert. 1999. Immunization with 
amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 
400:173-7. 
219. Schenk, D. B., and T. Yednock. 2002. The role of microglia in Alzheimer's disease: 
friend or foe? Neurobiol Aging 23:677-9; discussion 683-4. 
220. Schmitz, J. E., M. J. Kuroda, S. Santra, V. G. Sasseville, M. A. Simon, M. A. Lifton, 
P. Racz, K. Tenner-Racz, M. Dalesandro, B. J. Scallon, J. Ghrayeb, M. A. Forman, 
D. C. Montefiori, E. P. Rieber, N. L. Letvin, and K. A. Reimann. 1999. Control of 
viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 
283:857-60. 
221. Selkoe, D. J. 1994. Cell biology of the amyloid beta-protein precursor and the 
mechanism of Alzheimer's disease. Annu Rev Cell Biol 10:373-403. 
222. Shah, F., S. P. Hume, V. W. Pike, S. Ashworth, and J. McDermott. 1994. Synthesis of 
the enantiomers of [N-methyl-11C]PK 11195 and comparison of their behaviours as 
radioligands for PK binding sites in rats. Nucl Med Biol 21:573-81. 
223. Sharer, L. R., E. S. Cho, and L. G. Epstein. 1985. Multinucleated giant cells and 
HTLV-III in AIDS encephalopathy. Hum Pathol 16:760. 
224. Simard, A. R., D. Soulet, G. Gowing, J. P. Julien, and S. Rivest. 2006. Bone marrow-
derived microglia play a critical role in restricting senile plaque formation in Alzheimer's 
disease. Neuron 49:489-502. 
225. Smith, M. A., P. L. Richey Harris, L. M. Sayre, J. S. Beckman, and G. Perry. 1997. 
Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 17:2653-
7. 
226. Solomon, B., R. Koppel, D. Frankel, and E. Hanan-Aharon. 1997. Disaggregation of 
Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci U S A 94:4109-12. 
227. Sonnerborg, A., J. Saaf, B. Alexius, O. Strannegard, L. O. Wahlund, and L. 
Wetterberg. 1990. Quantitative detection of brain aberrations in human 
immunodeficiency virus type 1-infected individuals by magnetic resonance imaging. J 
Infect Dis 162:1245-51. 
228. Stalder, M., T. Deller, M. Staufenbiel, and M. Jucker. 2001. 3D-Reconstruction of 
microglia and amyloid in APP23 transgenic mice: no evidence of intracellular amyloid. 
Neurobiol Aging 22:427-34. 
229. Stalder, M., A. Phinney, A. Probst, B. Sommer, M. Staufenbiel, and M. Jucker. 
1999. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. 
Am J Pathol 154:1673-84. 
230. Starosta-Rubinstein, S., B. J. Ciliax, J. B. Penney, P. McKeever, and A. B. Young. 
1987. Imaging of a glioma using peripheral benzodiazepine receptor ligands. Proc Natl 
Acad Sci U S A 84:891-5. 
231. Stephenson, D. T., D. A. Schober, E. B. Smalstig, R. E. Mincy, D. R. Gehlert, and J. 
A. Clemens. 1995. Peripheral benzodiazepine receptors are colocalized with activated 
microglia following transient global forebrain ischemia in the rat. J Neurosci 15:5263-74. 
232. Stephenson, F. A. 1995. The GABAA receptors. Biochem J 310 ( Pt 1):1-9. 
233. Stewart, W. F., C. Kawas, M. Corrada, and E. J. Metter. 1997. Risk of Alzheimer's 
disease and duration of NSAID use. Neurology 48:626-32. 
234. Stoebner, P. E., P. Carayon, P. Casellas, M. Portier, T. Lavabre-Bertrand, P. Cuq, 
J. P. Cano, J. Meynadier, and L. Meunier. 2001. Transient protection by peripheral 
 16 
benzodiazepine receptors during the early events of ultraviolet light-induced apoptosis. 
Cell Death Differ 8:747-53. 
235. Stoll, G., and S. Jander. 1999. The role of microglia and macrophages in the 
pathophysiology of the CNS. Prog Neurobiol 58:233-47. 
236. Tan, J., T. Town, D. Paris, T. Mori, Z. Suo, F. Crawford, M. P. Mattson, R. A. 
Flavell, and M. Mullan. 1999. Microglial activation resulting from CD40-CD40L 
interaction after beta-amyloid stimulation. Science 286:2352-5. 
237. Trincavelli, M. L., L. Marselli, A. Falleni, V. Gremigni, E. Ragge, F. Dotta, C. 
Santangelo, P. Marchetti, A. Lucacchini, and C. Martini. 2002. Upregulation of 
mitochondrial peripheral benzodiazepine receptor expression by cytokine-induced 
damage of human pancreatic islets. J Cell Biochem 84:636-44. 
238. Turner, M. R., A. Cagnin, F. E. Turkheimer, C. C. Miller, C. E. Shaw, D. J. Brooks, 
P. N. Leigh, and R. B. Banati. 2004. Evidence of widespread cerebral microglial 
activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission 
tomography study. Neurobiol Dis 15:601-9. 
239. Tyner, J. W., O. Uchida, N. Kajiwara, E. Y. Kim, A. C. Patel, M. P. O'Sullivan, M. 
J. Walter, R. A. Schwendener, D. N. Cook, T. M. Danoff, and M. J. Holtzman. 2005. 
CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during 
viral infection. Nat Med 11:1180-7. 
240. Ulvestad, E., K. Williams, R. Matre, H. Nyland, A. Olivier, and J. Antel. 1994. Fc 
receptors for IgG on cultured human microglia mediate cytotoxicity and phagocytosis of 
antibody-coated targets. J Neuropathol Exp Neurol 53:27-36. 
241. UNAIDS. 2004. AIDS epidemic update: 2004 Joint United Nations Programme on 
HIV/AIDS and Worls Health Organization. 
242. Valcour, V. G., C. M. Shikuma, M. R. Watters, and N. C. Sacktor. 2004. Cognitive 
impairment in older HIV-1-seropositive individuals: prevalence and potential 
mechanisms. Aids 18 Suppl 1:S79-86. 
243. Vassar, R., and M. Citron. 2000. Abeta-generating enzymes: recent advances in beta- 
and gamma-secretase research. Neuron 27:419-22. 
244. Veenman, L., S. Leschiner, I. Spanier, G. Weisinger, A. Weizman, and M. Gavish. 
2002. PK 11195 attenuates kainic acid-induced seizures and alterations in peripheral-type 
benzodiazepine receptor (PBR) protein components in the rat brain. J Neurochem 
80:917-27. 
245. Venneti, S., B. J. Lopresti, G. Wang, S. J. Bissel, C. A. Mathis, C. C. Meltzer, F. 
Boada, S. Capuano, 3rd, G. J. Kress, D. K. Davis, J. Ruszkiewicz, I. J. Reynolds, M. 
Murphey-Corb, A. M. Trichel, S. R. Wisniewski, and C. A. Wiley. 2004. PET 
imaging of brain macrophages using the peripheral benzodiazepine receptor in a macaque 
model of neuroAIDS. J Clin Invest 113:981-9. 
246. Vowinckel, E., D. Reutens, B. Becher, G. Verge, A. Evans, T. Owens, and J. P. 
Antel. 1997. PK11195 binding to the peripheral benzodiazepine receptor as a marker of 
microglia activation in multiple sclerosis and experimental autoimmune 
encephalomyelitis. J Neurosci Res 50:345-53. 
247. Webster, S. D., M. D. Galvan, E. Ferran, W. Garzon-Rodriguez, C. G. Glabe, and A. 
J. Tenner. 2001. Antibody-mediated phagocytosis of the amyloid beta-peptide in 
microglia is differentially modulated by C1q. J Immunol 166:7496-503. 
 17 
248. Weissman, B. A., G. T. Bolger, L. Isaac, S. M. Paul, and P. Skolnick. 1984. 
Characterization of the binding of [3H]Ro 5-4864, a convulsant benzodiazepine, to 
guinea pig brain. J Neurochem 42:969-75. 
249. Wenserski, F., H. J. von Giesen, H. J. Wittsack, A. Aulich, and G. Arendt. 2003. 
Human immunodeficiency virus 1-associated minor motor disorders: perfusion-weighted 
MR imaging and H MR spectroscopy. Radiology 228:185-92. 
250. Wesselingh, S. L., and K. A. Thompson. 2001. Immunopathogenesis of HIV-associated 
dementia. Curr Opin Neurol 14:375-9. 
251. Westmoreland, S. V., E. Halpern, and A. A. Lackner. 1998. Simian 
immunodeficiency virus encephalitis in rhesus macaques is associated with rapid disease 
progression. J Neurovirol 4:260-8. 
252. Wiley, C. A., and C. Achim. 1994. Human immunodeficiency virus encephalitis is the 
pathological correlate of dementia in acquired immunodeficiency syndrome. Ann Neurol 
36:673-6. 
253. Wiley, C. A., C. L. Achim, C. Christopherson, Y. Kidane, S. Kwok, E. Masliah, J. 
Mellors, L. Radhakrishnan, G. Wang, and V. Soontornniyomkij. 1999. HIV mediates 
a productive infection of the brain. Aids 13:2055-9. 
254. Wiley, C. A., E. Masliah, M. Morey, C. Lemere, R. DeTeresa, M. Grafe, L. Hansen, 
and R. Terry. 1991. Neocortical damage during HIV infection. Ann Neurol 29:651-7. 
255. Wiley, C. A., R. D. Schrier, J. A. Nelson, P. W. Lampert, and M. B. Oldstone. 1986. 
Cellular localization of human immunodeficiency virus infection within the brains of 
acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A 83:7089-93. 
256. Williams, K. C., and W. F. Hickey. 2002. Central nervous system damage, monocytes 
and macrophages, and neurological disorders in AIDS. Annu Rev Neurosci 25:537-62. 
257. Wilt, S. G., E. Milward, J. M. Zhou, K. Nagasato, H. Patton, R. Rusten, D. E. 
Griffin, M. O'Connor, and M. Dubois-Dalcq. 1995. In vitro evidence for a dual role of 
tumor necrosis factor-alpha in human immunodeficiency virus type 1 encephalopathy. 
Ann Neurol 37:381-94. 
258. Wong, P. C., H. Cai, D. R. Borchelt, and D. L. Price. 2002. Genetically engineered 
mouse models of neurodegenerative diseases. Nat Neurosci 5:633-9. 
259. Woods, R. P., S. R. Cherry, and J. C. Mazziotta. 1992. Rapid automated algorithm for 
aligning and reslicing PET images. J Comput Assist Tomogr 16:620-33. 
260. Yan, Q., J. Zhang, H. Liu, S. Babu-Khan, R. Vassar, A. L. Biere, M. Citron, and G. 
Landreth. 2003. Anti-inflammatory drug therapy alters beta-amyloid processing and 
deposition in an animal model of Alzheimer's disease. J Neurosci 23:7504-9. 
261. Zhang, K., G. A. McQuibban, C. Silva, G. S. Butler, J. B. Johnston, J. Holden, I. 
Clark-Lewis, C. M. Overall, and C. Power. 2003. HIV-induced metalloproteinase 
processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nat 
Neurosci 6:1064-71. 
262. Zhang, M. R., T. Kida, J. Noguchi, K. Furutsuka, J. Maeda, T. Suhara, and K. 
Suzuki. 2003. [(11)C]DAA1106: radiosynthesis and in vivo binding to peripheral 
benzodiazepine receptors in mouse brain. Nucl Med Biol 30:513-9. 
263. Zink, M. C., J. P. Spelman, R. B. Robinson, and J. E. Clements. 1998. SIV infection 
of macaques--modeling the progression to AIDS dementia. J Neurovirol 4:249-59. 
264. Zink, M. C., K. Suryanarayana, J. L. Mankowski, A. Shen, M. Piatak, Jr., J. P. 
Spelman, D. L. Carter, R. J. Adams, J. D. Lifson, and J. E. Clements. 1999. High 
 18 
viral load in the cerebrospinal fluid and brain correlates with severity of simian 
immunodeficiency virus encephalitis. J Virol 73:10480-8. 
 
 
 19 
